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Allergic asthma is a disease characterized by chronic airway inflammation, reversible airway 
obstruction, and non-specific airway hyperresponsiveness, which result from inappropriate 
immune responses to common aeroallergens in genetically susceptible individuals. CD4+ T 
cells of the Th2 phenotype play a pivotal role in the pathogenesis of this disease. Despite 
increasing understanding of its etiology, the incidence, morbidity, and mortality of allergic 
asthma continue to increase world wide over the last two decades, for reasons unknown. As 
estimated by recent epidemiology studies, one in every five Singaporean children suffers 
from allergic asthma. Current treatments for this disease are mainly symptomatic. They do 
not reverse the underlying immunological and molecular cellular mechanisms, and therefore 
cannot stop the ongoing airway inflammation and airway remodeling and will not prevent the 
re-occurrence of asthma.  
 
The long term goal of this study is to develop DNA vaccines for more effective treatment and 
prevention of mite allergen induced allergic asthma, which is the most prevalent subtype of 
this disease. The specific aim of this thesis was to develop a DNA vaccine encoding Der p 1 
for allergic asthma. Der p 1, a protein produced by Dermatophagoides pteronyssinus mites, is 
one of the top allergen candidates for dust mite allergy vaccine design. DNA plasmids were 
constructed using mammalian expression vectors as plasmid backbone to engineer in the 
allergen genes in the form of cDNA. Immunization was performed by intramuscular injection 
with naked plasmid DNA in mice. In vivo protein expression after DNA immunization was 
examined by confocal microscopy. Serum antibody levels and T cell cytokine profiles were 
used as readouts of antigen specific humoral and cellular immune responses induced by DNA 
construct. Optimization strategies focused on modifications on the design of DNA constructs. 
 xxv
In this regards, codon optimization to increase antigen expression levels in vivo, utilization of  
\] 
more effective signal peptide sequences, and inclusion of a lysosomal targeting sequence in 
the construct design were tested. In addition, heterologous prime-boost immunization 
protocol aiming to boost the DNA – induced immune responses by protein boost was 
investigated and found to be a potential useful mixed modality approach to further improve 
immunization efficiency against allergy. Preclinical evaluation of the Der p 1 DNA 
immunization for potential prophylactic and therapeutic applications for allergic asthma were 
performed using an experimental mouse model for allergic asthma.  
 
Results showed that Der p 1 mite allergen could be expressed by mouse muscle cells after 
intramuscular injection with naked plasmid DNA. This protein expression peaked on day 10, 
and persisted for at least 3 weeks. The immunogenicity of DNA constructs was demonstrated 
by the production of allergen specific immune responses in immunized mice.  By combining 
the various strategies stated above, a Der p 1 DNA construct containing the sequence 
encoding for the full length mature Der p1 protein in the presence of a strong signal peptide, 
designated as LHM, was found to be most immunogenic. The Th1 skewed Der p 1 specific 
immune responses were capable of down regulating IgE and Th2 responses prophylactically 
and therapeutically. Furthermore, immunization with LHM could attenuate airway 
inflammation and airway hyperresposiveness in a prophylactic allergic asthma model, but 
such protection of the airway could not be achieved by this construct in a therapeutically. 
Since it is common for allergic asthma patients to be allergic to multiple mite allergens,  a 
DNA construct containing three major mite allergen genes, Der p 1, Der p 2 and Blo t 5,  
were also developed in this study. The preliminary data showed that it is feasible to immunize 
mice to induce Th1 skewed responses specific for all respective allergens encoded by a single 
 xxvi
plasmid DNA. In conclusion, this study has successfully developed a Der p 1 DNA construct 
that is suitable for further development of a Der p 1 DNA vaccine for human clinical trial. 
The optimization strategies employed in this study could be useful in the design of DNA 

















                              Chapter 1 General introduction 
Asthma is a disease characterized by reversible airway obstruction, chronic airway 
inflammation, and non-specific airway hyperresponsiveness. It affects significantly the 
quality of life in patients with asthma. The incidence of asthma has increased dramatically in 
the past 20 years, especially in developed countries, for reasons that are not exactly clear 
(Wills-Karp M, 1999). Although the exact underlying mechanisms for asthma are still 
elusive, it is known that this disease is frequently related to allergy, which is an immune 
response induced in the body against harmless environmental antigens, such as proteins 
present in house dust mites, peanuts, grass pollen, etc. Indeed, patients with asthma induced 
by allergens accounts for about 80% of all asthma cases (Cohn L et al., 2004). Allergic 
asthma is, therefore, the major category of asthma cases. Among all the allergens that can 
induce abnormal immunological responses in atopic patients, house dust mite allergens are 
the most common cause of asthma worldwide. Up to 80% of children with asthma are 
sensitized to dust mite allergens (Pittner G et al., 2004). Current treatments for allergic 
asthma are mainly symptomatic. Beta2-adrenoceptor agonists and glucocorticosteroids are 
commonly prescribed for bronchodilation and suppression of inflammation so as to relieve 
asthma symptoms (McAllister J, 2004). However, those drugs do not reverse the underlying 
immunological and molecular cellular mechanisms, and, therefore, cannot prevent the re-
occurrence of asthma. People have been searching for more effective therapies based on the 
understanding of its immunological mechanisms. Allergen specific immunotherapy could be 
feasible in this regard. Conventional immunotherapy tries to reverse the established disease-
causing immune responses in patients with asthma induced by allergens. Nevertheless, the 
efficacy is low, results from different studies are inconsistent; and the safety issue has not 
been addressed adequately in human subjects (Wolf BL and Hamilton RG, 1998; Bernstein 
DL et al., 2004). Therefore, a safer and more effective treatment is warranted for allergic 
asthma patients. The development of such a new therapeutic approach relies on a thorough 
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understanding of this disease, especially the underlying molecular cellular mechanisms, and 
also the biochemical and immunological properties of the allergens. Therefore, in the 
following sections, an overview of allergic asthma will be given, with a specific emphasis on 
the interaction between the human immune system and those major allergens from house dust 
mites, e.g., Der p 1, Der p 2 and Blo t 5. 
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1.1  An overview of allergic asthma 
 
To have a thorough understanding of allergic asthma and the underlying immunological and 
molecular cellular mechanisms, its clinical manifestations and the underlying pathological 
changes are examined first (Section 1.1.1), followed by a detailed review on the 
immunological mechanisms underlying the disease (Section 1.1.2). Finally, the emphasis will 
be on the specific properties of those major allergens from the House Dust Mites, and their 
interaction with human immune system (Section 1.1.3). A simplified schematic 
representation of the process from allergen exposure to manifestations of the disease is shown 
in figure 1.1. 
 
1.1.1 Clinical manifestations 
 
“Asthma” is a Greek word that is derived from the verb “aazein”, meaning to exhale with 
open mouth, or to pant (Marketos D and Ballas CN, 1982). It originally did not define a 
disease as we understand it today but was employed to connote respiratory symptoms. Over 
time, the meaning has contracted, and now asthma is defined to be a unique illness 
characterized by reversible airway obstruction, non-specific airway hyperresponsiveness, 
chronic airway inflammation and airway remodeling (Wills-Karp M, 1999; Maddox L and 
Schwartz DA, 2002; McFadden ER Jr, 2004).  
 
At early stages of asthma, airway obstruction is the result of bronchial spasm in response to 
certain stimuli such as aero-allergens. With appropriate treatment or on their own, the airway 
muscular contractions can stop, and the airflow into and out of the lungs will then return to 
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normal. Airway obstruction can be measured by Forced Expiratory Volume per second 
(FEV1). A significant drop in FEV1 is a critical parameter for asthma diagnosis.  
 
Airway hyper-responsiveness is an increased sensitivity of the airway smooth muscle to a 
wide variety of bronchospasmogenic stimuli such as methacholine. Clinically, airway hyper 
responsiveness is demonstrated by a reduction of Provocative Concentration of inhaled 
methacholine that induces a 20% decrease in FEV1 (PC20).  
 
Asthma was suspected to be inflammation in nature in 1898 after microscopic examination of 
expectorated phlegm (Fowler JK and Godlee RJ, 1898). With the development and 
widespread use of fiber optic bronchoscopy, it is now well established that chronic 
inflammation is a feature of asthma in all of its stages of manifestation (Djukanovic R et al., 
1990). Mucosal infiltration by eosinophils, mast cell degranulation, goblet cell hyperplasia, 
epithelial cell desquamation, collagen deposition was consistently observed even in mild 
clinical and sub-clinical patients (Beasley R et al., 1989). As a result of the chronic 
inflammation, airway tissue is continuously being injured and healed resulting in subsequent 
airway remodeling, which involves structural changes in most airway components, including 
wall thickening, sub epithelial fibrosis, increased mucus production and goblet cell mass, 
myofibroblast hyperplasia, myocyte hyperplasia and hypertrophy, and epithelial cell 
hypertrophy (Maddox L and Schwartz DA, 2002). These structural changes account for the 
decline in airway function seen in late stage asthmatic patients. 
 
Most asthma cases are related to sensitization by allergens, which can account for 
approximately 80% of patients with allergic asthma (Cohn L et al., 2004). In allergic asthma, 
the inflammatory process is thought to arise as a result of inappropriate immune response to 
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commonly inhaled allergens in genetically susceptible individuals. In the next section, we 
will review the immunological basis of allergic asthma. 
 
1.1.2 Immunological mechanisms 
 
Allergic asthma accounts for most of the asthmatic cases. Not surprisingly, allergy has been 
acknowledged as a major risk factor for asthma (Holt PG et al., 1999). The word “allergy” 
originally intended to mean “deviation from the original state”. Nowadays it is used to 
describe Th2 associated immune reactions to common environmental proteins, known as 
allergens. 
 
Upon allergen exposure, an allergic process is initiated in atopic individuals that are 
genetically predisposed to develop allergic reactions to otherwise innocuous substances.  The 
allergic process can be divided into two phases, the “sensitization phase” and the 
“provocation phase”. In the sensitization phase, allergens (proteins) are broken down into 
small peptides and presented to T helper cells in the context of class II major 
histocompatibility complex (MHC) molecules by Antigen Presenting Cells (APC). The 
allergen specific T helper cells are then differentiated into Th2 phenotype, producing Th2 
cytokines, such as IL-4, IL-5, IL-9, IL-13, etc. Allergen specific Th2 cells communicate with 
specific B cells to promote their growth and differentiation, which results in the synthesis of 
allergen-specific IgE. In the provocation phase, when atopic individuals encounter the same 
allergen again, IgE receptor-positive cells, mainly mast cells, are activated due to receptor 
cross-linking, which leads to rapid release of preformed and newly synthesized mediators, 
among which histamines, lipid mediators, proteases, chemokines and cytokines are the most 
well known ones, and the immediate onset of mucosal edema, airway smooth muscle 
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constriction and airway narrowing. Another late phase response begins three to six hours later 
and may continue for several days in the absence of treatment. The late phase response is 
associated with the influx of T cells, monocytes, and eosinophils. It has been appreciated that 
all these cells and the mediators they produce during the allergic process play critical roles in 
the pathogenesis of asthma. They are responsible for the increase in airway smooth muscle 
tone, persistence of airway inflammation, and progression of airway remodeling. 
 
Mast cells are the one of major effector cells in allergic reactions. These cells are bone 
barrow derived CD34+ mononuclear cells that express the high affinity IgE receptor FcεRI. 
Cross linking of IgE bound to this high affinity receptor induces the activation of signaling 
cascades and results in the release of preformed and newly formed granules containing 
histamine, tryptase, cysteinyl leukotrienes, chemokines and cytokines. Histamine induces the 
constriction of airway smooth muscle, mucus secretion, as well as vasodilation. These effects 
are further amplified by tryptase and chymase (Bousquet J et al., 2000). Cysteinyl 
leukotrienes, chemokines and cytokines recruit and activate eosinophils, neutrophils and T 
cells to initiate the repetitive cycle of inflammation and tissue damage, which is sustained, 
even in the absence of allergen (Rothenberg ME, 1998). 
 
IgE is the key to mast cell activation and degranulation. It is the least abundant antibody class 
in serum, with a concentration of around 150 ng/ml, in comparison with 10 mg/ml for IgG in 
the circulation of normal individuals (Gould HJ et al., 2003). Allergen specific IgE level is 
closely related to asthma symptoms and it can be 1000 times higher in asthma patients 
(Smurthwaite L and Durham SR, 2002). Immediate hypersensitive reaction is initiated after 
cross-linking of IgE bound to its high affinity receptor FcεRI on the surface of mast cells 
upon allergen challenge. The interaction between IgE and FcεRI is characterized by an 
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association constant Ka of 1010 M-1 (Keown MB et al., 1997). This exceptionally high affinity 
results in slow dissociation of IgE from FcεRI, and contributes to the long-lasting 
sensitization of the mucosal mast cells. Furthermore, the binding of IgE to FcεRI can promote 
the survival of mast cells (Katoh N et al., 2000; Asai K et al., 2001; Kalesnikoff J et al., 
2001), and upregulate FcεRI expression on its surface (Yamaguchi M et al., 1997; Borkowski 
TA et al., 2001). In addition to FcεRI, IgE also interacts with another low affinity receptor 
FcεRII, better known as CD23. It has been shown that CD23 could facilitate antigen 
presentation in an IgE dependent manner, so as to promote immune responses to allergens 
(van der Heijden FL et al., 1993; Santamaria LF et al., 1993). Clearly, IgE is important not 
only in the development but also in the progression of allergic asthma.  
 
T helper lymphocytes are the primary organizer of any specific immune response. The pivotal 
role of CD4+ T cells in the pathogenesis of allergic asthma has been recognized. Subsets of 
effector CD4+ T cells can be distinguished by the profiles of cytokines they produce and their 
unique functions. Th2 cells produce IL-4, IL-5, IL-9, and IL-13 and are important in the 
development of humoral immune response. The Th2 cytokines are critical for the stimulation 
of IgE production, mucosal mastocytosis, and eosinophilia, therefore their relationship with 
the pathogenesis of asthma is apparent (Mosmann TR, et al., 1986; Street et al., 1991). 
Furthermore, Th2 cytokine IL-13 has been shown to induce features of asthma, such as 
airway hyperresponsiveness and mucus hypersecretion, independently of eosinophil 
infiltration, which suggests a direct effect of IL-13. On the other hand, Th1 cells produce 
interferon gamma (IFN-γ) and are critical in the development of cell-mediated immunity 
(Mosmann TR, et al., 1986; Street NE and Mosmann TR, 1991). Th1 cytokine can promote 
the Th1 phenotype and downregulate the differentiation of Th2 cells (Abbas AK et al., 1996). 
It has been shown that the propensity to develop asthma is associated with low levels of IFN- 
 8
                              Chapter 1 General introduction 
γ production at 9 months age, suggesting that Th1 response is protective (Martinez FD et al., 
1995). In sensitized animals, nebulized IFN- γ inhibits eosinophilic inflammation induced by 
allergen exposure (Lack G et al., 1996). It is also reported that allergen immunotherapy 
increases IFN-γ production by circulating T cells in patients with clinical benefit 
(Benjaponpitak S et al., 1999). Adoptive transfer of Th1 clones was recently shown to 
suppress both lung eosinophilia and airway hyperresponsiveness in the murine model (Irifune 
K et al., 2005). A third subset of CD4+ T cells is the regulatory T cells, which is a 
heterogeneous population and may comprise different sub groups (Bach JF, 2003). 
Regulatory T cells can suppress both Th2 and Th1 type adaptive immune response by 
producing immunosuppressive cytokines, such as IL-10 and TGF-β, or via cell contact 
dependent mechanism, which may involve inhibitory molecule CTLA-4 (von Boehmer H, 
2005). The possibility of treating allergic asthma by induction of regulatory T cells is under 
active exploration (Hawrylowicz CM and O’Garra A, 2005). However, the airway 
remodeling activity of the immunosuppressive cytokine TGF- β should be noted. It has been 
suggested that some of the airway changes, such as the subepithelial fibrosis, is actually 
correlated with attempts by the immune system to stop inflammation (Maddox L and 
Schwartz DA, 2002).  
 
In summary, the Th2 dominant response to aero-allergens is the basis of the pathogenesis of 
allergic asthma. I will further review the role of allergens in the differentiation Th2 cells and 
the development of allergic asthma in the next section. 
 
1.1.3 Role of allergens 
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Allergens are a subset of antigens that are associated with induction of Th2 responses and IgE 
production, and thus atopic diseases. Common allergen sources include house dust mites, 
grass pollens and animal danders.  Antigen E from Ragweed pollen, which is now named 
Amb a 1, was the first allergen to be purified and identified using ion exchange and gel 
filtration techniques in the 1960s (King TP and Norman PS, 1962). The first cDNA clone 
encoding a major house dust mite allergen, Der p 1, was isolated in 1988 (Chua  KY et al., 
1988). Since then, the molecular cloning techniques have been fully exploited to clone and 
characterized numerous important allergens. Some 492 proteins from vertebrate, invertebrate 
and plant have been described as allergens in the list of the Allergen Nomenclature Sub-
Committee of the International Union of Immunological Societies 
(http://www.allergen.org/List.htm As of September 12, 2005). These proteins (allergens) are 
responsible for various allergic diseases, such as allergic rhinitis, atopic dermatitis, food 
allergy, and allergic asthma. More than 50% of allergic patients and up to 80% of children 
with asthma are sensitized to dust mite allergens, which  are arguably the most common 
cause of allergic asthma cases worldwide (Pittner G et al., 2004). 
 
Dust mites have been discovered as the major source of allergen in house dust for almost 40 
years (Voorhorst R and Spieksma FT, 1967). They are classified into Phylum Arthropoda, 
Subphylum Chelicerata, Order Acari, and Suborder Astigmata. Thirteen species have been 
found in house dust, among which Dermatophagoiodes pteronyssinus, Dermatophagoides 
farinae, and Euroglyphus maynei are the most common ones in homes worldwide and are the 
major source of mite allergens. In tropical countries such as Singapore, the storage mite 
Blomia tropicalis and Dermatophagoiodes pteronyssinus are the most common and dominant 
species found in home environment (Arlian LG et al., 2001; Yeoh SM et al., 2003; see Fig. 
1.2 for their pictures and linage information).  
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Der p 1 is a major allergen from Dermatophagoiodes pteronyssinus. Significant associations 
between the concentration of Der p 1 in house dust and the prevalence of HDM sensitivity 
has been demonstrated (Warner AM et al., 1996). Der p 1 showed reactivity with IgE in more 
than 70% allergic sera (O'Brien RM et al., 1994A), and over 90% dust mite allergic 
individuals have IgE antibody directed against Der p 1 (Warner AM et al., 1996). These 
epidemiological data implicates a critical role of Der p 1 in the origin, development and 
provocation of allergic asthma. Physiologically, Der p 1 is a digestive enzyme produced in 
the mid gut of the mite. It was first purified from aqueous extracts of Dermatophagoiodes 
pteronyssinus culture by gel filtration some 20 years ago (Chapman MD et al., 1980), and its 
cDNA sequence has been determined (Chua KY  et al., 1988). The full length Der p 1 cDNA 
encodes a precursor of 320 amino acid residues, including an 18 amino acid signal peptide, a 
pro-enzyme region of 80 amino acids, and a mature 25 kDa enzyme of 222 amino acid 
residues. It shows high degree of sequence similarity with cysteine proteases, such as papain, 
actinidin, cathepsin B, and cathepsin H. Most notably, the residues involved in the enzyme 
active sites are well conserved, i.e., glutamine at position 28, glycine, serine and cysteine at 
position 32-34, histidine at position 170, and asparagines, serine and tryptophan at position 
190-192. The Der p 1 structure has been modeled on the crystal structure of papain (Topham 
CM et al., 1994). It suggests that Der p 1 comprises two domains separated by a cleft, which 
contains the active site with its characteristic catalytic triad of Cys34, His170 and Asn190. 
This modeled structure is consistent with the recently determined crystal structure of yeast 
expressed recombinant proDer p 1, which includes both the proenzyme region and the mature 
region of Der p 1 (Fig. 1.3, Meno K et al., 2005). The proteolytic activity of Der p 1 has been 
characterized using fluorogenic peptide substrates, and can be specifically inhibited by 
cysteine protease inibitor E-64 (Schulz O et al., 1998A). The knowledge of cleavage sites of 
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known Der p 1 substrates, CD23, alpha1-antitrypsin, and insulin beta-chain, suggests that Der 
p 1 has a preference for small hydrophobic residues (Val/Ala) in the P2 position, charged 
residues (Glu/Arg) in the P1 position and small hydrophilic/hydrophobic residues (Ser/Ala) 
in the P1’ position (Schulz O et al., 1997, Kalsheker NA et al., 1996, Hewitt CR et al., 1997). 
The proteolytic activity and other biochemical properties of Der p 1 may contribute to the 
development of Th2 response and the pathogenesis of allergic asthma via various aspects. It 
has been shown that Der p 1 can cause disruption of epithelial cell tight junctions by cleaving 
occludin, so as to facilitate the transepithelial movement of allergen (Wan H et al., 1999). 
Alpha1-antitrypsin is another pathologically relevant substrate of Der p 1. It is one of the 
major antiproteases involved in the homeostasis of airway environment. Inhibition of alpha1-
antitrypsin activity by Der p 1 could result in the loss of host defense against epithelial tissue 
damage by other proteases, such as neutrophil elastase and bacterial proteases, thus 
potentiating the damage to the airway tissue and local inflammation. Der p 1 could also bias 
the immune response towards a Th2 pathway by cleaving CD25, the alpha subunit of IL-2 
receptor on T lymphocytes, which leads to the diminished proliferation and IFN-γ production 
(Schulz O et al., 1998). CD23 is the low affinity Fcε receptor on B lymphocytes, eosinophils 
and dendritic cells, and it is also sensitive to cleavage by Der p 1 (Hewitt CR et al., 1995). 
Since binding of IgE to CD23 was thought to provide a negative feedback signal to IgE 
synthesis, it can be postulated that CD23 cleavage by Der p 1 could inhibit the normal 
suppressive feedback mechanism and enhance IgE synthesis as well as allergic responses. 
Clearly, Der p 1 is not only epidemiologically important but also could contribute to the 
pathogenesis of allergic asthma by affecting a variety of components of the innate and 
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Figure 1.1 Schematic representation of the pathogenesis of allergic asthma (adapted from 
Holt PG et al., 1999). ThP refers to Th-precursor (naïve T cells); Th2M refers to Th2-
polarized memory cells. 
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Class Phylum Order Genus Species
 
 
Figure 1.2 Scanning electron micrographs of house dust mites Dermatophagoiodes 
pteronyssinus (A) and Blomia tropicalis (B) and their lineages 
 
Family
Arthropoda     Arachnida      Astigmata  — Pyroglyphida — Dermatophagoides pteronyssinu
—Glycyphagida Blomia                      tropicalis
 14






Figure 1.3 Overall structure of proDer p 1. A, Schematic representation of the mature 
region, including the visible part of the His-tag (colored green). Alpha-Helices are shown as 
red coils, Beta-strands are shown as orange arrows, and disulfide bridges are shown as yellow 
sticks with the residue numbers indicated. The side chains of the active site residues Q108, 
A114, H250, and N270 are shown as cyan sticks (Note that the numbering of the residues is 
according to the proDer p 1, which contains 80-amino acid proenzyme region in the N 
terminal. The yeast recombinant protein used here contains two point mutations, N132E and 
C114A, to reduce glycosylation and to abolish the enzymatic activity of Der p 1). B, The 
folding of the pro region on the surface of the mature region. The residues from the pro-
peptide that are visible in the electron density are shown schematically in green, and the part 
of the structure that corresponds to the mature protein (i.e., without pro-peptide and His-tag) 
is represented by the molecular surface. The N-terminal nitrogen atom of the first visible 
residue in the mature region (N82) is colored blue. The C-beta atom of A114 corresponding 
to the active site Cys residue has been colored red. (Adapted from Meno K et al., 2005). 
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1.2  Management of allergic asthma and existing problems 
 
To have an overall idea of how allergic asthma is managed, I shall first review the current 
treatments available in the clinics and their associated problems (1.2.1), after which emphasis 
will be given to the ongoing research on the development of novel treatments for allergic 
asthma and the current status (1.2.2). 
 
1.2.1 Current treatments 
 
Currently, most of the drugs for asthma treatment aim at relaxation of airway smooth muscle, 
attenuation of airway inflammation, or general suppression of immune responses. Some of 
them are very effective in relief of the symptoms for the mild asthmatics. 
 
β2-adrenergic receptor agonists, or β2-agonists, are the most frequently used drugs to relieve 
asthma symptoms. β2-agonists are sympathomimetic agents capable of relaxing airway 
smooth muscles by increasing the concentration of cyclic AMP and by opening potassium 
channels. Drugs such as salbutamol, terbutaline, fenoterol, formoterol and salmeterol belong 
to this category. Although they are highly effective in bronchodilation and suggested to be 
prescribed to all patients with symptomatic asthma (British Thoracic Society, 2003; Global 
Initiative for Asthma, 1995), they have no effect on the underlying inflammatory process, and 
therefore, are not able to stop the process of airway remodeling. 
 
Theophylline is another effective bronchodilator. It was first isolated in 1888 and its use in 
the management of allergic asthma dated back to the 1930s (Rogers DF and Giembycz MA, 
1998, Somerville LL et al., 2001). Although it is classified as a phophodiesterase (PDE) 
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inhibitor, which could elevate cAMP level and inhibit cell secretion and contraction, the 
exact therapeutic mechanisms remain to be determined. Due to its adverse effects, such as 
nausea, vomiting, headache, tachycardia and arrhythmia, which could be very severe in some 
of the patients, nowadays, theophylline is generally reserved for patients with more severe 
asthma symptoms. Novel PDE inhibitors are currently under development. Given that PDE4 
is predominant in inflammatory cells, PDE4 inhibitors are of particular interests. However, 
the results of clinical trials have been disappointing and side effects such as nausea and 
vomiting, similar to those observed for theophylline, have been observed (Giembycz MA, 
2001). It is of interest to see whether inhibitors specifically targeting PDE4B, a subtype of 
PDE4, could offer greater benefits and reduce side effects. 
 
Corticosteroids are the most effective anti-inflammatory drugs currently available for the 
treatment of asthma and other allergic diseases. They bind to cytosolic glucocorticoid 
receptors, which subsequently translocate to the nucleus and initiate or regulate the 
transcriptions of the downstream genes. Corticosteroids could suppress multiple 
inflammatory mediators and their receptors by inhibiting transcription factors such as 
activator protein-1 (AP-1), nuclear factor-κB (NF- κB) and nuclear factor of activated T cells 
(NF-AT) and, thus, have direct effects on a variety of inflammatory cells, particularly 
eosinophils (Barnes PG, 1998B). Improvements in asthma symptoms, general health status, 
and lung function in asthma patients after usage of corticosteroids have been demonstrated in 
various studies (Djukanovic R et al., 1992; Mahajan P et al., 1997; Haahtela T et al., 1991). 
However, the potential side effects of long term usage of corticosteroids have been the major 
concerns of both patients and clinicians. Although not clinically significant at low doses, it 
does become a problem when used in high doses. Local and systemic reactions, such as 
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dysphonia, bruising and atrophy of the skin, reduced bone mineral density, suppression of the 
adrenocotical axis can occur. 
 
The cromones (sodium cromoglycate and nedocromil sodium) are so far the most specific 
drugs that inhibit allergic inflammation. Although the mechanisms of their effect are still 
elusive, they are believed to inhibit mast cell degranulation by affecting the phosphorylation 
status of moesin (Wang L et al., 1999). However, they appear to be much less effective than 
corticosteroids and, therefore, their use has been superseded by the introduction of inhaled 
steroids (Szefler SJ and Nelson HS, 1998). 
 
Inflammatory mediator antagonists are another group of drugs that are used in asthma 
therapy. There are more than 50 mediators identified to be involved in allergic inflammation 
(Barnes PJ et al., 1998A). Inhibition of any single mediator is therefore not likely to have 
significant effects, unless it has a more dominant role than other mediators. 5’-lipoxygenase 
(5-LO) inhibitors (zileuton) and cysteinyl-leukotriene receptor antagonists (pranlukast, 
zafirlukast and montelukast) have been developed to treat asthma patients. However, 
although strikingly effective in some of the patients, generally the efficacy has been very 
weak (Drazen JM et al., 1999B; Dahlen B et al., 1998). Pharmacogenetic studies of the 
leukotrine synthesis pathway may help to predict and select a special subgroup for optimal 
use of these drugs.  
 
There is still another group of drugs in clinical use to either suppress inflammation or inhibit 
immune responses in general. These drugs, such as methotrexate, Troleandomycin, Gold, 
Cyclosporine, and Heparin, could help to limit the use of corticosteroids and, therefore, are 
referred to as Corticosteroid Sparing Agents (Niven AS and Argyuros G, 2003). However, 
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due to side effects and safety concerns, their use is confined to severe asthma patients who 
are poorly controlled by standard therapy. Researchers are developing novel anti-
inflammation drugs by targeting the molecules in pro-inflammatory signaling pathways, 
including NF-κB signaling pathway (Roshak AK et al., 2002), MAP kinase pathway 
(Kankaanranta H et al., 1999), Jun N-terminal kinase (JNK) signaling pathway (Huang TJ et 
al., 2001), and protein tyrosine kinase (PTK) signaling pathways (Costello PS et al., 1996; 
Stenton GR et al., 2002; Adachi T et al., 1999; Wong WS, 2005). Although some of them are 
effective in pre-clinical and clinical studies, concerns about the potential side effects of long-
term administration of inhibitors of these general signaling pathways need to be addressed 
before their clinical applications. 
 
Most mild asthmatic patients could be effectively managed by the above mentioned drugs in 
terms of symptom relief. The development of anti-inflammation drugs further improved the 
effectiveness by controlling airway remodeling and delaying disease progression. However 
general suppression of inflammation or the immune system could have conceivable side 
effects. Furthermore, the existing therapies could not completely solve the clinical symptoms 
of moderate and severe asthmatic patients. Therefore, researchers are looking for more 
effective drugs by specifically modulating the underlying allergic immune responses.  
 
1.2.2 Novel treatments under development 
 
In order to improve the efficacy of asthma therapy and to reduce the side effects of existing 
drugs, new therapeutic approaches have been intensively explored worldwide. With the 
advancement in our understanding of the basic molecular, cellular, and immunological 
mechanisms of allergic asthma, more and more potential drug targets appear, making the 
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development of novel treatments possible. Some of these developments have been discussed 
in the previous section.  
 
As has been discussed in Section 1.1.2, IgE plays an important role in the development and 
manifestation of allergic asthma, suppression of IgE is, therefore, one of the potential targets 
for the management of this disease. Omalizumab, a humanized monoclonal anti-IgE 
antibody, has been developed. It specifically binds to the Cε3 domain of IgE, thereby 
preventing its binding to FcεRI. It has been shown that Omalizumab could reduce serum IgE 
levels (Fahy JV et al., 1997), down regulate IgE receptors on basophils and dendritic cells 
(MacGlashan DW Jr et al., 1997; Prussin C et al., 2003), attenuate airway eosinophilia and 
inhibit both early phase asthmatic reactions and late phase asthmatic reactions in asthma 
patients (Fahy JV et al., 1997). When used in combination with existing asthma drugs, 
omalizumab was shown to improve symptom scores, reduce the use of β2-agonists and 
corticosteroids, and reduce the rate of exacerbations (Milgrom H et al., 1999; Milgrom H et 
al., 2001; Soler M et al., 2001; Busse W et al., 2001). In addition, Omalizumab appears to be 
safe and well-tolerated during long term administration to asthma patients. These clinical 
results formed the basis of its approval for use in USA, Canada, Brazil, Australia and New 
Zealand for moderate and severe asthmatics. However, the existence of IgE independent, T 
cell induced asthmatic reactions (Hogan SP et al., 1998; Haselden BM et al., 1999; Haselden 
BM et al., 2001), predicts a limited efficacy of anti-IgE therapy. Indeed, although 
omalizumab could nearly eliminate systemic IgE, its clinical efficacy, as observed in the 
above mentioned studies, is relatively modest. 
 
IL-4 is one of the key Th2 cytokines that is critical for Th2 cell development and IgE 
production by B cells. Since both Th2 cells and allergen-specific IgE are important players in 
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allergic asthma development, interrupting the IL-4 signaling pathway is thought to be a 
possible approach for treatment of the disease. Soluble recombinant IL-4 receptors, which 
could compete with endogenous IL-4 receptors, are in clinical development. There is some 
preliminary evidence of efficacy in moderate asthma patients (Borish LC et al., 1999; Borish 
LC et al., 2001). However, another recent large scale clinical trial indicated that soluble IL-4 
receptor has no clinical efficacy (Jonkers RE and van der Zee JS, 2005). Further evaluation is 
necessary to elucidate the potential of this agent. Other approaches to inhibit downstream 
molecules, such as Stat6 and GATA-3, in the IL-4 signaling pathway are under investigation 
(Popescu FD et al., 2003).  
 
IL-5 is crucial in orchestrating the eosinophilic inflammation of asthma. The efficacy of anti-
IL-5 antibody in reducing airway inflammation and inhibiting airway hyperresponsiveness 
was demonstrated in animal models (Mauser PJ et al., 1995). Humanized anti-IL-5 
monoclonal antibody has been developed, and a single injection of this anti-IL-5 antibody 
resulted in reduction of blood eosinophils and eosinophil recruitment into the airway (Leckie 
MJ et al., 2000). However, it had no effect on late asthmatic reaction and airway 
hyperresponsiveness. These results suggested a less important role of eosinophils in the 
pathogenesis of allergic asthma. It is likely that anti-IL-5 therapy could be effective for a 
subgroup of patients where eosinophilic inflammation contribute more significantly to the 
symptoms of asthma. 
 
IL-12 is the key regulator of Th1 responses. It was demonstrated in animal models that 
administration of IL-12 could inhibit allergic inflammation (Gavett SH et al., 1995). 
However, the recombinant human IL-12 has no effect on late asthmatic reactions and airway 
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hyperresponsiveness (Bryan SA et al., 2000) in asthma patients. Furthermore, side effects, 
such as malaise and cardiac arrhythmia were observed.  
 
As can be seen, the potential therapeutic approaches that have been discussed above aim to 
modulate the allergic immune responses by either inhibiting the Th2 response or promoting 
the Th1 response. Some of them have been shown to be effective and are on their way to 
clinical applications. However, as could be expected, general suppression of Th2 or 
stimulation of Th1 could result in severe side effects. Therefore, immune modulation in an 
allergen specific manner is more desirable. In this regard, allergen specific immunotherapies, 
which aim at allergen-specific desensitization, have been under investigation for almost a 
century. 
 
Specific immunotherapy was first introduced by Leonard Noon in 1911 to treat allergic 
rhinoconjunctivitis (Noon L, 1911). It was found in his study that hay fever patients treated 
with distilled water extract of timothy grass pollen demonstrated significant improvements 
upon conjunctival testing. The effectiveness of immunotherapy for pollen allergic patients 
was further demonstrated by many subsequent studies (Freeman J, 1911; Frankland AW and 
Augustin R, 1954; Johnstone DE, 1957; Viander M and Koivikko A, 1978; Creticos PS et al., 
1989), and led to its application in patients that are allergic to other environmental allergens 
including those from house dust. 
 
House dust has been recognized as the main source of indoor allergens that trigger IgE 
mediated symptoms of various allergic diseases (Pollart SM and Platts-Mills TA, 1989). The 
earliest study of immunotherapy in house dust allergic patients was conducted in 1949 by 
Bruun using extracts from house dust (Bruun E, 1949). In this two-year, single blinded, 
 22
                              Chapter 1 General introduction 
placebo-controlled study, 78% of patients in the treatment group demonstrated clinical 
improvements. In a subsequent three-year, double blinded, placebo-controlled study, Aas 
reported similar results (Aas K, 1971). However, in these studies, unusually large amounts of 
house dust extract, as measured by protein nitrogen, were necessary to achieve effectiveness 
(May CD et al., 1970). Better materials for house dust allergy immunotherapy are, therefore, 
needed. 
 
When it became clear that mites were the main source of allergens in house dust, researchers 
began to test the effectiveness of using house dust mite extracts for immunotherapy. As 
expected, extracts from house dust mites appeared to be more effective material. Several 
blinded trials demonstrated its efficacy in controlling allergy symptoms and decreasing IgE 
antibodies (Smith AP, 1971; D’Souza MF et al., 1973; Chapman MD et al., 1980). Further 
improvements were investigated by use of adjuvants, denaturation of extracts and different 
mode of administration (Norman PS et al., 1982). Currently, the most effective and 
frequently used form of immunotherapy involves repeated subcutaneous injection of 
adjuvant-bound allergen extracts (Bousquet J et al., 1998). In a recent retrospective study, 
long term effects of immunotherapy using house dust mite extracts were demonstrated by 
significant less asthmatic symptoms in the group that had been treated with immunotherapy 
during childhood (Cools M et al., 2000). 
 
The mechanisms underlying the effectiveness of immunotherapy have been extensively 
studied. It has been observed that immunotherapy is associated with increases in allergen-
specific IgG1, IgG4 and IgA levels. After immunotherapy with house dust mite extracts, 
specific IgG4 was detected within 60 days (Jutel M et al., 2003). Immunotherapy-induced 
IgG4 has little inflammatory activity and was proposed as blocking antibody, which could 
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compete with IgE for allergen binding. Indeed, it has been demonstrated that IgG4 induced 
by immunotherapy could reduce allergen-induced IgE-dependent histamine release by 
basophils (Garcia BE et al., 1993). In addition to its effects on immunoglobulins, 
immunotherapy could also affect peripheral T cell phenotypes. IL-10 producing T cells were 
consistently observed after immunotherapy (Jutel M, et al., 2003; Bellinghausen I et al., 
1997; Akdis CA et al., 2001). After immunotherapy with house dust mite extracts, Jutel M et 
al. observed that IL-10 production was associated with a suppression of Th2 response (Jutel 
M, 2003). Furthermore, the source of IL-10 appeared to be CD4+CD25+ T cells. Given the 
immunotolerogenic effects of IL-10, these results implicate the induction of tolerance by 
immunotherapy. The induction of CD4+CD25+ regulatory T cells and their involvement in 
immunotherapy remain to be clarified. 
 
Despite the apparent efficacy and increased understanding of immunotherapy, inconclusive 
results were also reported by others, and severe side effects have been observed (Wolf BL 
and Hamilton RG, 1998), with fatal reactions occurred at a rate of 1 per 2.5 million 
injections, and 3.4 deaths per year (Bernstein DL et al., 2004). These observations could be 
related to the limitations of crude extracts, which are difficult to characterize and standardize. 
Furthermore, the instability of protein products could also cause problems in their storage and 
transportation. These apparent obstacles have been preventing allergen specific 
immunotherapy from wide spread usage. With the identification of allergen genes and the 
development of molecular cloning technology, it is postulated that allergen specific immune 
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In the next section, I shall address the emerging of a new technology, DNA vaccine, and its 
possible application in the treatment of allergic asthma as a safer curative approach with 
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1.3 DNA vaccines for prevention and treatment of allergic asthma 
 
In this section I shall discuss the development of DNA vaccines as a novel treatment and 
prevention method for allergic asthma. I shall first review the history of vaccine and the 
recent emerging of DNA vaccines (1.3.1). The application of DNA vaccine for allergic 
diseases will then be discussed with an emphasis on those aiming at allergic asthma (1.3.2). 
Finally I shall review the current situation of DNA vaccine development and its problems in 
light of the results from clinical trials (1.3.3). 
 
1.3.1 History of vaccine and DNA vaccine 
 
The history of vaccination can be dated back to ancient China, when pus (variolation) from 
smallpox patients was inoculated to healthy people to prevent severe natural smallpox. This 
ancient Chinese practice was introduced into England by Lady Mary Wortly Montagu in the 
early eighteenth century (Bellanti JA and Kadlec JV, 1985) and led to the creation of the 
sciences of vaccinology and immunology by Edward Jenner. Although farmer Benjamin 
Justy inoculated his family with the cowpox pus to prevent smallpox much earlier than 
Edward Jenner, it was Jenner who conducted the first scientific investigations and clinical 
studies to demonstrate that dermal inoculation of cowpox pus could prevent smallpox upon 
virulent virus challenge in 1796 (Jenner E, 1798). The practice of vaccination then spread 
rapidly around Europe and North America. It was considered as the greatest triumph of 
medicine in the eighteenth century. 
 
The rudimentary success of vaccination in the eighteenth century was greatly expanded by 
the French chemist Louis Pasteur, who established the germ theory of disease (Castiglioni A, 
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1958), in late Nineteenth Century. He observed that laboratory cultivation could attenuate 
fowl plague bacteria, and the attenuated bacteria could induce resistance to subsequent 
challenge with virulent bacteria, giving rise to the idea that laboratory attenuation could 
generate safe and protective vaccines. Subsequent studies by him and others led to the 
development of the remarkable vaccines against anthrax, cholera, rabies, typhoid fever, 
shigellosis, diphtheria and tetanus, which continue to be researched and improved to present. 
 
Modern era of vaccinology began around 1950 based on the discovery of chick embryos and 
minced tissues for propagation of viruses and rickettsiae in vitro and the development of 
other technologies such as cell culture, molecular biology and immunology. It yielded many 
live and killed viral and bacterial vaccines including those against meningococcus, 
pneumococuss, hemophilus influenza, measles, mumps, rubella, varicella, poliomyelitis, 
hepatitis A, and notably cancer (Hilleman MR et al., 2000). The first vaccine using 
recombinant protein was developed in the 1980s for hepatitis B. It is also the world’s first 
subunit vaccine and the first licensed vaccine to prevent human cancer. The yeast expressed 
recombinant antigen performed the same as plasma-derived vaccine (McAleer WJ et al., 
1984), and thus providing an alternative source of vaccine supply. 
 
Gene-based immunization, or DNA vaccines, represent the most recent advance in 
vaccinology. It is called “the third vaccine revolution” (Dixon B, 1995). Unlike conventional 
vaccines that are composed of proteins, DNA vaccines are bacterial plasmids containing a 
strong viral promoter, a gene encoding the disease-related antigen, a polyadenylation 
sequence, and a bacterial selection marker (Fig. 1.4). The idea of a DNA vaccine was 
conceived from the observation that naked plasmid DNA injections resulted in transfection of 
muscle cells and production of the encoded β-galactosidase protein (Wolff JA, 1990). 
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Subsequent studies further demonstrated that specific humoral and cellular immune responses 
to the encoded antigen could be induced efficiently by simple plasmid DNA immunizations 
(Tang DC et al., 1992; Ulmer JB et al., 1993). These exciting findings have since led to 
researches aiming at application of this new technology in a variety of diseases including not 
only infectious diseases for which conventional vaccines have not been successful, but also 
cancer, autoimmunity and allergic diseases, because of its apparent advantages besides 
induction of both humoral immune response and cellular immune response. DNA vaccines 
are easy to prepare and simple to manipulate; they are safe for immunocompromised host as 
compare to live attenuated viruses; they do not induce vector immunity and, therefore, can be 
used for repeated boosting; they do not replicate in the host; they are more stable than protein 
and can be stored in a dry precipitated form, thus do not require a cold chain for storage and 
transportation. Therefore, it is not surprising to see an explosive growth of DNA vaccine 
research, among which application of DNA vaccines for treatment and prevention of allergic 
diseases is one of those extensively investigated. 
 28
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Figure 1.4 Schematic representation of a plasmid DNA construct used for DNA 
vaccination. 
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1.3.2 DNA vaccine for allergic asthma and other allergic diseases 
 
It was postulated that DNA immunization can preferentially induce Th1 responses while 
concomitantly inhibiting Th2 responses in an allergen specific manner, which offers great 
advantages over the existing drugs discussed in section 1.2.1. Efficient reduction of allergic 
responses by DNA vaccination has been demonstrated in animal models. The house dust mite 
allergen Der p 5 and a model antigen β-galactosidase were the first to be described (Hsu CH 
et al., 1996A; Hsu CH et al., 1996B; Raz E et al., 1996), followed by reports that DNA 
vaccines decrease hypersensitivity to latex, peanut, OVA, and bee venom in mice (Slater JE 
et al., 1997; Roy K et al., 1999; Maecker HT et al., 2001; Jilek S et al., 2001). 
 
The vaccine produced by Hsu and coworkers consisted of a recombinant naked plasmid DNA 
carrying a house dust mite allergen (Hsu CH et al., 1996A). These authors first established an 
allergy model, in which intraperitoneal immunization of rats with the Der p 5 allergen in 
alum stimulated production of allergen-specific IgE.  IgE production was accompanied by 
high levels of IL-4 and IL-5 but not IFN-γ secretion by splenic T cells. Intramuscular 
injection of a vector encoding a full-length Der p 5 protein, termed pCMVD induced high 
levels of IgG2a and IgG1 anti-Der p 5 antibodies, but no IgE.  Vaccinated rats upon challenge 
with the Der p 5 allergen were protected against the induction of IgE antibodies. In addition, 
Der p 5-sensitized rats upon challenge with aerosolized Der p 5 showed increased pulmonary 
resistance within 20 minutes, which could be circumvented by pCMVD vaccination. This 
protection was also long-lasting. Rats that had received Der p 5 encoding plasmid showed 
reduction of airway hyperresponsiveness and histamine release into the broncheoalveolar 
lavage fluid upon exposure to the allergen 6 months after immunization. In a subsequent 
study, the authors further demonstrated a significant down-regulation of ongoing IgE 
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response by allergen gene immunization in a mouse model for atopic asthma, proving the 
concept that DNA vaccine could also be effective therapeutically (Hsu CH et al., 1996B). 
 
Using naked plasmid DNA delivered intradermally, Raz and coworkers reported similar 
findings in a β-galactosidase model of allergy (Raz E et al., 1996). They demonstrated that 
mice immunized with a plasmid DNA encoding β-gal from E. coli (pCMV-LacZ) produced 
an IgG2a antibody response to β-gal, whereas immunization with protein in alum or in saline 
induced IgG1 and IgE.   Analysis of lymphokine secretion indicated that plasmid DNA 
induced T cells secreting IFN-γ but not IL-4 or IL-5, whereas β-galactosidase induced T cells 
secreting IL-4 and IL-5 but not IFN-γ.  Plasmid-primed mice developed starkly reduced IgE 
antibody responses upon subsequent challenge with β-gal. The β-gal system was also used to 
explore therapeutic efficacy of DNA vaccination. Indeed, pCMV-LacZ treatment after 
priming with β-gal protein in alum resulted in a 75% decrease in the IgE antibody titer within 
6 weeks (Raz E and Spiegelberg HL, 1999). 
 
A DNA vaccine encoding latex allergen Hev b 5 was also developed, and shown to be 
effective in inhibiting IgE in mice (Slater JE et al., 1997). This construct carries the sequence 
of Hev b 5 allergen in the p394 expression vector. However, in a subsequent study when the 
plasmid was injected subcutaneously at the base of the tail, Hev b 5 transcripts were observed 
not only at the injection site, but also in the lymph nodes, spleen, lungs, blood and tongue 
(Slater JE et al., 1998). The wide biodistribution of Hev b 5 transcripts may be attributable to 
transcript expression by migratory cells such as dendritic cells and monocytes. This 
observation should be taken into account when considering application to the clinics. In this 
regard, subcutaneous injection might not be a suitable route of administration of DNA 
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vaccines for allergic diseases, as widespread distribution of allergens could cause allergen 
sensitization and other undesirable responses in the vaccinated hosts.  
 
One of the most common and potentially fatal food allergens for human is present in peanuts. 
An oral DNA vaccine expressing the Ara h 2 peanut allergen was tested in rodents for 
induction of a protective immune response. The vaccine consisted of nanoparticles produced 
by coacervation of plasmid encoding the peanut allergen Ara h2 (Roy K et al., 1999) and 
chitosan, a biocompatible vehicle.  Chitosan is a non-immunogenic, mucoadhesive 
polysaccharide derived from crustacean shells already in clinical use for controlled drug 
delivery.  The chitosan protects the DNA from rapid degradation in the intestinal lumen, thus 
allowing for transfection of the stomach and the intestinal epithelia. Vaccinated mice 
produced Ara h2-specific secretory IgA and serum IgG2a antibodies and showed a reduction 
in allergen-specific IgE, allergen-induced anaphylaxis, decreased plasma histamine levels and 
reduced vascular leakage  upon challenge 
 
 A persistant preventive as well as therapeutic efficacy was also observed for plasmid DNA 
encoding the major allergen from honeybee venom, Phospholipase A2 (PLA2) (Jilek S et al., 
2001). Intradermal injection of naked plasmid DNA given 7 months before challenge with 
PLA2 in alum, reduced induction of PLA2 specific-IgE and IgG1 titers, and instead boosted 
the vaccine-induced IgG2a and IgG3 titers.  Splenocytes recovered 5-6 months after the last 
DNA immunization secreted IFN-γ and IL-10 but not IL-4 PLA2 protein challenge of DNA 
vaccinated mice boosted the vaccine-induced T cell response, suggesting  the reactivation of 
quiescent memory lymphocytes.  In a therapeutic model, treatment of mice with plasmid 
DNA after PLA2 sensitization resulted in a high percentage (65%) of recovery from 
subsequent anaphylactic shock inducing challenge. 
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Pollen is a major source of inhalant allergens. It has been reported that a DNA construct 
encoding Japanese cedar pollen allergen Cry j 1 induced a strong Th1 skewed immune 
response in mice receiving intramuscular injection of this DNA construct (Toda M et al., 
2000). This Th1 skewed immune response subsequently inhibited the production of Cry j 1 
specific IgE upon challenge by alum-precipitated Cry j 1 injections (Toda M et al., 2000). 
DNA vaccine carrying another important pollen allergen Bet v 1a gene under the control of 
CMV promoter was also constructed, and shown to be effective for both preventive and 
therapeutic strategies in the mouse model (Hartl A et al., 1999; Hartl A et al., 2004). 
 
These initial successes proved the concept that DNA immunization could be effective for 
allergic diseases, including allergic asthma, both prophylactically and therapeutically. As 
compared to the existing therapies discussed in Section 1.2, DNA vaccine has several 
advantages. Firstly, it is curative rather than providing symptomatic relief. Secondly, it 
inhibits Th2 immune responses in an allergen specific manner rather than general 
suppression. Thirdly, DNA is much easier to manipulate and deliver than protein, making 
DNA vaccine more flexible and convenient than allergen immunotherapy. 
 
1.3.3 Current status and problems 
 
The encouraging preclinical results for allergy and other diseases propelled DNA vaccines 
into clinical trials for a number of diseases, including HIV, malaria, influenza, hepatitis B, 
and cancer. DNA vaccines were also tested in veterinary settings, and two of them were 
recently approved for use in real world by regulatory autorities, one for equine in US and 
another one for salmon in Canada. Although the clinical trials of DNA vaccines for allergic 
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diseases are yet to be conducted, we already learned a lot from the completed and ongoing 
trials. 
 
Safety is always the first concern, and it has been demonstrated in human by various studies. 
DNA vaccination was well tolerated at doses up to 2.5 mg over three or more injections given 
intramuscularly or intradermally. It induced no serious local or systemic reactions, no 
significant laboratory abnormalities, no integration of DNA and no detectable anti-DNA 
antibody in human subjects (MacGregor RR et al., 1998; Le TP et al., 2000). Moreover, both 
humoral and cellular immune responses were successfully generated in some studies, as 
demonstrated by increased level of antibodies against the encoded antigen and enhanced T 
cell (helper T cells and cytotoxic T cells) activity (MacGregor RR et al., 1998; Ugen KE et 
al., 1998; Calarota SA et al., 1999; Le TP et al., 2000; Roy MJ et al., 2000; Calarota SA et 
al., 2001; Wang R et al., 2001). However, other than these notable cases, the potency of 
DNA vaccination in human has generally been low (Letvin NL, 2005). The disappointing 
potency underscores the challenges faced by DNA vaccine designers. 
 
Further optimization to improve the efficiency of DNA vaccination is the most apparent one. 
Strategies to enhance the immunogenicity and immune modulation efficacy of DNA vaccines 
specifically to the encoded antigen are urgently needed. There are several aspects that could 
be modified to enhance the potency of DNA vaccine, including direct modification of the 
plasmid, the use of boosting strategies, and the choice of adjuvants. Given the critical role of 
Th2 immune response in allergic diseases, DNA vaccines for these diseases should 
specifically and efficiently inhibit Th2 responses, potentially by enhancing Th1 responses or 
other immune modulation mechanisms. The choices of plasmid and adjuvant, delivery 
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methods, and boosting strategies to achieve such a vaccine are to be investigated in this 
thesis. 
 
On the other hand, the huge differences between allergens in terms of biochemical properties, 
expression efficiency and immunogenicity represent another big problem that DNA vaccine 
designers have to overcome. Despite the many successes reviewed in section 1.3.2, a 
satisfying DNA vaccine for house dust mite major allergen Der p 1, which is of real clinical 
importance, has not been developed yet, partly due to its unique biochemical properties as a 
cysteine protease and the expected detrimental effects of expression of an enzymatically 
active protein in vivo. DNA sequences encoding the Der p 1 specific T cell epitopes have 
been exploited for the Der p 1 vaccine design to overcome this problem (Kwon SS et al., 
2001; Jarman ER and Lamb JR, 2004). However, as indicated by the published data, 
numerous important human T cell epitopes that have been mapped were located throughout 
the Der p1 molecule (Hales BJ and Thomas WR, 1997; O’Brien RM et al., 1994). Given the 
complexity and polymorphic nature of the MHC genes, DNA vaccine containing the full Der 
p 1 gene, that would offer a broader spectrum of protective immunity in the highly 
heterogeneous human populations, needs to be developed. Development of such a vaccine is 
the main objective of this thesis. 
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1.4 Objectives of the research project 
 
As has been reviewed in the previous sections, the development of new treatments for 
allergic asthma has been an intensive field of biomedical research world wide. However, up 
to now, a safe curative treatment for this airway disease is still unavailable. The main 
problems are as follows. Firstly, symptomatic treatments are not able to prevent the disease 
from re-occurring or to stop the ongoing airway remodeling. Secondly, general suppression 
of inflammation or the immune system could possibly delay the progression of the disease, 
but the side effects of long term suppression could be severe. Thirdly, allergen-specific 
immunotherapy that could possibly modulate the immune response in an allergen specific 
manner, produced inconsistent results in clinical studies, which could be due to the 
difficulties in allergen extracts preparation, storage and standardization, and severe near-fatal 
reactions have been observed. In addition, the underlying mechanisms of immunotherapy are 
still elusive. 
 
Therefore, the main objective of this thesis was to develop a safer, more specific and more 
effective treatment for allergic asthma, with potential for prophylaxis, using the specific 
allergen genes and the DNA vaccine technology. In this study, cDNA encoding Der p 1 
allergen was used as a model candidate gene for DNA immunization against allergy and 
allergic asthma.  
The specific aims of the study were: 
 
1. To examine the expression kinetics of Der p 1 protein and Der p 1 derived peptides in 
vivo following intramuscular immunization with naked plasmid DNA constructs 
containing Der p 1 gene or gene fragment in mice. 
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2. To examine the phenotype, magnitude and specificity of the immune responses 
induced by the various Der p 1 DNA constructs following DNA immunization in 
mice.  
3. To design DNA constructs to achieve optimal and long term immune responses  
4. To establish a Der p 1 specific experimental mouse asthma model for efficacy 
evaluation of Der p 1 DNA  immunization 
5. To evaluate the efficacy of DNA immunization for prevention and therapy of allergic 
asthma using an experimental  mouse asthma model 
6. To develop a DNA construct that contains multiple allergen genes (Der p 1, Der p 2, 
and Blo t 5) for immunization against sensitization by multiple allergens 
 
Various biomedical technologies were employed in this study, including molecular cloning, 
biochemical assays, immunological tests, flowcytometry analysis, cell culture work, and 
animal experiments. These technologies form the basis of the experimental findings presented 
in this thesis. Therefore, a detailed description of each of these methods, as well as the 
materials used, will be provided in the next chapter. 
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In this chapter we will describe in details the various materials (2.1) and methods (2.2) 
employed in this thesis to facilitate the understanding of the experimental findings 




2.1.1 Reagents for molecular cloning 
 
Mammalian expression vectors pcDNA3, pCIneo, pEGFP-N3, and pVAX1 were used in 
the construction of DNA plasmids for immunization. The pcDNA3 and pVAX1 were 
purchased from Invitrogen (San Diego, CA, USA), pCIneo from Promega (Madison, WI, 
USA) and pEGFP-N3 from Clontech (Palo Alto, CA, USA). Majority of vaccinations 
presented in this thesis were carried out using DNA constructs in pVAX1 vector. pVAX1 
is designed according to the Food and Drug Administration, Center for Biologics 
Evaluation and Research (FDA CBER) regulations for vectors to be used in human DNA 
vaccination protocols (Food and Drug Administration, 1996). It contains a human 
cytomegalovirus immediate-early (CMV) promoter, a bovine growth hormone (BGH) 
polyadenylation signal, and a kanamycin resistance gene. This vector was designed to be 
simple and does not contain any redundant sequences, thus minimizing the possibility of 
homologous recombination with human genomic DNA.
 
The Der p 1 cDNA λgt10RecλL3a was used as DNA template for application of Der p 1 
sequences by Polymerase Chain Reaction (PCR) (Chua KY et al., 1988). The pSecTag2A 
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vector from Invitrogen (San Diego, CA, USA) was used as DNA template to amplify the 
mouse Igκ chain leader sequence. The plasmid constructs, 
pVAX/hTPA/Myc/MCS/TMCYD, pVAX/hTPA/Myc/MCS, and pVAX/MCS/TMCYD 
containing DNA sequences encoding the transmembrane domain and the cytoplasmic 
domain of mouse Lysosome Associated Membrane Protein 1 (LAMP1) was generously 
provided by Dr. J. Thomas August from Johns Hopkins Singapore International Medical 
Center. DNA polymerases (pfu and Taq), restriction enzymes, and T4 DNA ligase were 
purchased from Promega (Madison, WI, USA). All oligonucleotides used in this study 
were synthesized by Alpha DNA (Montreal, Quebec, Canada). 
 
The GFX PCR DNA and gel band purification kit and DYEnamic™ ET Terminator 
Cycle Sequencing Kit were purchased from Amersham Pharmacia Biotech (Piscataway, 
NJ, USA). Wizard® Plus SV miniprep DNA Purification System was purchased from 
Promega (Madison, WI, USA). Endotoxin-free plasmid DNA preparation kit (QIAGEN® 
Plasmid Giga) was purchased from QIAGEN (Chatsworth, CA, USA). 
 
2.1.2 Bacterial strains 
 
Escherichia coli strain DH5α [Genotype: supE44 deltalacU169 (phi80 lacZ deltaM15) 
hsdR17 recA1 endA1 gyrA96 thi-1 relA1] was used for the propagation and maintenance 
of plasmid DNA. 
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Escherichia coli strain TG-1 [Genotype: supE hsd∆5 thi ∆ (lac-proAB) F’ (traD36 
proAB+ lacIq lacZ∆M15)] was used for the expression of recombinant Der p 1 fragments. 
 
Pichia pastoris strain GS115 (Invitrogen, Carlsbad, CA, USA) [Genotype: his4 mut] was 
used for production of recombinant allergens, Der p 1, Der p 2 and Blo t 5. 
 
2.1.3 Bacteria and yeast culture media 
 
Yeast Nitrogen Base (YNB), Bacto-yeast extract, peptone, Bacto-tryptone, and Bacto-
agar were purchased from Difco Laboratories (Detroit, MI, USA). Ampicillin and IPTG 
were purchased from Calbiochem (San Diego, CA, USA). NaCl, KH2PO4 and K2HPO4 
were purchased from Sigma (St Louis, MO, USA). Glycerol was purchased from Merck 
(Whitehouse station, NJ, USA). LB Medium was prepare with 10 g of bacto-tryptone, 5 g 
of bacto-yeast extract, and 10 g of NaCl dissolved in 1000 ml deionized H2O. 
 
2.1.4 Spent mite medium 
 
The Dermatophagoides pteronyssinus spent mite medium was a gift from CSL Limited, 
Melbourne, Australia. It is used to purify native Der p 1 protein by monoclonal antibody 
affinity chromatography as described in Section 2.2.2. 
 
2.1.5 Reagents for protein purification, identification and analysis 
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Der p 1 specific monoclonal antibody (mAb) 4C1 was a gift from Dr. Martin Chapman 
(INDOOR biotechnologies, Charlottesville, VA, USA). Protein purification resins 
(cynogen bromide-activated Sepharose 4B, Sephadex G-25, Butyl Sepharose 4 Fast 
Flow, Q Sepharose Fast Flow, Hi-Trap Q-Sepharose, and Hi-Trap SP-Sepharose) and the 
Fast Performance Liquid Chromatography (FPLC) system for protein chromatography 
were purchased from Pharmacia (Uppsala, Sweden). Glutathione agarose, DNase, and 
lysozyme were purchased from Sigma (St. Louis, MO, USA). Protein concentrator 
Amicon® Centricon Plus-20 (PL-10, PL-30) was purchased from Millipore (Bedford, 
MA, USA). 
 
The mAb 46 was generated from native Der p 1-immunized mice by former research 
fellow Dr. Claudia Betina Wolfowicz in our laboratory. This mAb recognizes an epitope 
at the C-terminal of Der p 1 protein (residues 117-222). The Der p 2 specific mAbs C1, 
C2, and C5 were generated from mice immunized with recombinant Der p 2 fused to 
glutathione S-transferase (GST) and these were generously provided by Dr. Jaw-Ji Tsai 
from the Section of Allergy and Clinical Immunology, Cathay General Hospital, and Dr. 
Jing-Long Huang from Chang-Gung Children’s Hospital, Taoyuan, Taiwan. The mAb 
4A7, specific for Blo t 5, was generated by Yi Fong Cheng in our labortory by DNA 
immunization with Blo t 5 gene. The respecitive Der p 1, Der p 2, and Blo t 5 specific 
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The Bio-Rad Protein Assay kit was purchased from Bio-Rad (Richmond, CA, USA). 
Coomassie Plus Protein Assay Reagent and SuperSignal® West Pico Chemiluminescent 
were purchased from Pierce (Rockford, IL, USA). Coomassie blue R was purchased from 
Sigma (St Louis, MO, USA). BioMax film was purchased from EASTMAN KODAK 
(Rochester, NY, USA). 
 
2.1.6 Reagents for immunoassays 
 
Anti-mouse Igκ light chain antibody, mouse immunoglobulins (Ig) IgG1, IgG2a, IgE, 
cytokines IL-4, IL-5, and IFN-γ used as standards for ELISA, and anti-mouse IL-4, IL-5, 
and IFN-γ were obtained from Pharmingen (San Diego, CA, USA). Mouse cytokines IL-
10 and IL-13 used as standards for ELISA, and anti-mouse IL-10 and IL-13 were 
obtained from R&D systems (Minneapolis, USA). Biotin conjugated anti-mouse IgG1, 
IgG2a, and IgE were purchased from Serotec (Oxford, England, UK). Biotin-conjugated 
anti-mouse total immunoglobulins, ExtraAvidine Alkaline Phosphatase, ExtraAvidin-
Peroxidase conjugate, para-nitrophenyl phosphate substrate, and bovine serum albumin 
were obtained from Sigma (St. Louis, MO USA). Reagents for flow cytometry analysis 
were purchased from Pharmingen (San Diego, CA, USA). 
 
2.1.7 Reagents for cell culture 
 
The cell culture medium, RPMI 1640, was purchased from HyClone (Logan, UT, USA). 
Cell culture medium supplements L-glutamine, sodium pyruvate, sodium bicarbonate, 
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and fetal calf serum (FCS) were purchased from Hyclone (Logan, UT, USA). The 2-
mercaptoethanol was obtained from Life technology (Grand Island, NY). Fungizone™ 
antimycotic solution was purchased from Life Technologies (GibcoBRL) (Grand Island, 
NY, USA). Hank’s balanced salt solution (HBSS) without calcium and magnesium were 
from Hyclone (Logan, UT, USA). Penicillin and streptomycin antibiotic solutions were 
purchased from HyClone (Logan, UT, USA). Recombinant mouse IL-2 was purchased 




The Balb/cJ, C3H/HeJ, CBA/J, and AKR mice originated from The Jackson Laboratory 
(Bar Harbor, Me, USA) were bred in the Sembawang Laboratory Animals Centre 
Singapore. Female mice, between 6 to 8 weeks of age, were used and housed under 
conventional conditions in the Animal Holding Unit, National University of Singapore. 
All animal experiments were performed according to Institutional Guidelines for Animal 
Care and Handling, National University of Singapore. 
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2.2 Methods 
 
2.2.1 Plasmid construction 
 
The various mammalian expression constructs generated in pcDNA3, pCIneo, pEGFP-
N3, or pVAX1 are shown in Table 2.1. Plasmid construction was carried out by 
conventional molecular cloning techniques (Ausubel FM et al., Current Protocols in 
Molecular Biology).  
 
In general, cDNA sequences encoding full length or fragments of Der p 1, mouse Igκ 
chain leader sequence, and lysosome targeting sequences, were respectively amplified by 
polymerase chain reaction (PCR) from λgt10RecλL3a Der p 1 cDNA, pSecTag2A, or 
pVAX/hTPA/Myc/MCS/TMCYD DNA templates using synthetic oligonucleotide 
primers. The 64-bp Der p 5 leader sequence (sense sequence 5’-
TCGAGATCAATCATGAAATTCATCATTGCTTTCTTTGTTGCCACTTTGGCAGTT
ATGACTGRTT-3’) was, however, incorporated as synthetic oligonucleotides.  
 
The codon optimized DNA sequences encoding Der p 1, Der p 2 and Blo t 5 were 
designed based on codon preference of highly expressed human transcripts. Partially 
overlapping oligonucleotide sequences spanning the Der p 1, Der p 2, or Blo t 5 coding 
sequences were synthesized and used to generate the respective codon optimized DNA 
sequences (hDerp1, hDer p 2, and hBlo t 5) in a two-step PCR amplification (Massaer M 
et al., 2001), as shown in Fig. 2.1. The hDer p 1, hBlo t 5 and hDer p 2 (in this order) 
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DNA sequences were fused via PCR using synthetic primers containing linker sequences 
(GGGSGGGSGG). 
 
Fusion of relevant DNA sequences was achieved by overlapping extension, which was 
performed by the mixing of two PCR products or synthesized oligonucelotides for 1 PCR 
cycle before carrying out the final PCR amplification. 
 
PCR amplified DNA fragments or DNA fragments from restriction digests were purified 
from agarose gel using the GFX PCR DNA and Gel Band Purification Kit and 
sequentially cloned into the restriction endonuclease sites of the respective vectors. The 
ligated DNA plasmids were then transformed into the Escherichia coli strain DH5α. 
Antibiotics-resistant transformants were selected, and used for plasmid production and 
purification using Promega Wizard Plasmid DNA Extraction Kit and QIAGEN® Plasmid 
Giga Kit (QIAGEN, Chatsworth, CA, USA). DNA sequences were confirmed by DNA 
automatic sequencing (ABI PRISMTM sequencing kit). 
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 Plasmids Inserted Gene Cloning Sites 
1 pcDNA3-pre-pro-Der p 1 Der p 1 (-294 - 666) Bam HI & Xho I 
2 pEGFP-Der p 1 (1-222) Der p 1 (1-666)-EGFP Xho I & Bst XI 
3 pEGFP-Der p 1 (1-116) Der p 1 (1-348)-EGFP Xho I & Bst XI 
 pEGFP-Der p 1 (114-222) Der p 1 (342-666)-
EGFP 
Xho I & Bst XI 
4 pEGFP-Der p 5 L/Der p 1 (1-222) Der p 5 leader – Der p 
1 (1-666) - EGFP 
Bam HI & Xho I 
5 pEGFPDer p 5 L/Der p 1 (1-116) Der p 5 leader – Der p 
1 (1-348) – EGFP 
Bam HI & Xho I 
6 pEGFPDer p 5 L/Der p 1 (114-
222) 
Der p 5 leader – Der p 
1 (342-666) – EGFP 
Bam HI & Xho I 
6 pCI-neo-Der p 1 (1-222) Der p 1 (1-666) Xho I & Not I 
7 pCI-neo-Der p 1 (1-116) Der p 1 (1-348) Xho I & Not I 
 pCI-neo-Der p 1 (114-222) Der p 1 (342-666) Xho I & Not I 
8 pCI-neo-Der p 5 L/Der p 1 (1-
222) 
Der p 5 leader – Der p 
1 (1-666) 
Xho I & Not I 
9 pCI-neo-Der p 5 L/Der p 1 (1-
116) 
Der p 5 leader – Der p 
1 (1-348) 
Xho I & Not I 
10 pCI-neo-Der p 5 L/Der p 1 (114-
222) 
Der p 5 leader – Der p 
1 (342-666) 
Xho I & Not I 
11 pVAX1-Der p 1 (M) Der p 1 (1-666) Bam HI & Xba I 
12 pVAX1-κL-Der p 1 (LM) Igκ leader – Der p 1 
(1-666) 
Bam HI & Xba I 
13 pVAX1-κL-pro-Der p 1 (LPM) Igκ leader – Der p 1 (-
237-666) 
Bam HI & Xba I 
14 pVAX1-κL-hDer p 1 (LHM) Igκ leader – codon 
optimized sequence 
encoding mature Der 
p 1 
Bam HI & Xba I 
15 pVAX1-κL-hDer p 1-LAMP 
(LHML) 
Igκ leader – codon 
optimized sequence 
Bam HI & Xba I 
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encoding mature Der 
p 1 – Lysosome 
targeting sequence 
from LAMP1 (Fig. 
7.2). 
16 pVAX1-κL-Der p 1-Blo t 5-Der p 
2 
Igκ leader – codon 
optimized sequence 
encoding mature Der 
p 1 - Linker sequence- 
codon optimized 
sequence encoding 
Blo t 5 - codon 
optimized sequence 
encoding Der p 2 (Fig. 
7.9) 
Bam HI & Xba I 
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     f1           f3            f5            f7          fn           
        r2           r4            r6          r8           rn           











Codon optimized fragment 
 
 
Fig. 2.1 Schematic representation of the strategy used to generate synthetic codon-
optimized DNA fragment. Primary PCR was performed using partially overlapping 
oligonucleotides (f1, r2, f3, r4…, fn, rn). Secondary PCR was conducted using 
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2.2.2 Purification of native Der p 1 by monoclonal antibody affinity 
chromatography 
 
Native Der p 1 was purified from spent mite media by mAb 4C1 affinity 
chromatography. The mAb 4C1 was coupled to cynogen bromide-activated Sepharose 4B 
(Pharmacia) according to the manufacturer’s instructions. Spent mite extract was 
prepared by suspending one gram of spent mite medium in 10 ml of Tris-buffered saline 
(TBS; 10 mM Tris, 150mM NaCl pH 7.4) containing 2 mM PMSF at 4°C for 2 hrs. 
Supernatants were separated by centrifugation at 17,000 g in 4°C for 30 mins. 
Subsequently, the clear spent mite media extracts were passed through tandem 4C1 
columns and columns were washed with TBS until the OD280nm reached zero. The bound 
native Der p 1 was eluted with 10 mM Glycine, 50% ethylene glycol, pH 10. Eluents 
were neutralized with 1 M Tris-HCl, pH 6.5 and dialysed immediately against 50 mM 
NH4HCO3, and lyophilized. The samples were resuspended in PBS and quantitated by 
comparison with a protein standard using a colorimetric assay (BioRad, Hercules, CA, 
USA). The purity and identity of Der p 1 was confirmed by SDS-PAGE and immunoblot 
assay. 
 
2.2.3 Production and purification of recombinant Der p 1 protein fragments 
 
E. coli clones producing GST fused recombinant Der p 1 protein fragments spanning 
residues 1-116, 114-222, 1-56, 15-94, 53-99, 57-130, 98-140, 131-187, and 188-222 
were, respectively, grown in LB medium containing 100 µg/ml of ampicillin for 3 h after 
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induction with 0.5 mM IPTG.  The bacteria were pelleted and resuspended in TBS 
containing 1 mM PMSF, 20 µg/ml of DNase I, 20 µg/ml of lysozyme, and Tween 20 to 
1% of the cell suspension. The bacteria were disrupted by sonication on ice, and the 
supernatant was collected after centrifugation. The recombinant GST-fused peptides were 
subsequently purified by passage over a column of glutathione agarose beads pre-
equilibrated in TBS, and elution was carried out with 10 mM reduced glutathione in 50 
mM Tris HCl, pH 8 buffer. The concentrations of the recombinant GST fused peptides 
were quantified by a colorimetric assay and purity was assessed by SDS-PAGE.   
 
2.2.4 Production and purification of recombinant Der p 2 
 
Recombinant Der p 2 protein was produced from the P. pastoris yeast expression system 
(Kuo et al., 1999). Yeast transformant carrying the Der p 2 cDNA was grown in 5ml of 
buffered glycerol-complex medium (1% yeast extract, 2% peptone, 1.34% yeast nitrogen 
base with ammonium sulfate, 1% glycerol, 0.4 mg/l biotin, and 0.1 M potassium 
phosphate, pH 6.0) and subsequently used to inoculate of 2-liters culture and allowed to 
grow until the OD600nm = 6. Cells were harvested by centrifugation at 1000 g and gently 
suspended in 400 ml of buffered methanol-complex medium containing 0.5% methanol. 
The cells were cultured for another 2 days for induction of protein expression and 
methanol was replenished to 0.5% final concentration every 24 hrs. The yeast media 
containing the recombinant Der p 2 was applied to an SP-Sepharose column equilibrated 
with 10 mM sodium acetate, pH 5.5. Bound proteins were eluted with 600 ml of a linear 
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sodium chloride gradient from 0 to 500 mM. The purity of recombinant Der p 2 was 
examined by SDS-PAGE and immunoblot. 
 
2.2.5 Production and purification of recombinant yeast Blo t 5 
 
Recombinant yeast Blo t 5 proteins were produced from the P. pastoris yeast expression 
system (Kuo IC et al., 1999). The yeast transformant carrying the Blo t 5 cDNA was 
grown in 5ml of buffered glycerol-complex medium (1% yeast extract, 2% peptone, 
1.34% yeast nitrogen base with ammonium sulfate, 1% glycerol, 0.4 mg/l biotin, and 0.1 
M potassium phosphate, pH 6.0) and subsequently used to inoculate 2-liters of medium 
culture and allowed to grow until the OD600nm = 6. Cells were harvested by centrifugation 
at 1000 g and gently suspended in 400 ml of buffered methanol-complex medium 
containing 0.5% methanol. The cells were cultured for another 2 days for induction of 
protein expression and methanol was replenished to 0.5% final concentration every 24 
hrs. The yeast media containing Blo t 5 was applied to a Q-Sepharose column 
equilibrated with with 10 mM Tris-HCl, pH 7.5. Bound proteins were eluted with 600 ml 
of a linear sodium chloride gradient from 0 to 500 mM. The purity of recombinant Blo t 5 
was examined by Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) followed by immunoblot. 
 
2.2.6 Determination of protein concentration 
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The concentrations of purified native Der p 1, recombinant Der p 1 protein fragments, 
recombinant Der p 2, and recombinant Blo t 5 proteins were determined using the 
Coomassie Plus protein assay reagent (Pierce, Rockford, IL, USA) with bovine serum 
albumin as standard, and colormetric quantification by Bio-Rad Model GS-700 Imaging 
Densitometer (Bio-Rad Laboratories, Richmond, CA, USA). 
 
2.2.7 Gel electrophoresis 
 
The purity of purified native or recombinant proteins were determined using 7.5% 
Tricine SDS-PAGE (Schagger H et al., 1987). Electrophoresis was performed at 100 V 
for 90 minutes and subsequently gels were stained in Coomassie blue R (Sigma, St Louis, 
MO, USA). 
 
2.2.8 Western immunoblotting 
 
The purified native Der p 1, recombinant Der p 1 protein fragments, recombinant Der p 2, 
and recombinant Blo t 5 proteins were electrophoresed on 7.5% SDS-PAGE, and 
transferred to Hybond C nitrocellulose membranes (Amershampharmacia Biotech AB, 
England, UK). After blocking with 5% non-fat milk in PBS-T, membranes were 
incubated respectively with mAbs 46 specific for native Der p 1, 6BC specific for 1-116 
peptide, 1BB specific for 114-222 peptide, C1 specific for Der p 2,  or 4A7 specific for 
Blo t 5, at 4°C for overnight. The membrane was washed 3 times with PBS-T and biotin-
conjugated anti-mouse total immunoglobulins (1:10,000 dilution; Sigma) were added for 
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1 hr at room temperature. After washing, ExtraAvidin-Peroxidase conjugate (1:10,000 
dilution; Sigma) was added and incubated for 1 hr. The signals were developed with 
SuperSignal chemiluminescence substrate (Pierce, Rockford, IL, USA) on BioMax film 
(EASTMAN KODAK Company, Rochester, NY, USA). 
 
2.2.9 Detection of antigen-specific Ig in mouse serum by Enzyme-linked 
immunosorbent assay (ELISA) 
  
A total of 5 µg/ml purified native Der p 1, recombinant Der p 1 fragments, recombinant 
Blo t 5 or Der p 2 was dissolved in coating buffer (0.1 M NaHCO3, pH 8.2) and coated 50 
µl/well to Costar high binding plates (Costar, Corning, NY, USA) at 4oC, overnight. For 
standard, anti-mouse Igκ was used for coating. Plates were washed three times with PBS 
containing 0.05% Tween 20 (PBS-T) and blocked for one hr at room temperature with 
100 µl of 1 % bovine serum albumin (BSA; Sigma) in PBS-T. Coated plates were 
incubated with optimal dilution of mouse sera in blocking buffer, whereas IgE, IgG1, or 
IgG2a were used in the standard wells. After three washes, bound Der p 1-, Blo t 5-, or 
Der p 2-specific IgE, IgG1, and IgG2a antibodies were detected with 50 µl/well biotin-
conjugated rat anti-mouse IgE, IgG1 or IgG2a monoclonal antibodies (1:2000 dilution, 
Serotec, UK) for 1 hr at room temperature. After another three washes, ExtraAvidine 
Alkaline Phosphatase-conjugated sheep anti-rat monoclonal antibody (1:2000 dilution, 
Sigma, MO, USA) was added and incubated for 1 h at room temperature. Finally, plates 
were washed six times, developed with para-nitrophenyl phosphate substrate (pNPP; 
Sigma), and the optical density at 405nm was determined using an ELISA plate reader 
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(Tecan, Austria). The antibody production index units of Der p 1-, Blo t 5- or Der p 2-
specific antibodies were determined by comparison of the plot of absorbance versus 
dilutions of the sample to that of the standard versus its concentration. 
 
2.2.10 Detection of cytokines in culture medium by sandwich ELISA 
 
The 96-well high-binding plate (Costar) was coated with 50 µl of purified rat anti-mouse 
IL-4, IL-5, IL-10, IL-13 or IFN-γ diluted in coating buffer (0.1M NaHCO3, pH8.2) to a 
concentration of 2 µg/ml and incubated at 4°C overnight. After washing the plate with 
0.05% Tween/PBS, 100 µl of blocking buffer (1% BSA (Sigma)/PBS) was added to each 
well and incubated at room temperature for 2 hours. The plate was washed again. Fifty 
microliters of cultured supernatants were added to wells and the plate was incubated 
again at 4°C overnight. For quantification purpose, fifty microliters of recombinant 
mouse IL-4, IL-5, IL-10, IL-13 or IFN-γ prepared in two-fold serial dilution in blocking 
buffer were included in each plate. The next day, plate was washed and fifty microliters 
of biotinylated anti-mouse IL-4, IL-5, IFN-γ mAbs (2 µg/ml) or biotinlyated anti-mouse 
IL-10 (400 ng/ml), IL-13 (200 ng/ml) polyclonal Abs diluted in blocking buffer were 
added to each well. The plate was incubated at room temperature for 1 hour followed by 
washing with 0.05% Tween/PBS. Fifty microliters of ExtraAvidin®-alkaline phosphatase 
(Sigma, St Louis) (1:2000) diluted in blocking buffer were added and incubated at room 
temperature for additional 1 hour. The colour reaction was developed with the addition of 
50 µl of phosphatase substrate p-nitrophenyl phosphate, Disodium (Sigma, St Louis). 
Plates were read in a microplate autoreader at wavelength of 405 nm.  
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2.2.11 Culture of mouse splenocytes 
 
2.2.11.1  Preparation of single cell suspension 
 
Spleens were obtained from Balb/cJ, AKR, CBA/J, or C3H/HeJ mice aseptically in a 
laminar flow hood, and were placed in Petri dishes containing 10 ml of Hanks balanced 
salt solution (HBSS) (Sigma). Single cell suspension was prepared by homogenizing the 
spleen tissues using two the frosted sides of two autoclaved slides. Cells were washed 
with HBSS and pelleted at 1200 rpm for 10 min to remove cellular debris. The cell pellet 
was re-suspended in red blood cell lysis buffer (10 mM Tris, 0.83% ammonium chloride, 
pH 8.2-8.4) for 90 seconds, and the cells was then washed 3 times with HBSS. The 
splenocytes suspension was quantified using a hematocytometer. 
 
2.2.11.2  Co-culture with native Der p 1 or recombinant Der p 1 protein 
fragments 
 
Cells were cultured in RPMI 1640 supplemented with 10% (v/v) heat-inactivated fetal 
calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 1 mM 
sodium pyruvate, and 55 µM 2-mercaptoethanol, in the presence of 20 µg/ml native Der p 
1 or equal molar amount of recombinant Der p 1 protein fragments. Cell cultures were 
incubated at 37°C in the presence of 5 % CO2. 
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To determine the cytokine production in freshly isolated splenocytes, cells were cultured 
in duplicate with 20 µg/ml native Der p 1 or medium control in 96-well U bottom plate 
(Nunc, Roskilde, Denmark) at a density of 4x105 cells/200 µl medium/well. Culture 
supernatants were collected at 48 and 72 hrs and stored in -20oC before using for 
cytokine ELISA assay.  
 
To obtain and analyse Der p 1-specific T cells, splenocytes were cultured for 10 days 
with 20 µg of Der p 1 in 6-well plates. Recombinant IL-2 in fresh culture media were 
added to the cell culture on day 3, day 5, and day 7 to a final concentration of 10 U/ml. 
On day 10, cells were harvested and viable T cells were obtained by Ficoll-Paque density 
gradient centrifugation (Amersham Pharmacia, NJ, USA). Purified T cells were used for 
staining of surface markers and/or intracellular cytokine staining, and subject to 
FACScan analysis. 
 
2.2.12 Determination of cell proliferation by Thymidine Incorporation Assay 
 
Splenocytes were isolated as described in Section 2.2.11.1 and cultured with medium 
control, 20 µg/ml native Der p 1, or equal molar amount of recombinant Der p 1 
fragments in 96-well U bottom plate (Nunc, Roskilde, Denmark) at a density of 4x105 
cells/200 µl medium/well. Cells were pulsed with 1 µCi of [3H]-thymidine (Amersham 
Bioscience, UK) for the remainder 16 hrs  of culture and harvested at 96 hrs on to glass 
filters (Skatron Instruments AS, Lier, Norway) using a cell harvester. The amount of 
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[3H]-thymidine incorporation was determined using a liquid scintillation counter. Cell 
proliferation was presented as counts per min (cpm). 
 
2.2.13 Purification of CD8+ T cells by AutoMACS 
 
Splenocytes were isolated from mice as described in Section 2.2.11.1. Cell suspensions 
were incubated with Biotin-conjugated rat anti mouse CD8β antibody (Pharmingen, San 
Diego, CA) for 10 mins at 4oC. The cells were washed and incubated with Avidine-
conjugated magnetic beads (Miltenyi Biotec) for another 10 mins. Cells were washed 
twice and magnetic beads bound CD8+ T cells were isolated using AutoMACS (Miltenyi 
Biotec, Gladbach, Germany). The purity of CD8+ T cells was determined by flow 
cytometry and found to be greater than 90%. Purified CD8+ T cells were then stimulated 
in the presence of immobilized anti-CD3 (5 µg/ml) and soluble anti-CD28 (2 µg/ml) 
(PharMingen, San Diego, CA) in 96 well U-bottom plates for 72 hrs. Supernatants were 
harvested and stored at -20oC for future cytokine ELISA assays. 
 
2.2.14 Flow cytometry analysis 
 
Rat and hamster monoclonal antibodies (mAbs) were used for FACScan analysis. They 
were FITC-conjugated anti-CD4 (RM4.5), APC-conjugated IFN-γ (XMG-2.1), PE-
conjugated anti-CD8α (53-6.7) and anti-IL-4 (BVD4-1D11). All mAbs and reagents 
were purchased from PharMingen (San Diago, CA) unless specified otherwise. 
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2.2.14.1 Cell surface marker staining and Flow Cytometry  
 
For staining of cell surface markers, cells were washed and suspended in 1 x PBS 
containing 1% (v/v) FCS and incubated with anti-mouse specific fluorescence labeled 
monoclonal antibodies (Pharmingen, San Diego, CA, USA) for 30 min on ice in 5 ml 
Falcon® polystyrene round-bottom tube (Becton Dickson, NJ, USA). Cells were washed 
twice and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, CA, USA) 
using the CellQuest program. 
 
2.2.14.2 Intracellular cytokine staining 
 
Intracellular cytokine staining was performed by modification of a standard method from 
PharMingen. A 24-well plate was coated with 200 µl/well of anti-CD3 mAb (10 µg/ml) 
diluted in PBS and incubated at 37oC for 2 hrs. The plate was washed with 1 ml of PBS. 
In each well, a total of 2x106 cells in 1 ml culture medium were added and cells were 
cultured for 10 hrs in the presence of 2 µg/ml of rat anti-mouse CD28 mAb and 3 µM of 
monensin (Sigma, St. Louis, MO USA). Cells were harvested and stained for surface 
markers as described in Section 2.2.14.1. Subsequently, cells were fixed and 
permeabilized with 0.1% saponin (Sigma, St. Louis, MO USA)/4% paraformaldehyde 
(BDH Laboratory supplies, England) for 30 mins at room temperature. After washing the 
cells with 0.1% saponin/1% BSA/PBS, the cells were further stained with fluorescence 
labeled anti-IL-4, or IFN-γ mAbs for another 30 min. The cells were then washed twice 
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with 0.1% saponin/1% BSA/PBS and re-suspended in 1% paraformaldehyde/PBS. Flow 
cytometry was performed using FACScalibur as described in section 2.2.14.1. 
 
2.2.15 DNA immunization and in vivo electroporation 
 
Approximately six to eight weeks old female Balb/cJ mice were anesthetized with a 
cocktail of Hypnorm plus Midazolam provided by the Animal Holding Unit, National 
University of Singapore. Anesthetized mice were then immunized by intramuscular 
injection of 50 µl of naked plasmid DNA (1 µg/µl) in the left quadriceps (Fig. 2.2) using 
a 1 ml insulin syringe and a 27 G needle. For immunization with electroporation, the 
front of the upper left leg was shaved, and DNA was injected as before, in the anterior 
tibialis (Fig. 2.3), followed by immediate electroporation with an ECM 830 apparatus 
(BTX, Genetronics, San Diego, CA). Electroporation was performed with a 0.5 cm 2-
needle array inserted 2 mm deep in parallel to the muscle fibers. Four pulses of 20 ms, 80 
V each, with a 200 ms interval were delivered. Seven days later, mice were boosted in the 
same way on the opposite leg. Serum was collected before (day 0) and weekly after 
immunization. 
 
2.2.16 Protein immunizations 
 
Approximately six to eight weeks old female BALB/cJ, C3H/Hej, CBA/J, and AKR mice 
were sensitized or boosted intraperitoneally, subcutaneously, or intratracheally with 
native Der p 1 or a mixture of three allergens (native Der p 1, recombinant Der p 2, and 
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recombinant Blo t 5) adsorbed to 4 mg of aluminum hydroxide gel (Amphojel®, 
Whitehall Laboratories, NSW, Australia) in a final volume of 200 µl.  
 
2.2.17 Detection of protein expression in cryosections of muscle tissue after DNA 
immunization 
 
Muscle tissue samples from the injection site were collected at 1 h, 6 h, and 1, 2, 4, 7, 10, 
14, 21, and 28 days after DNA injection. The samples were embedded in O.C.T 
compound (Tissue-Tek, Sakura, Torrance, CA, USA) snap frozen in liquid nitrogen and 
stored at –20oC. Cryosections of 10 µm in thickness were obstained using a cryostat and  
mounted with fluorescence quenching medium (DAKO). The sections were analysed on a 
confocal microscope (Fig. 2.6).   
 
2.2.18 Airway allergen exposure by aerosol 
 
Aerosol or inhalation challenge was performed by generating a Der p 1 aerosol via an 
ultrasonic nebulizer (model UltraNEB 99, DeVilbiss Health Care, Sommerset, PA; Fig. 
2.4) from 0.1 mg/ml solution of Der p 1 in PBS. The mice were kept unrestrained in a 
desiccator chamber with continual flow of aerosol for 30 mins. 
 
2.2.19 Non-invasive measurement of airway responsiveness 
 
 61
   Chapter 2 Materials and methods 
The airway responsiveness was assessed in conscious, unrestrained mice by the whole-
body plethysmography (model PLY3211, Buxco Electronics Inc., Troy, New York, USA; 
Fig. 2.5) as described previously (Hamelmann E et al., 1997). This system calculates a 
dimensionless parameter known as enhanced pause (Penh) reflecting the changes in 
waveform of the chamber pressure, measured with a transducer (model TRD5100) 
connected to preamplifier modules (model MAX2270) and analyzed by BioSystem XA 
software (model SFT 1410, all from Buxco Electronics). Measurements consisted of 
respiratory rate, tidal volume, pause (PEF/PIF), and Penh ((Te/RT-1) x PEF/PIF), where 
PEF = peak expiratory flow (ml/s), PIF = peak inspiratory flow (ml/s), Te = expiratory 
time, and RT = relaxation time. Measurements of methacholine responsiveness were 
obtained by exposing mice to an aerosol of PBS (baseline readings), and cumulative 
increased doses (5 to 40 mg/ml) of aerosolized methacholine. The aerosol was generated 
by a portable ultrasonic nebulizer (model 5500D, DeVilbiss Health Care, Sommerset, 
PA) and drawn through the chamber for 3 mins with the Bias Flow Supply (model 
PLY1040). The signals were recorded for the subsequent 5 mins. The interval between 
each dose was 1 min. This whole-body plethysmographic method for measurement of 
airway responsiveness has been validated by direct comparison with the conventional 
invasive measurement (Hamelmann E et al., 1997). 
 
2.2.20 Collection of broncheoalveolar lavage and cytospin preparation for 
differential cell counts 
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Mice were anesthetized with intraperitoneal injection with a lethal dose of a mixture 
containing 1.25 mg/ml midazolam, 2.5 mg/ml fluanisone and 0.079 mg/ml fentanyl 
citrate. The trachea was cannulated by tracheotomy (20G cannula) and lung was lavaged 
with 0.8 ml of ice-cold Hank’s balanced salt solution (HBSS) without calcium and 
magnesium for four times. Cells were centrifuged at 1,200 rpm for 10 min and 
resuspended in PBS with 1% BSA. Cytospin was prepared by centrifugation of 1 x 105 
cells in 100 µl at 600 rpm for 10 mins using Cytospin® 3 (Shandon Lipshaw) (Cytospin, 
Runcorn, Cheshire, U.K.). The cells were stained with the Liu stain (Riu CH, 1953). 
Cells were identified and differentiated into macrophages, lymphocytes, neutrophils, and 
eosinophils based on standard hematological characteristics under the light microscope. 
For each slide, 500 cells were counted and the percentage of each cell type was 
calculated. 
 
2.2.21 Statistical analysis 
 
Statistical differences were determined using SPSS, Version 11.0.1 (SPSS Inc., Chicago, 
IL, USA). For all tests, p < 0.05 was considered to indicate statistical significance. All 
standard errors shown in the figures represent the Standard Error of Mean (SEM).  
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Figure 2.2 Anatomy of mouse hind leg showing the quadriceps and tibialis anterior 
muscles. (Adapted from Sasaki S et al., 2003) 
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Figure 2.3 In vivo electroporation after DNA immunization 
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Figure 2.4 Ultrasonic nebulizer (model UltraNEB 99, DeVilbiss Health Care, 
Sommerset, PA) to generate Der p 1 aerosol for inhalation challenge.
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Figure 2.5 Whole-body plethysmography (model PLY3211, Buxco Electronics Inc., 
Troy, New York, USA). Mice were individually kept in the chambers shown at the left 






























EXPRESSION AND IMMUNOGENICITY OF MAJOR HOUSE 
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3.1 Introduction 
 
The main objective of this thesis was to develop a DNA vaccine encoding Der p 1 for allergic 
asthma. From an epidemiological point of view, Der p 1, a protein produced by 
Dermatophagoides pteronyssinus mites, is one of the top allergen candidates for dust mite 
allergy vaccine design. House dust mites are major indoor triggers of atopic allergy; the 
majority of allergic individuals are sensitized to one or more mite species that are commonly 
found in their environment; Dermatophagoides pteronyssinus is one of the three most 
common species of mites in temperate and tropical regions; the majority of mite sensitive 
patients respond to group I and group II allergens, and Der p 1 is one of the most important 
member of the group I allergens in this mixture (Meyer C et al., 1994; Platts-Mills TA et al., 
1997; Thomas WR and Smith W, 1998). The amino acid sequence is highly conserved among 
group I allergens of different mite species. Exposure and initiation of an allergic process by a 
major mite allergen may facilitate sensitization to other less prevalent allergens (Silvestri M 
et al., 1999). 
 
Der p 1 protein is a cysteine protease; its full-length cDNA encodes a precursor of 320 amino 
acid residues, including an 18-amino acid signal peptide, a proenzyme region of 80-amino 
acid, and a mature enzyme of 222 amino acid residues (Chua KY et al., 1988). Like its 
homologues papain and actinidin, Der p 1 has a two-domain structure. The left domain 
(approximately corresponding to amino acid sequence 1-116) consists of three α-helices and 
the right domain (approximately corresponding to amino acid sequence 114-222) is largely 
composed of β-pleated sheets (Greene WK et al., 1991). This assumption has recently been 
confirmed by the crystal structure of yeast expressed recombinant proDer p 1 (Fig. 1.3, Meno 
K et al., 2005). 
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The synthetic pathway of Der p 1 has imposed limitations to the production of large 
quantities of recombinant protein for immunotherapy or vaccination (Chua KY et al., 1992). 
The recombinant allergen is trapped as a zymogen inside inclusion bodies. Der p 1 
maturation does not occur naturally in bacterial or insect systems and, therefore, the protein 
has to be solubilized and renatured. Removal of the pro-sequence by autocatalysis was 
problematic and often resulted in protein degradation (Jacquet A et al., 2000; Massaer M et 
al., 2001). 
 
Genetic immunization with Der p 1 gene could be a feasible alternative strategy to develop 
useful prophylactic and therapeutic reagents for mite allergy (Hsu CH et al., 1996A; Huang 
SK et al., 1997; Spiegelberg HL et al., 1997; Raz E et al., 1996; Jilek S et al., 2001; Maecker 
HT et al., 2001; Slater JE et al., 1997; Roy K et al., 1999). In this regard, DNA sequences 
encoding the T cell epitopes have been exploited for the vaccine design (Kwon SS et al., 
2001; Jarman ER and Lamb JR, 2004). However, as indicated by the published data, 
numerous important human T cell epitopes that have been mapped were located throughout 
the Der p 1 molecule (Hales BJ and Thomas WR, 1997; O’Brien RM et al., 1994A). Given 
the complexity and polymorphic nature of the MHC genes, vaccine design using the full Der 
p 1 gene or large gene fragments would offer a broader spectrum of protective immunity in 
the highly heterogenous human populations.  
 
Since Der p 1 is a cysteine protease with demonstrated proteolytic activity (Stewart GA et al., 
1989; Hewitt CR et al., 1995; Schulz O et al., 1998A; Wan H et al., 1999), prolonged 
endogenous synthesis in a vaccinated host may have unpredictable effects. Therefore, DNA 
encoding enzymatically inactive immunogenic forms of the allergen may represent a feasible 
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and safer Der p 1 vaccine. It has been reported that the pro-enzyme peptide of cysteine 
proteases serves as an intramolecular chaperon, and is essential for correct folding of the 
mature protein (Shinde U and Inouye M, 1993). It has been shown that incorrectly folded Der 
p 1 lacked enzymatic activity (Chua KY et al., 1992; Jacquet A et al., 2000). Therefore, we 
rationale that excluding the pre-pro-region of Der p 1 in the DNA construct is a feasible 
strategy to produce immunogenic but enzymatically inactive Der p 1 in vivo. 
 
In the study described in this chapter, we evaluated IgG reactivity to native Der p 1 and 
antigen expression in vivo after immunization with Der p 1 gene or gene fragments. Various 
DNA constructs encoding either Der p 1 full-length gene or gene fragments, with or without 
its own pre-pro sequences, were evaluated. 
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Six to eight-week-old female BALB/cJ mice were purchased from Laboratory Animals 
Centre (Sembawang, Singapore). Mice were housed at the National University of Singapore 
Animal Holding Unit and cared for under institutional guidelines for the care and use of 
laboratory animals.  Immunization experiments were performed with groups of 4 to 10 
animals.  For DNA immunizations, mice were anesthetized with a cocktail of Hypnorm plus 
Midazolam provided by the Animal Holding Unit, National University of Singapore.  
 
3.2.2 Preparation of DNA constructs 
 
Mammalian expression vectors, pcDNA3, pCI-neo, and pEGFP-N3, were used in this study 
to construct the various DNA plasmids. Figure 3.1 shows the maps of these vectors. pcDNA3 
vector was purchased from Invitrogen. This vector is designed for constitutive expression of 
encoded protein in mammalian cells. It contains a CMV enhancer-promoter, a Bovine 
Growth Hormone (BGH) polyadenylation signal, and an ampicillin resistance gene. pCI-neo 
vector is another mammalian expression vector purchased from Promega. This vector 
contains similar features as the pcDNA3 vector, such as CMV enhancer and promoter, and 
the ampicillin resistance gene. It also contains a beta-globin/IgG chimeric intron located 
downstream of the CMV enhancer/promoter, which could further enhance the expression. 
Therefore, pCI-neo vector was used to construct most of the DNA constructs for the 
immunogenicity study in this chapter (Fig. 3.5). pEGFP-N3 vector was purchased from 
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Clontech. This vector contains CMV promoter as well as the DNA sequence encoding EGFP. 
Genes cloned into the multiple cloning site of pEGFP vector are expressed as fusions to the 
N-terminus of EGFP, which retain the fluorescent properties, allowing identification of 
protein expression in vivo. Therefore, this vector was used for construction of DNA plasmids 
to study in vivo expression after naked DNA immunization (Fig. 3.6). 
 
Thirteen DNA constructs were made and used for immunization in this study. Schematic 
representations of the constructs used for immunogenicity and expression study are shown in 
Fig. 3.5 and Fig. 3.6, respectively, and described as follow: Der p 1 full-length cDNA (pre-
pro-Der p 1; see Fig. 3.2 for the DNA sequence and Fig. 3.3 for the encoded amino acid 
sequence) inserted into pcDNA3 for initial immunogenicity study; Der p 1 (1-222), Der p 5 
L/Der p 1 (1-222), Der p 1 (1-116), Der p 5 L/Der p 1 (1-116), Der p 1 (114-222), and Der p 
5 L/Der p 1 (114-222), each encoding full length mature Der p 1 or fragments of mature Der 
p 1, were inserted into pEGFP for expression study or into pCI-neo for the immunogenicity 
study. 
 
The construction of plasmid pcDNA3-pre-pro-Der p 1 was carried out by insertion of the 
PCR amplified full-length cDNA fragment of Der p 1, using oligonucleotide primers (5’-
CCCGGATCCAACATGAAAATTGTTTTGGCC-3’ and 5’-GCGCTCGAGTTTAGAG 
AATGACAACATATGG-3’) and the λgt10RecλL3a Der p 1 cDNA as DNA template, into 
the BamHI and XhoI sites of mammalian expression vector pcDNA3 (InvitrogenTM Life 
Technologies). 
 
PCR was used to amplify the sequences of Der p 1 DNA coding for the N-terminal domain 
(residues 1-116) and the full-length mature protein (residues 1-222).  The sequences of the 
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synthetic oligonucleotide primers (Operon, Qiagen, Alameda, CA) specific for PCR 
amplification of Der p 1 are 5’-AATCCGGAACTAACGCCTGCAG TATCAAT-3’, 5’-
AAGGATCCATAGTTTGAGATACCGAAACGTTG-3’ and 5’-
CCTCCGGATCAAACTATTGCCAAATTTACCCA-3’. Each individual primer was 
engineered to include a unique restriction endonuclease site at its 5’ terminus for compatible 
cloning of the PCR fragment into the pEGFP-N3 (Clontech, Palo Alto, CA) expression 
vectors. The PCR amplification and cloning procedure were performed with standard 
protocols as previously described (Ausubel FM et al., current protocols in molecular 
biology). PCR fragment were cloned into pCR2.1 vector for sequence confirmation by 
automatic sequencing (ABI PRISMTM sequencing kit).  
 
In order to link the Der p 5 signal peptide sequence to the Der p 1 fragments, the pCR2.1-Der 
p 1 recombinant constructs were digested with BspEI and XhoI restriction endonucleases. The 
64-basepairs synthetic oligonucleotides corresponding to the Der p 5 leader (sense sequence 
5’-
TCGAGATCAATCATGAAATTCATCATTGCTTTCTTTGTTGCCACTTTGGCAGTTAT
GACTGTTT-3’ and anti-sense sequence 5’CCTGAAA 
CAGTCATAACTGCCAAAGTGGCAACAAAGAAAGCAATGATGAATTTCATGATTG
ATC3’) were then inserted into the BspEI and XhoI sites of the 4.7 kb vector to generate 
pCR2.1-Der p 5 L/Der p 1 (1-116), and pCR2.1-Der p 5 L/Der p 1 (1-222). The resulting 
plasmids were sequenced using ABI PRISMTM sequencing kit. 
 
To generate the pEGFP-N3-based expression vectors, the inserts encoding the Der p 5 L/ Der 
p 1 (1-116), and Der p 5 L/ Der p 1 (1-222)  fusion proteins were released from plasmids 
pCR2.1-Der p 5 L/ Der p 1 (1-116) and pCR2.1-Der p 5 L/ Der p 1 (1-222)  by digestion with 
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XhoI, BamHI and EcoRI.  Subsequently, the agarose gel purified DNA fragments were 
extracted from the gel using the QIAEX II kit and inserted into the XhoI-BamHI gap of 
pEGFP-N3 vector. The ligated plasmid DNA was then transformed into the E. coli strain 
DH5 α.  Kanamycin resistant transformants were selected by screening for pEGFP-Der p 5 L/ 
Der p 1 (1-116) and pEGFP-Der p 5 L/ Der p 1 (1-222) DNA, respectively.    Subsequent 
construction of pCI-neo-based Der p 5 L/ Der p 1 variant constructs was carried out by PCR 
amplification of the encoding sequences using three specific synthetic oligonucleotide 
primers and the DNA templates pEGFP-Der p 5 L/ Der p 1 (1-116) and pEGFP-Der p 5 L/ 
Der p 1 (1-222). The sequence of these specific primers corresponding to the Der p 5 signal 
peptide sequence, the C-terminal sequence of the N-terminal domain of Der p 1 and the C-
terminal sequence of the C-terminal domain of Der p 1 domain are 5’-
GCCTCGAGCCACCATGAAATTCATCATTGCT-3’, 5’-
GCGGATCCGCGGCCGCTTAGAGAATGACAACATATGG-3’ and 5’-
CCGCGGCCGCTAATAGT TTGAGATACCGAAACGTTG-3’, respectively. The PCR 
products were subcloned into pCR2.1 vector to generate plasmid constructs termed pCR2.1-
Der p 5 L/ Der p 1(1-116) ter and pCR2.1-Der p 5 L/ Der p 1(1-222) ter. The expression constructs 
pCI-neo-Der p 5 L/ Der p 1 (1-116) and pCI-neo-Der p 5 L/ Der p 1 (1-116) were produced 
by insertion of the Der p 5 L/ Der p 1 encoding sequences released from pCR2.1-Der p 5 L/ 
Der p 1(1-116) ter and pCR2.1-Der p 5 L/ Der p 1(1-222) ter into the XhoI and NotI sites of the pCI-
neo (Promega, Madison, WI). Similar PCR amplification strategy was employed to generate 
pCR2.1-Der p 1(1-116) and pCR2.1-Der p 1(1-222) using specific oligonucleotide primers 5’-
GCCTCGAGCCACCAGACTAACGCCTGCAGTATCATG GAAAT-3’, 5’-
GCGGATCCGCGGCCGCTTAGAGAATGACAACATATGG-3’, 5’-
CCGCGGCCGCTAATAGTT TGAGATACCGAAACGTTG-3’, the DNA templates 
pCR2.1-Der p 5 L/Der p 1(1-116) ter and pCR2.1-Der p 5 L/ Der p 1(1-222) ter. The XhoI-BstXI 
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fragments encoding for the Der p 1(1-116) and Der p 1(1-222) fusion proteins released from the 
vectors pCR2.1-Der p 1(1-116) and pCR2.1-Der p 1(1-222) were used to replace the XhoI-BstXI 
fragments of pEGFP-Der p 5 L/Der p 1(1-116) and pEGFP-Der p 5 L/ Der p 1(1-222) and resulted 
in pEGFP-Der p 1(1-116) and pEGFP-Der p 1(1-222). To generate pCI-neo-Der p 1(1-116) and pCI-
neo-Der p 1(1-222) the BstXI-NotI fragments from pCI-neo-Der p 5 L/Der p 1(1-116) and pCI-
neo-Der p 5 L/Der p 1(1-222) and the XhoI-BstXI fragments from pEGFP-Der p 1(1-116) and 
pEGFP-Der p 1(1-222) were linked together with the XhoI and NotI sites of pCI-neo, 
respectively.  
 
3.2.3 Mice immunization 
 
BALB/cJ mice were immunized under anesthesia, by intramuscular injection of 50 µl of 
naked DNA at 1µg/µl in the left quadriceps using a 1 ml insulin syringe and a 27 G needle.   
For immunization with electroporation, the front of the upper left leg was shaved, and DNA 
was injected as above, in the anterior tibialis, followed by immediate electroporation with an 
ECM 830 apparatus (BTX, Genetronics, San Diego, CA).  Electroporation was performed 
with a 0.5 cm 2-needle array inserted 2 mm deep in parallel to the muscle fibres, that 
delivered 4 pulses of 20 ms, 80V each, with a 200ms interval (Fig. 3.7). Animals received 
pEGFP-N3-Der p 1 or pCI-neo- Der p 1 constructs with or without electroporation. Serum 
was collected before (day 0) and sequentially after immunization. 
 
3.2.4 Purification of native Der p 1 and Der p 1 recombinant peptides 
 
Spent Mite Media (a gift from CSL Limited, Melbourne, Australia) was resuspended to 10% 
(w/v) in a 0.5 M NaCl in 10mM Tris-HCl pH 7.5 solution containing 1mM PMSF and 1mM 
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EDTA and the suspension was stirred at 4oC overnight.  The next day the suspension was 
centrifuged at 12,100g for 15min and the supernatant was collected for purification, using a 
protocol that was previously described (Chapman MD et al., 1980). Briefly, A monoclonal 
antibody (4C1) sepharose affinity column was equilibrated with 5 bed volumes of the 
suspension buffer and the supernatant of spent mite medium was applied to the column, Der p 
1 was eluted with 5 mM glycine in 50% ethylene-glycol pH 10 and the fractions were 
collected in tubes containing 100µl/1ml fraction of 0.2 M Na2HPO4 pH 7 neutralizing buffer.  
The peak samples were pooled, dialysed immediately against 50 mM NH4HCO3, and 
lyophilized.  The samples were resuspended in PBS and quantitated by comparison with a 
protein standard using a colorimetric assay (BioRad, Hercules, CA). 
 
Recombinant Ecoli clones producing Der p 1 recombinant peptides GST- (1-116) and GST- 
(114-222) were grown in LB medium containing 100 µg/ml of ampicillin and induced for 3 h 
with 0.5 mM IPTG (Calbiochem, LaJolla, CA).  The bacteria were pelleted and resuspended 
in TBS with 1 mM PMSF, 20 µg/ml of Dnase I, 20 µg/ml of Lysozyme and Tween 20 to 1% 
of the cell suspension. The bacteria were disrupted by sonication on ice, and the supernatant 
was collected after centrifugation. The peptides were purified by passage over a column of 
glutathione agarose beads preequilibrated in TBS, and elution of the bound material with 
10mM reduced glutathion in 50 mM Tris HCl pH 8 buffer.  The concentration of recombinant 
peptide was quantified by a colorimetric assay (Biorad, Hercules, CA) and purity was 
assessed by SDS-PAGE (Fig. 3.8).   For Western analysis, aliquots of the eluted peak were 
run on 7.5% SDS-PAGE, transferred to Hybond C nitrocellulose membranes 
(Amershampharmacia Biotech AB, Malaysia) and probed with monoclonal antibodies 6BC, 
specific for 1-116 peptide, and 1BB specific for 114-222 peptide, produced for this purpose.   
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3.2.5 Protein expression in cryosections of muscle   
 
Muscle samples from the injection site were collected at 1h, 6h, and 1, 2, 4, 7, 10, 14, 21, and 
28 days after injection.  The samples were embedded in O.C.T compound (Tissue-Tek, 
Sakura, Torrance, CA) snap frozen in liquid nitrogen and stored at –20oC. 10 µm 
cryosections were cryostatically sectioned and  mounted with fluorescence quenching 
medium (DAKO).  Fluorescent images were captured by confocal microscopy.   
 
3.2.6 Detection of antigen specific antibodies in mouse serum by ELISA 
 
Maxisorp Immuno plates (Nalge Nunc Intl, Naperville, IL) were coated with 5 µg/ml of 
native Der p 1 in 0.1M NaHCO3 pH 8.3, overnight at 4oC.  The plates were then flicked to 
remove uncoated antibody and blocked for 1 hour with a solution of 1% BSA in 
PBS/0.05%Tween 20 (washing buffer).  The plates were washed three times with PBS/tween-
20.  Dilutions of sera were added and incubated overnight at 4oC. Dilutions of standard 
mouse IgG2a or mouse IgG1 (PharMingen, San Diego, CA) were added to each plate onto 
wells coated with anti-mouse kappa light chain clone 187.1 (PharMingen).  The plates were 
washed three times and Biotin conjugated IgG2a- or IgG1- specific monoclonal antibody 
(clone LO-MG2a-7 and clone LO-MG1-2 respectively, Serotec, Oxford, England) were 
added for 1h, followed by alkaline phosphatase conjugated ExtrAvidin (Sigma-Aldrich) and 
p-Nitrophenylphosphate substrate (Sigma-Aldrich).  The Antibody Production Units of 
antigen-specific antibodies were determined by comparison of the plot of absorbance versus 
dilutions of the sample to that of the standard versus its concentration. 
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Similar methods were used for detection of peptide-specific antibodies, except that the plates 
were coated with 5 µg/ml of purified Der p1-derived peptides GST- (1-116) or GST- (114-
222) peptides.   The amount of peptide coated on each well was comparable, as determined 
by binding of peptide specific monoclonal antibodies. Replicas of the antisera were tested on 
plates coated with GST for specificity control.    
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Figure 3.1 Maps of the plasmid DNA vectors used in this chapter (Adapted from the 
websites of respective suppliers). Vector pcDNA3 is from Invitrogen; pEGFP-N3 was 
purchased from Clontech; and pCI-neo was purchased from Promega.  
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        1 gaattccttt ttttttcttt ctctctctaa aatctaaaat ccatccaaca tgaaaattgt 
       61 tttggccatc gcctcattgt tggcattgag cgctgtttat gctcgtccat catcgatcaa 
      121 aacttttgaa gaatacaaaa aagccttcaa caaaagttat gctaccttcg aagatgaaga 
      181 agctgcccgt aaaaactttt tggaatcagt aaaatatgtt caatcaaatg gaggtgccat 
      241 caaccatttg tccgatttgt cgttggatga attcaaaaac cgatttttga tgagtgcaga 
      301 agcttttgaa cacctcaaaa ctcaattcga tttgaatgct gaaactaacg cctgcagtat 
      361 caatggaaat gctccagctg aaatcgattt gcgacaaatg cgaactgtca ctcccattcg 
      421 tatgcaagga ggctgtggtt catgttgggc tttctctggt gttgccgcaa ctgaatcagc 
      481 ttatttggct taccgtaatc aatcattgga tcttgctgaa caagaattag tcgattgtgc 
      541 ttcccaacac ggttgtcatg gtgataccat tccacgtggt attgaataca tccaacataa 
      601 tggtgtcgtc caagaaagct actatcgata cgttgcacga gaacaatcat gccgacgacc 
      661 aaatgcacaa cgtttcggta tctcaaacta ttgccaaatt tacccaccaa atgtaaacaa 
      721 aattcgtgaa gctttggctc aaacccacag cgctattgcc gtcattattg gcatcaaaga 
      781 tttagacgca ttccgtcatt atgatggccg aacaatcatt caacgcgata atggttacca 
      841 accaaactat cacgctgtca acattgttgg ttacagtaac gcacaaggtg tcgattattg 
      901 gatcgtacga aacagttggg ataccaattg gggtgataat ggttacggtt attttgctgc 
      961 caacatcgat ttgatgatga ttgaagaata tccatatgtt gtcattctct aaacaaaaag 
     1021 acaatttctt atatgattgt cactaattta tttaaaatca aaatttttag aaaatgaata 
     1081 aattcattca caaaaatta 
 
Figure 3.2 cDNA sequence of pre-pro-Der p 1. Coding sequence: 50-1012; sequence 
encoding signal peptide (pre): 50-109; sequence encoding Pro region (pro): 110-343; 
sequence encoding mature peptide: 344-1009. The nucleotide sequence has been deposited to 
Genbank with accession number U11695. 
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          atg aaa att gtt ttg gcc atc gcc tca ttg ttg gca ttg agc gct gtt  
      -98  M   K   I   V   L   A   I   A   S   L   L   A   L   S   A   V 
          tat gct cgt cca tca tcg atc aaa act ttt gaa gaa tac aaa aaa gcc  
      -82  Y   A   R   P   S   S   I   K   T   F   E   E   Y   K   K   A 
          ttc aac aaa agt tat gct acc ttc gaa gat gaa gaa gct gcc cgt aaa  
      -66  F   N   K   S   Y   A   T   F   E   D   E   E   A   A   R   K 
          aac ttt ttg gaa tca gta aaa tat gtt caa tca aat gga ggt gcc atc  
      -50  N   F   L   E   S   V   K   Y   V   Q   S   N   G   G   A   I 
          aac cat ttg tcc gat ttg tcg ttg gat gaa ttc aaa aac cga ttt ttg  
      -34  N   H   L   S   D   L   S   L   D   E   F   K   N   R   F   L 
          atg agt gca gaa gct ttt gaa cac ctc aaa act caa ttc gat ttg aat  
      -18  M   S   A   E   A   F   E   H   L   K   T   Q   F   D   L   N 
          gct gaa act aac gcc tgc agt atc aat gga aat gct cca gct gaa atc  
       -2  A   E   T   N   A   C   S   I   N   G   N   A   P   A   E   I 
          gat ttg cga caa atg cga act gtc act ccc att cgt atg caa gga ggc  
       15  D   L   R   Q   M   R   T   V   T   P   I   R   M   Q   G   G 
          tgt ggt tca tgt tgg gct ttc tct ggt gtt gcc gca act gaa tca gct  
       31  C   G   S   C   W   A   F   S   G   V   A   A   T   E   S   A 
          tat ttg gct tac cgt aat caa tca ttg gat ctt gct gaa caa gaa tta  
       47  Y   L   A   Y   R   N   Q   S   L   D   L   A   E   Q   E   L 
          gtc gat tgt gct tcc caa cac ggt tgt cat ggt gat acc att cca cgt  
       63  V   D   C   A   S   Q   H   G   C   H   G   D   T   I   P   R 
          ggt att gaa tac atc caa cat aat ggt gtc gtc caa gaa agc tac tat  
       79  G   I   E   Y   I   Q   H   N   G   V   V   Q   E   S   Y   Y 
          cga tac gtt gca cga gaa caa tca tgc cga cga cca aat gca caa cgt  
       95  R   Y   V   A   R   E   Q   S   C   R   R   P   N   A   Q   R 
          ttc ggt atc tca aac tat tgc caa att tac cca cca aat gta aac aaa  
      111  F   G   I   S   N   Y   C   Q   I   Y   P   P   N   V   N   K 
          att cgt gaa gct ttg gct caa acc cac agc gct att gcc gtc att att  
      127  R   E   A   L   A   Q   T   H   S   A   I   A   V   I   I 
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          ggc atc aaa gat tta gac gca ttc cgt cat tat gat ggc cga aca atc  
      143  G   I   K   D   L   D   A   F   R   H   Y   D   G   R   T   I 
          att caa cgc gat aat ggt tac caa cca aac tat cac gct gtc aac att  
      159  I   Q   R   D   N   G   Y   Q   P   N   Y   H   A   V   N   I 
          gtt ggt tac agt aac gca caa ggt gtc gat tat tgg atc gta cga aac  
      175  V   G   Y   S   N   A   Q   G   V   D   Y   W   I   V   R   N 
          agt tgg gat acc aat tgg ggt gat aat ggt tac ggt tat ttt gct gcc  
      191  S   W   D   T   N   W   G   D   N   G   Y   G   Y   F   A   A 
          aac atc gat ttg atg atg att gaa gaa tat cca tat gtt gtc att ctc 
      207  N   I   D   L   M   M   I   E   E   Y   P   Y   V   V   I   L 
 
Figure 3.3 Deduced amino acid sequence of pre-pro-Der p 1 protein. Signal peptide (pre): -
98 - -79 (highlighted in yellow); Pro region (pro): -78 - -1 (highlighted in pink); Mature 
peptide: 1-222. Note that the cDNA sequence (bases 50-1009 in Fig. 3.1) is indicated as 
three-letter codons above the amino acids. The amino acid sequence has been deposited to 
Genbank with accession number AAB60215. The amino acids were numbered here according 
to mature Der p 1 sequence, i.e. amino acid number 1 is the first amino acid of mature Der p 
1. 
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 atg aaa ttc atc att gct ttc ttt gtt gcc act ttg gca gtt atg act 
    M   K   F   I   I   A   F   F   V   A   T   L   A   V   M   T 
 
 
Figure 3.4 Nucleotide sequence encoding the signal peptide of Der p 5 (upper line; Der p 5 
leader sequence), and the encoded amino acid sequence (lower line). The full length cDNA 
sequence and amino acid sequence of Der p 5 have been deposited to Genbank with 
accession numbers S76337 and P14004, respectively. 
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Constructs in pcDNA3 or pCI-neo for immunogenicity study 
 
Mature Dp1 (1-222) Pre Pro-regionpcDNA3-pre-pro-Der p 1  
 
Mature Dp1 (1-222) pCI-neo-Der p 1 (1-222) 
 
1st half (1-116)pCI-neo-Der p 1 (1-116) 
 
2nd half (114-222) pCI-neo-Der p 1 (114-222) 
 
Mature Dp1 (1-222) Der p 5 LeaderpCI-neo-Der p 5 L/Der p 1 (1-222) 
 
1st half (1-116)Der p 5 LeaderpCI-neo- Der p 5 L/Der p 1 (1-116) 
 
pCI-neo- Der p 5 L/Der p 1 (114-222) 2nd half (114-222) Der p 5 Leader
 
Figure 3.5 Schematic representation of the constructs used in immunogenicity study. 
Please refer to text and Fig. 3.1 for information of pcDNA3 and pCI-neo vectors; Fig. 3.2 for 
nucleotide sequence of full length Der p 1 cDNA; Fig. 3.3 for deduced amino acid sequences 
of the pre, pro and mature region of Der p 1; Fig. 3.4 for nucleotide and amino acid 
sequences of Der p 5 leader. 
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Constructs in pEGFP for in vivo expression study 
 
Mature Dp1 (1-222) pEGFP-Der p 1 (1-222) 
 
1st half (1-116)pEGFP-Der p 1 (1-116) 
 
2nd half (114-222) pEGFP-Der p 1 (114-222) 
 
Mature Dp1 (1-222) Der p 5 LeaderpEGFP-Der p 5 L/Der p 1 (1-222) 
 
1st half (1-116)Der p 5 LeaderpEGFP- Der p 5 L/Der p 1 (1-116) 
 
pEGFP- Der p 5 L/Der p 1 (114-222) 2nd half (114-222) Der p 5 Leader
 
 
Figuure 3.6 Schematic representation of the constructs used in expression study. Please 
refer to text and Fig. 3.1 for information of pEGFP vector; Fig. 3.2 for nucleotide sequence of 
full length Der p 1 cDNA; Fig. 3.3 for deduced amino acid sequences of mature region of Der 
p 1; Fig. 3.4 for nucleotide and amino acid sequences of Der p 5 leader. 
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Figure 3.7 In vivo electroporation after DNA immunization 
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Figure 3.8 Electrophoresis of purified native Der p 1 (lane 3), and recombinant Der p 1 
fragments (lane 1: 114-222; lane 2: 1-116), stained by Coomassie blue. 
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3.3 Results 
 
3.3.1 Immunogenicity of pcDNA3-pre-pro-Der p 1 plasmid    
 
To determine whether naked full length Der p 1 cDNA inserted into a mammalian expression 
plasmid could induce Der p 1-specific humoral immune responses, pcDNA3 engineered pre-
pro-mature Der p 1 plasmids were injected into the muscle of Balb/cJ mice. The animals were 
boosted using similar protocol one or two weeks after priming (Fig. 3.9). ELISA experiments 
were performed with sera from immunized mice to determine Der p 1 specific IgG2a, IgG1 
and IgE. Two injections of naked DNA given one week apart (Fig. 3.9A) induced a IgG2a 
response peak by the third week after priming that had almost returned to baseline by day 56. 
Two injections of naked DNA, given two weeks apart (Fig. 3.9B), induced two IgG2a 
response peaks. The first peak was of very low magnitude between 21 and 28 days after 
priming, and returned to baseline by day 35. The second peak occurred during the sixth week 
(day 42 sample), and the anti-Der p 1 IgG2a antibodies could still be detected by day 70 in 
this group of mice. In contrast, Der p 1 specific IgG1 and IgE were not detectable, indicative 
of predominant Th1 immunity. These results suggested that two doses of full length Der p 1 
gene given intramuscularly could produce Th1 skewed immune response to Der p 1, 
demonstrated by induction of IgG2a antibodies that recognized the native Der p 1 protein and 
lack of IgG1 and IgE, and a longer interval of two weeks between the two doses helped to 
generate more persistent antibody production, although a delay in IgG2a production is also 
observed.  
 
3.3.2 Immunogenicity of Der p 5 L/Der p 1 plasmid 
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Although the pre-pro-Der p 1 construct is capable of inducing Der p 1-specific Th1 skewed 
immune response as demonstrated in the previous section, the enzymatic activity of the in 
vivo expressed Der p 1 was of concern. To limit the possibility of production of enzymatically 
active form of Der p 1 in the vaccinated host, new constructs were made, where the 
proenzyme sequence, which is necessary for a right conformation of mature Der p 1, was 
deleted.  It was also of interest to determine if engineering a different leader peptide into the 
expression vector could turn the plasmid into a more potent immunogen. It had been shown 
that Der p 5 cDNA could successfully induce a protective response to the house dust mite 
allergen Der p 5 (Hsu CH et al., 1996). Therefore, the autologous Der p 1 leader sequence 
was replaced by the Der p 5 leader. Der p 5 L/Der p 1 (1-222) encodes the whole mature Der 
p 1 was inserted into the pCI-neo vector, which is designed to contain a beta-globin/IgG 
chemic intron to enhance protein expression. Sera from mice injected with this plasmid were 
collected sequentially and tested for the presence of Der p 1-specific antibodies. As shown in 
Fig. 3.10, the peak anti-Der p 1 IgG2a responses induced by the products of the pre-pro-Der p 
1 plasmid and chimeric Der p 5 L/Der p 1 (1-222) DNA were comparable. Der p 1 specific IgG1 
and IgE was not detectable. These data suggests that the proenzyme sequence is not necessary 
for the production of Der p 1 specific antibody, and that substitution of the Der p 1 leader 
sequence with the Der p 5 leader sequence does not result in significant differences in 
immunogenicity. 
 
3.3.3 Effect of electroporation on protein expression induced by DNA immunization 
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It has been demonstrated in the previous sections that either the pre-pro-Der p 1 construct or 
the Der p 5 L/Der p 1 (1-222) construct is immunogenic. However, the magnitude of antibody 
production observed in these experiments was low, ranging from 50 to 700 antibody 
production index units of IgG2a in all the immunized animals. Electroporation has been 
shown to increase the efficiency of DNA vaccination by permeabilization of the muscle fibers 
(Mathiesen I, 1999). To test whether electroporation could enhance the expression of Der p 1 
following DNA immunization, Der p 5 L/Der p 1 (1-222) was inserted into the pEGFP-N3 
vector, so that Der p 1 will be expressed as fusions to the N-terminus of EGFP in vivo, which 
retain the fluorescent properties and allow comparison of protein expression. Two additional 
DNA constructs, Der p 5 L/Der p 1 (1-116) encoding the N-terminal 116 amino acids and Der 
p 5 L/Der p 1 (114-222) encoding the C-terminal 109 amino acids, were also engineered into 
the pEGFP vector. As has been discussed previously, the N-terminal domain (1-116) and C-
terminal domain (114-222) is structurally quite different, with the N-terminal domain forming 
α-helices and the C-terminal domain forming β-pleated sheets (Greene WK et al., 1991; Meno 
K et al., 2005). It is of interest to determine whether the structural differences could result in 
any differences in protein expression and immunogenicity. 
 
Mice were immunized intramuscularly with or without electroporation by PBS or the above 
described pEGFP constructs on day 0. Cryosections of the muscle samples were collected 4 
days after the injection (the time point of muscle collection was determine by kinetic study as 
shown in Fig. 3.16, which will be discussed in Section 3.3.6). Expression of Der p 1 protein 
or fragments, indicated by fluorescence from EGFP, was observed and compared using 
confocal microscopy. As it is shown in Fig. 3.11, intramuscular injection without 
electroporation resulted in low level in vivo expression for either Der p 5 L/Der p 1 (1-222),  
Der p 5 L/Der p 1 (1-116), or Der p 5 L/Der p 1 (114-222). In contrast, immunization with 
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electroporation resulted in significant increase in protein expression for Der p 5 L/Der p 1 (1-
222) and Der p 5 L/Der p 1 (1-116), while the increase for the Der p 5 L/Der p 1 (114-222) by 
electroporation is not significant. 
 
3.3.4 Effect of electroporation on immunogenicity of DNA vaccination 
 
It is next studied whether the increased protein expression by electroporation could further 
result in enhanced immune response. Mice were immunized with pCI-neo-Der p 5 L/Der p 1 
(1-222), pCI-neo-Der p 5 L/Der p 1 (1-116), or pCI-neo-Der p 5L/Der p 1 (114-222), with or 
without electroporation. Der p 1-specific IgG2a in the sera was detected by ELISA. As shown 
in Fig. 3.12, both the frequency of responders and the general anti-Der p 1 IgG2a titers were 
significantly increased by electroporation for Der p 5 L/Der p 1 (1-222) and Der p 5 L/Der p 1 
(1-116) constructs. The long-lasting antibody response induced by these 2 plasmids using 
naked DNA injection with electroporation is demonstrated and shown in Figure 3.13. Anti-
Der p 1 antibodies peaked between days 56 and 101 for both constructs. Detectable 
circulating antibodies persisted for at least 128 days after the last plasmid injection. It was 
noted, however, that the Der p 5 L/Der p 1 (114-222) construct did not induce any Der p 1 
specific antibody (IgG2a, IgG1, or IgE) production, with or without electroporation. 
 
No Der p 1-pecific IgE was induced by any of the constructs. Der p 1-specific IgG1 was 
detected in mice immunized with Der p 5 L/Der p 1 (1-222) or Der p 5 L/Der p 1 (1-116). The 
levels of Der p 1-specific IgG2a and IgG1 antibodies in animals receiving these two plasmids 
were compared. The control vector did not induce an anti-Der p 1 antibody response. As 
shown in Figure 3.14, both Der p 5 L/Der p 1 (1-116) and Der p 5 L/Der p 1(1-222) 
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immunization resulted in a skewed antibody response dominated by IgG2a antibodies, 
especially in mice receiving the Der p 5 L/Der p 1 (1-222) plasmid. The Der p 5L/Der p 1 (1-
116) plasmid induced relatively larger amounts of IgG1 as compared to the Der p 5 L/Der p 1 
(1-222) construct. 
 
3.3.5 Immunogenicity of leaderless plasmids 
 
It has been demonstrated in the previous sections that the chimeric plasmids Der p 5 L/Der p 
1 (1-222) and Der p 5 L/Der p 1 (1-116) could induce Der p 1-specific humoral immune 
response, which could be further enhanced by electroporation. It is of interest to see whether 
the Der p 5 leader sequence is necessary at all to induce anti-Der p 1 antibody production. 
Two leaderless plasmids encoding either the complete mature sequence of Der p 1, pCI-neo-
Der p 1 (1-222), or the first 116 amino acids, pCI-neo-Der p 1 (1-116), were designed as 
described in Materials and Methods (Fig. 3.5). These plasmids were administered on days 0 
and 21 with electroporation, and the results of this experiment are shown in Fig. 3.15. In the 
absence of a signal peptide (leader sequence), the anti-Der p 1 antibody response to pCI-neo-
Der p 1 (1-222) was very low (Fig. 3.15A), and for pCI-neo-Der p 1 (1-116) it was below 
detection levels (Fig. 3.15B).  
 
The lack of detection of a significant anti-Der p 1 response in the mice immunized by pCI-
neo-Der p 1 (1-116) could result from the absence of native epitopes in the expressed product 
of this leaderless plasmid. To explore this possibility, a recombinant peptide corresponding to 
the first half of Der p 1, amino acid sequence 1-116, was produced and used to coat the 
ELISA plates. Anti-Der p 1 monoclonals specific for the 1-116 domain were used to 
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standardize the test. Figure 3.15B shows that the anti-peptide response induced by leaderless 
plasmids was also insignificant. These results indicate that a leader sequence is required to 
induce antibodies to Der p 1 by DNA immunization. 
 
3.3.6 Der p 1 expression after DNA immunization   
 
Next we examined whether the lack of a prominent humoral response to leaderless Der p 1 
constructs was due to a failure to express these proteins in vivo. pEGFP-N3 constructs 
encoding Der p 1 amino acids 1-116, or the chimeric Der p 5  L/Der  p 1 (1-116) were 
produced and injected intramuscularly.  The Der p 1 sequence was inserted 5’ of the GFP 
reporter sequence; therefore, fluorescence reported Der p 1 fragment translation.  
Cryosections of injected muscle were observed by confocal microscopy. In the absence of 
electroporation, naked plasmids resulted in very low frequency of dimly fluorescent cells 
(Fig. 3.11). Naked DNA injection and electroporation resulted in marked expression of 
pEGFP-Der p 5 L/Der p 1 (1-116). The kinetics of the fluorescent signal were determined in 
muscle samples collected on days 1, 2, 4, 7, 10, 14, 21 and 28 after injection. Three animals 
were examined for every time point and representative images are shown in Figure 3.1.6. 
 
Expression of Der p 5 L/Der p 1 (1-116)-GFP was consistent, widespread, and frequently 
intense. It could be observed a few hours after immunization and continued to increase for a 
week. Expression was maintained at plateau levels for 7 to 14 days. 21 days after 
immunization, expression was lower and barely detectable on day 28. 
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Surprisingly, the fluorescence emitted by muscle transfected with leaderless pEGFP-Der p 1 
(1-116)  was just as intense as that observed for animals injected with pEGFP-Der p 5 L/Der 
p 1 (1-116) (Fig. 3.16). These results suggest that the lack of antibody response to the 
leaderless construct is not due to the lack of protein expression. 
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Figure 3.9 Kinetics of the anti-Der p 1 antibody response induced by intramuscular 
injection of pcDNA3-pre-pro-Der p 1 plasmid. A.  Mice were injected on day 0 and boosted 
on day 7. Sera were collected weekly and tested by ELISA on plates coated with native Der p 
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1. B.  Mice were injected on day 0 and boosted on day 14. Sera were collected and tested as 
in A. Each line represents the Ig titer of an individual mouse serum. IgG1 and IgE anti-Der p 
1 antibodies were undetectable. Note that a weak point in this experiment was noticed when 
writing up this thesis. Although pre-immune serum served as negative controls, inclusion of 
vector controls will make the data more convincing and scientifically valuable. 
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Figure 3.10 Comparison of the anti-Der p 1 antibody response induced by intramuscular 
injection of the pcDNA3-pre-pro-Der p 1 plasmid  (left panel) or the pCI-neo-Der p 5 L/Der 
p 1 (1-222) construct (right panel). Mice were immunized with respective DNA constructs on 
day 0 and day 14, and sera were collected weekly and tested by ELISA. Each dot represents 
the peak Ig titer response of an individual mouse. Statistically, there was no difference 
between the 2 groups, as determined by the student t test. Note that this experiment helped us 
to quickly prove the feasibility of deleting pre pro sequences of Der p 1. However, the 
experiment design did not allow us to further characterize the effects of other aspects of the 
new construct. Additional experiments were described in section 3.3.5 to investigate the 
effects of Der p 5 leader. 
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Figure 3.11 Electroporation (EP) increased expression of Der p 1-GFP after intramuscular 
injection of DNA constructs. Cryosections of muscle samples were collected 4 days after 
immunization with PBS, pEGFP-Der p 5 L/Der p 1 (1-222), pEGFP-Der p 5 L/Der p 1 (1-
116), or  pEGFP-Der p 5 L/Der p 1 (114-222), with or without  electroporation. Green 
fluorescence was observed using confocal microscopy.  
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Figure 3.12 Electroporation increases the frequency of responders and the titer of anti-Der 
p 1 IgG2a. Each panel represents a group of animals intramuscularly injected with one of the 
three constructs pCI-neo-Der p 5 L/Der p 1 (1-222), pCI-neo-Der p 5L/Der p 1 (1-116), or 
pCI-neo-Der p 5L/Der p 1 (114-222), with or without electroporation, on days 0 and 21. Der 
p 1 specific IgG2a in the sera was detected by ELISA. The two left panels show the data from 
animals receiving naked plasmid by intramuscular injection without electroporation. The two 
right panels show the data from animals receiving naked plasmid by intramuscular injection 
with electroporation. Each dot represents the peak Ig titre of an individual mouse. In Der p 5 
L/Der p 1 (114-222) immunized mice, no Der p 1 specific antibody response was detected. 
The statistical significance of differences of means between different groups were p <0.05 
(Der p 5 L/Der p 1 (1-222) with or without electroporation) and p<0.01 (Der p 5 L/Der p 1 (1-116) 
with or without electroporation), as determined by the Student t test. Note that a log scale was 
used in this figure to make the antibody titre generated without electroporation visible. 
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Figure 3.13 Persistent anti-Der p 1 antibody response after Der p 1 DNA immunization 
with electroporation. Mice received pCI-neo-Der p 5 L/Der p 1 (1-116) or pCI-neo-Der p 5 
L/Der p 1 (1-222) I.M. with electroporation on days 0 and 21. Sera from 5 mice in each 
groups were collected periodically and the titers of Der p 1-specific IgG2a in serum were 
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Figure 3.14 Preferential induction of Der p 1-specific IgG2a. The mice received pCI-neo-
Der p 5 L/Der p 1 (1-116) (left panel) or pCI-neo-Der p 5 L/Der p 1 (1-222) (right panel) 
with electroporation on days 0 and 21. Serum samples were collected on day 101 and assayed 
by ELISA. The statistical significance of differences of means between the concentration of 
Der p 1 specific IgG2a and IgG1 antibodies for both constructs were p <0.02, as determined 
by the Student t test. 
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Figure 3.15 Leaderless plasmids did not elicit a significant antibody response. Mice 
received pCI-neo-Der p 1 (1-222) (A) or pCI-neo-Der p 1 (1-116) (B) with electroporation on 
day 0 and day 21. Detection of IgG2a was assayed on Der p 1-coated plates (solid line) or on 
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1-116 peptide coated plates (dashed line). Each line represents one individual mouse. Note 
that this experiment was performed on the same batch of mice that were used in Fig. 3.13 and 
Fig. 3.14. The results shown there helped to validate the negative result shown in this 
experiment. 
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Figure 3.16 Time course of Der p 1-EGFP expression in the muscle.  Cryosections from 
injected muscles were collected at different times after immunization with electroporation, 
and fluorescence was detected under confocal microscopy. Panel A: representative sections 
of muscle from mice injected with PBS. Panels B to K: sections of muscle from mice injected 
with pEGFP-Der p 5 L/Der p 1 (1-116), collected 1h, 6h, 24h, days 2, 4, 7, 10, 14, 21, or 28 
after immunization, respectively. Panel L: representative section of muscle from mice 
injected with leaderless pEGFP-Der p 1 (1-116) collected 4 days after injection. 
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3.4 Discussion 
 
In this study we demonstrated that DNA immunization with plasmids encoding the complete 
Der p 1 sequence or fragments of it induced antibodies against the native allergen. Constructs 
encoding the full-length mature protein (amino acids 1-222), the globular predominantly α-
helix domain (amino acids 1-116), or the β-sheet predominant domain (114-222) were 
produced (Fig. 3.5, Fig. 3.6). Each of the constructs was inserted into the pEGFP-N3 reporter 
plasmid to determine its expression, or into pCI-neo for immunization. 
 
It was first determined that plasmid immunization with DNA carrying the complete Der p 1 
cDNA sequence, pcDNA3-pre-pro-Der p 1, could elicit antibodies with native Der p 1 
specificity (Fig. 3.9). At least two immunizations were required to detect the response. A 
booster injection given two to three weeks after the primary immunization resulted in 
circulating anti-Der p 1 antibodies for over 2 months.  
 
The design of the subsequent plasmids was based on several structural considerations. The 
pre-sequences of other cysteine proteases such as human cathepsin B and papain have been 
reported to be cytotoxic for E. coli in which they impaired protein synthesis (Chan MM and 
Bevan MJ, 1988; Vernet T et al., 1989). Therefore, we designed plasmids in which the Der p 
1 signal peptide was replaced by that of another mite allergen, Der p 5. The proenzyme 
sequence was deleted to avoid the production of enzymatically active Der p 1 in vivo. In order 
to enhance immunity, we tested these different constructs with different immunization 
protocols. Our results showed the antibodies induced by pro-region deleted, pre-region 
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substituted pCI-neo-Der p 5 L/Der p 1 (1-222) were comparable to those induced by full 
length Der p 1 DNA (Fig. 3.10). 
 
Addition of electroporation to the immunization protocol greatly enhanced both the frequency 
of responders (90 to 100% of the mice for all experiments) and the titer of anti-Der p 1 
antibodies. As shown for other DNA vaccines (Mathiesen I, 1999), electroporation enhances 
uptake of genes by permeabilization of the muscle fibers, and this results in a very high 
frequency of transfected bundles as well as higher intensity of expression. The enhancement 
of immunity apparently follows the increased availability of antigen (Fig. 3.11). Either the 
Der p 5 L/Der p 1 (1-116) fragment or the Der p 5 L/Der p 1 (1-222) resulted in transfectant 
protein synthesis and in the induction of comparative antibody responses (Fig. 3.12, Fig. 
3.13). 
 
While the humoral response was still dominated by IgG2a, it is noteworthy that the 
enhancement of the overall level of humoral response by electroporation also induced 
detectable amounts of IgG1 anti-Der p 1, in particular when using the Der p 5L/Der p 1 (1-
116)  (Fig. 3.14). The reason for one plasmid inducing a greater isotype shift than another is 
not clear. It could be due to higher levels of secretory protein. Although IgG1 is usually 
referred to as a Th2 antibody, IL-12-dependent IgG1 production has also been demonstrated 
(Faquim-Mauro EL et al., 1999). Whether the IgG1 anti-Der p 1 induced in this case is 
indicative of Th1 or Th2 response needs to be determined in the T cell level. 
 
Immunization with leaderless constructs (Fig. 3.15) resulted in no detectable antibody 
induction. This was confirmed by testing the antisera not only on native Der p 1, but also 
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recombinant peptides corresponding to the first 116 amino acids, GST- (1-116), or the second 
109 amino acids domain, GST- (114-222). Even if the conformation of the leaderless product 
induced antibodies that did not recognize the native allergen, antibodies specific for 
continuous epitopes present in the denatured sequence should be detected in this assay. Der p 
5 leader constructs induced high titers of anti-peptide antibodies and still no response could be 
detected when immunizing with the leaderless construct. 
 
It was reasoned that the lack of humoral response was possibly due to the lack of expression 
of the leaderless plasmids. In order to address this issue, immunogenic Der p 5 L/Der p 1 (1-
116) constructs or the leaderless Der p 1 (1-116) was each inserted into a reporter vector, 
pEGFP-N3. Fluorescence was indicative of biosynthesis of the inoculated gene. Confocal 
examination revealed that muscle cryosections transfected with Der p 5 L/Der p 1 (1-116) had 
bright green spots early after injection that extended to cover whole muscle bundles for 
extended periods of time. Surprisingly, the pictures looked quite similar for cryosections of 
muscles inoculated with Der p 1 (1-116). We conclude that the lack of antibody response was 
not due to lack of protein expression. With the leaderless constructs, we observed green 
fluorescence of similar intensity in the muscle samples, while there is no detectable antibody 
response. This could be possibly due to the different localization of the expressed protein. 
When the protein is expressed extracellularly, it can be endocytosed by antigen presenting 
cells, and processed in lysosome, loaded onto MHC class II molecules, so as to stimulate the 
CD4+ T cells, which is critical for the antibody production. However, when the protein is 
expressed in the cytoplasm, most likely it will enter the endogenous antigen presenting 
pathway, in which case the processed peptides are loaded onto MHC class I molecules and 
have less chance to activate CD4+ T cells. This finding raises the possibility that leaderless 
constructs exclusively induce cellular immunity, which could be useful for cancer and 
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infectious diseases. However, for allergic asthma, where CD4+ T cells play an important role, 
we propose that the leadless construct has to be used in combination with other strategies that 
could stimulate CD4+ T cells. 
 
It is noted that the Der p 5 L/Der p 1 (114-222) constructs encoding the C-terminal domain of 
Der p 1 did not result in any detectable antigen expression (Fig. 3.11) or antibody production. 
It is possible that this domain could not be correctly folded as a fragment and was degraded 
by the Ubiquitin-proteosome system. In this scenario, DNA vaccine design using full length 
mature Der p 1 sequence could be a better strategy. 
 
In the next chapter, further optimization will be studied to achieve higher immunogenicity, 















OPTIMIZATION OF IMMUNE RESPONSES INDUCED BY 
DER P 1 DNA IMMUNIZATION 
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4.1  Introduction 
 
It has been demonstrated in the previous chapter that intramuscular injection of plasmid 
DNA containing the Der p 1 gene sequence without its own pre and/or pro regions could 
induce the expression of Der p 1 in vivo and primed significant Der p 1-specific Th1 
skewed immune responses. It was also evident that incorporation of a signal peptide from 
another mite allergen gene, Der p 5, resulted in a construct that could also induce Der p 1 
specific IgG2a, and the use of electroporation could further enhance the humoral 
response. However, the relatively lower levels of immune responses observed, as 
compared to that induced by the conventional protein immunizations (Letvin, 2005), 
prompted us to generate further modifications to improve the immunization efficiency. 
 
The pVAX1 vector was chosen to be the plasmid backbone to carry out the modifications 
described in this chapter. pVAX1 is a commercial vector from Invitrogen. It is designed 
according to the guidelines and regulations of the Food and Drug Administration, Center 
for Biologics Evaluation and Research (FDA CBER) for vectors to be used in human 
DNA vaccination protocols (Food and Drug Administration, 1996). It contains a human 
cytomegalovirus immediate-early (CMV) promoter, a bovine growth hormone (BGH) 
polyadenylation signal, and a kanamycin resistance gene. This vector is engineered to be 
simple and does not contain any unnecessary sequences, thus minimizing the possibility 
of homologous recombination with human genome and, therefore, it is a safe and useful 
vector for DNA vaccine research in general.  
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As indicated by data shown  in the previous chapter that the pro-enzyme sequence of Der 
p 1 may not be necessary for the induction of specific immunity and, therefore, it could 
be excluded in the design of plasmid DNA vaccine construct. Exclusion of the pro-
enzyme could be a rational strategy to disrupt the correct folding of the mature protein so 
as to eliminate the possibility of expressing enzymatically active Der p 1 in vivo. Such 
strategy can also help to reduce the potential and undesirable risk of sensitization resulted 
from Der p 1 gene immunization, making the vaccine safer for the prophylactic and 
therapeutic use. In this study, DNA constructs encoding Der p 1 with or without the pro-
region were evaluated, aiming to gain more information for the DNA vaccine design.   
 
The second aspect of modification is the choice of a signal peptide sequence. It is known 
that a signal peptide is necessary for the encoded protein to be secreted, and the secreted 
protein can be taken up by antigen presenting cells, processed and presented in the 
context of MHC class II molecules, so as to prime the CD4+ T cells (Shortman et al, 
2002). As observed in the previous chapter, the plasmid construct containing a signal 
peptide sequence from Der p 5 mite allergen induced much higher levels of immune 
responses than the one without it. It is, therefore, hypothesized that a signal peptide that 
works more efficiently in the mammalian system could further boost the humoral and 
cellular immune responses. In this regard, the feasibility of using a mouse Igκ leader 
sequence to improve magnitude of the DNA- induced immune response was tested.   
 
Another way to enhance the DNA vaccine efficiency is to increase the in vivo antigen 
expression levels post DNA immunization. Genes in different organisms have non-
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random and distinct usage of synonymous codons. This phenomenon is known as codon 
usage bias (Grantham R et al., 1980; Grantham R et al., 1981). Codon usage bias usually 
reflects the relative abundance of the cognate tRNAs, and is thus related to the efficiency 
of mRNA translation. It has been demonstrated that expression of foreign proteins could 
be enhanced by the change of the codon usage of the foreign genes according to the 
preferences of the host cells, or by co-expression of the tRNA genes that are relatively 
rare in the host cells (Buell G et al., 1985; Devlin PE et al., 1988; Brinkmann U et al., 
1989; Del Tito BJ Jr et al., 1995; Massaer M et al., 2001). Recently, codon usage 
optimization was also being used to enhance the efficiency of plasmid DNA vaccines 
encoding Listeria monocytogenes, tetanus, HIV, malaria, and mycobacterial antigens 
(Uchijima M et al., 1998; Stratford R et al., 2000; Deml L et al., 2001; Narum DL et al., 
2001; Ko HJ et al., 2005). This strategy was being tested in this study aiming to increase 
the in vivo antigen expression levels and further enhance the magnitude of the desired 
immune responses. Furthermore, since the mammalian species have similar codon usage 
to human (Sharp PM et al., 1988), it is, therefore, feasible to test the efficacy of codon 
optimized constructs in the mouse model. 
 
In addition to the various modifications at the DNA construct level, I also explored a new 
immunization strategy to optimize the DNA-induced immune responses. It was reported 
that the relatively lower levels of Th1 immunity primed by DNA vaccine could be greatly 
enhanced by boosting with recombinant protein supports the idea of mixed modality 
approach (Doria-Rose NA and Haigwood NL, 2003). In this regard, the DNA prime – 
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protein boost protocol was performed and evaluated with the various modified DNA 
constructs in this study as another optimization strategy. 
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4.2 Materials and methods 
 
4.2.1 Construction of Der p 1 DNA plasmids 
 
The construction of plasmids was carried out by conventional molecular cloning 
techniques (Ausubel FM et al., Current Protocols in Molecular Biology). In general, 
cDNA sequences encoding full length or fragments of Der p 1 and mouse Igκ chain 
leader sequence were amplified by polymerase chain reaction (PCR) using 
oligonucleotide primers and the λgt10RecλL3a Der p 1 cDNA or pSecTag2A (see Fig. 
4.1 for the map of the vector and Fig. 4.2 for detailed sequence information) as DNA 
templates. The codon optimized Der p 1 gene (see Fig. 4.4 for the optimized DNA 
sequence, Fig. 4.5 for a comparison with the original sequence) was designed based on 
codon preference of highly expressed human transcripts (Table 4.1). Briefly, partially 
overlapping oligonucleotides (Table 4.2) spanning the mature part of Der p 1 coding 
sequence were synthesized and used to generate the codon optimized DNA fragment 
(hmDerp1) in a two-step PCR amplification (Massaer M et al., 2001; Fig. 4.6). The 
mouse Igκ light chain signal sequence (mκ, see Fig. 4.3 for sequence information) was 
amplified from the pSecTag vector (Fig. 4.1), tagged in-frame to the 5’ end of Der p 1 
genes by PCR, and subsequently the entire DNA fragment were cloned into the pVAX1 
expression vector and DNA sequence confirmed. Please refer to Fig. 4.7 for a schematic 
representation of the constructs studied in this chapter, and Fig. 4.8 for the ethidium 
bromide stained gel image. 
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4.2.2 DNA immunization with in vivo electroporation and protein boost 
 
DNA immunization and in vivo electroporatioin was performed on six to eight weeks old 
female Balb/cJ mice as described in chapter 2, section 2.2.15. Briefly, anesthetized mice 
were then immunized by intramuscular injection of 50 µl of naked DNA (1 µg/µl) in the 
left anterior tibialis using a 1 ml insulin syringe and a 27 G needle, followed by 
immediate electroporation with an ECM 830 apparatus (BTX, Genetronics, San Diego, 
CA). Mice were boosted the same way in the other leg 7 days later. Mice were further 
boosted intraperitoneally with 25 µg  native Der p 1 protein adsorbed in 4 mg of 
aluminum hydroxide gel (Amphojel®, Whitehall Laboratories, NSW, Australia) at a final 
volume of 200 µl on day 14. Serum was collected before (day 0) and sequentially after 
immunization. A schematic representation of the immunization protocol can be found in 
Fig. 4.9. 
 
4.2.3 Purification of native Der p 1 by monoclonal antibody affinity 
chromatography 
 
Native Der p 1 was purified from spent mite media by mAb 4C1 affinity chromatography 
as described in Chapter 2, Section 2.2.2. Briefly, spent mite media extracts were passed 
through tandem 4C1 columns and the columns were washed with TBS until the OD280nm 
had reached zero. The bound native Der p 1 was eluted with 10 mM Glycine, 50% 
ethylene glycol, pH 10. The eluents were neutralized with 1 M Tris-HCl, pH 6.5 and 
dialysed immediately against PBS and quantitated by comparison with a protein standard 
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using a colorimetric assay (BioRad, Hercules, CA, USA). The purity and identity of Der 
p 1 was confirmed by SDS-PAGE and Western blot. 
 
4.2.4 Detection of Der p 1 specific mouse immunoglobulin responses 
 
The levels of Der p 1 specific IgE, IgG1, and IgG2a were determined by ELISA as 
described in Chapter 2, Section 2.2.9. Mouse sera were incubated in duplicate with the 
Der p 1 coated wells for overnight at 4°C. Biotin-conjugated monoclonal rat anti-mouse 
IgE (R19-15), anti-mouse IgG1 (G1-1.5) and anti-mouse IgG2a (R35-92) were used for 
detection and followed by addition of ExtrAvidin-alkaline phosphatase. Signals were 
developed by addition of p-Nitrophenylphosphate substrate. ELISA index unit was 
defined as the OD405nm reading corresponding to the reading of 1 ng/ml of purified mouse 
IgE, IgG1, or IgG2a in a sandwich ELISA with anti-mouse Igκ as the capture antibody in 
the same plate. All the antibodies used were purchased from Pharmingen (Pharmingen, 
San Diego, CA). 
 
4.2.5 Flow cytometry analysis 
 
4.2.5.1 Cell  surface marker staining and Flow Cytometry  
For staining of cell surface markers, cells were washed and suspended in 1 x PBS 
containing 1% (v/v) FCS and incubated with anti-mouse specific fluorescence labeled 
monoclonal antibodies (Pharmingen, San Diego, CA, USA) for 30 min on ice in 5 ml 
Falcon® polystyrene round-bottom tube (Becton Dickson, NJ, USA). Cells were washed 
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twice and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, CA, USA) 
using the CellQuest program. 
 
4.2.5.2 Intracellular cytokine staining 
Intracellular cytokine staining was done by modification of a standard method from 
PharMingen. A 24-well plate was coated with 200 µl/well of anti-CD3 mAb (10 µg/ml) 
diluted in PBS and incubated at 37oC for 2 hrs. The plate was washed with 1 ml of PBS. 
In each well a total of 2x106 cells in 1 ml culture medium were added and cells were 
cultured for 10 hrs in the presence of 2 µg/ml of rat anti-mouse CD28 mAb and 3 µM of 
monensin (Sigma, St. Louis, MO USA). Cells were harvested and stained for surface 
markers as described in Section 2.2.14.1. Subsequently, cells were fixed and 
permeabilized with 0.1% saponin (Sigma, St. Louis, MO USA)/4% paraformaldehyde 
(BDH Laboratory supplies, England) for 30 mins at room temperature. After washing the 
cells with 01% saponin/1%BSA/PBS, the cells were further stained with fluorescence 
labeled anti-IL-4, or IFN-γ mAbs for another 30 min. The cells were then washed twice 
with 0.1% saponin/1%BSA/PBS and re-suspended in 1% paraformaldehyde/PBS. Flow 
cytometry was performed using FACScalibur as described in section 4.2.4.1.
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Figure 4.1 Maps of the pVAX1 and pSecTag vectors both from Invitrogen (adapted 
from www.invitrogen.com).  
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    1 gaattccttt ttttttcttt ctctctctaa aatctaaaat ccatccaaca tgaaaattgt 
   61 tttggccatc gcctcattgt tggcattgag cgctgtttat gctcgtccat catcgatcaa 
  121 aacttttgaa gaatacaaaa aagccttcaa caaaagttat gctaccttcg aagatgaaga 
  181 agctgcccgt aaaaactttt tggaatcagt aaaatatgtt caatcaaatg gaggtgccat 
  241 caaccatttg tccgatttgt cgttggatga attcaaaaac cgatttttga tgagtgcaga 
  301 agcttttgaa cacctcaaaa ctcaattcga tttgaatgct gaaactaacg cctgcagtat 
  361 caatggaaat gctccagctg aaatcgattt gcgacaaatg cgaactgtca ctcccattcg 
  421 tatgcaagga ggctgtggtt catgttgggc tttctctggt gttgccgcaa ctgaatcagc 
  481 ttatttggct taccgtaatc aatcattgga tcttgctgaa caagaattag tcgattgtgc 
  541 ttcccaacac ggttgtcatg gtgataccat tccacgtggt attgaataca tccaacataa 
  601 tggtgtcgtc caagaaagct actatcgata cgttgcacga gaacaatcat gccgacgacc 
  661 aaatgcacaa cgtttcggta tctcaaacta ttgccaaatt tacccaccaa atgtaaacaa 
  721 aattcgtgaa gctttggctc aaacccacag cgctattgcc gtcattattg gcatcaaaga 
  781 tttagacgca ttccgtcatt atgatggccg aacaatcatt caacgcgata atggttacca 
  841 accaaactat cacgctgtca acattgttgg ttacagtaac gcacaaggtg tcgattattg 
  901 gatcgtacga aacagttggg ataccaattg gggtgataat ggttacggtt attttgctgc 
  961 caacatcgat ttgatgatga ttgaagaata tccatatgtt gtcattctct aaacaaaaag 
 1021 acaatttctt atatgattgt cactaattta tttaaaatca aaatttttag aaaatgaata 
 1081 aattcattca caaaaatta 
 
Figure 4.2 cDNA sequence of pre-pro-Der p 1. Nucleotides 110-343 encode the pro 
region of Der p 1. Nucleotides 344-1009 encode mature Der p 1. Relevant part of the 
cDNA sequence was amplified and inserted into the pVAX1 vector to make different 
constructs. The nucleotide sequence has been deposited to Genbank with accession 
number U11695. 
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atg gag aca gac aca ctc ctg cta tgg gta ctg ctg ctc tgg gtt cca ggt tcc  
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S  
act ggt gac gcg gcc 





Figure 4.3 Nucleotide sequence (shown as three-letter codons) encoding the signal 
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   1 accaacgcct gcagcatcaa cggcaatgcc cccgctgaga ttgatctgcg ccagatgagg     
  61 accgtgactc ccatccgcat gcaaggcggc tgcgggtctt gttgggcctt ctcaggcgtg  
 121 gccgcgaccg agtctgcata cctcgcgtat cggaatcaga gcctggacct cgctgagcag  
 181 gagctcgttg actgcgcctc ccaacacgga tgtcatgggg atacgattcc cagaggtatc  
 241 gaatacatcc agcataatgg cgtcgtgcag gaaagctatt accgatacgt agctagggag  
 301 cagtcctgcc gccgtcctaa cgcccagcgc ttcggcattt ccaactattg ccagatctac  
 361 ccccctaatg tgaacaagat cagggaggcc ctggcgcaga cgcacagcgc catcgctgtc  
 421 atcatcggaa tcaaggatct ggacgcattc cggcactatg acgggcgcac aatcatccag  
 481 cgcgacaacg gataccagcc aaactatcac gcggtcaaca tcgtgggtta ctcgaacgcc  
 541 cagggggtgg actactggat cgtgcggaac agttgggaca ccaactgggg cgacaacggc  
 601 tacggctact ttgccgccaa catcgacctg atgatgatcg aagagtaccc gtacgtggtg  





Figure 4.4 Codon optimized mature Der p 1 DNA sequence with a stop codon 
(underlined) in the 3’ end.  This optimized sequence was prepared by introduction of 
silent mutations. Therefore, it encodes the same amino acid sequence as the original 
sequence (for the original sequence, see Fig. 4.2, nucleotides 344-1009; for a comparison, 
see fig. 4.5). Partial overlapping oligonucleotides spanning the mature part of the 
optimized Der p 1 coding sequence were synthesized and used to generate the codon 
optimized DNA sequence in a two-step PCR amplification as described in Section 2.2.1. 
The correct sequence was confirmed by DNA sequencing. 
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Optim: 1   accaacgcctgcagcatcaacggcaatgcccccgctgagattgatctgcgccagatgagg  
           || ||||||||||| ||||| || ||||| || ||||| || ||| |||| || ||| |  
Origi: 1   actaacgcctgcagtatcaatggaaatgctccagctgaaatcgatttgcgacaaatgcga  
 
                                                                        
Optim: 61  accgtgactcccatccgcatgcaaggcggctgcgggtcttgttgggccttctcaggcgtg  
           || || |||||||| || |||||||| ||||| || || |||||||| ||||| || ||  
Origi: 61  actgtcactcccattcgtatgcaaggaggctgtggttcatgttgggctttctctggtgtt  
 
                                                                        
Optim: 121 gccgcgaccgagtctgcatacctcgcgtatcggaatcagagcctggacctcgctgagcag  
           ||||| || || || || ||  | || || || |||||     |||| || ||||| ||  
Origi: 121 gccgcaactgaatcagcttatttggcttaccgtaatcaatcattggatcttgctgaacaa  
 
                                                                        
Optim: 181 gagctcgttgactgcgcctcccaacacggatgtcatggggatacgattcccagaggtatc  
           ||  | || || || || ||||||||||| |||||||| ||||| |||||  | |||||  
Origi: 181 gaattagtcgattgtgcttcccaacacggttgtcatggtgataccattccacgtggtatt  
 
                                                                        
Optim: 241 gaatacatccagcataatggcgtcgtgcaggaaagctattaccgatacgtagctagggag  
           ||||||||||| |||||||| ||||| || |||||||| || |||||||| ||  | ||  
Origi: 241 gaatacatccaacataatggtgtcgtccaagaaagctactatcgatacgttgcacgagaa  
 
                                                                        
Optim: 301 cagtcctgccgccgtcctaacgcccagcgcttcggcatttccaactattgccagatctac  
           || || ||||| || || || || || || ||||| || || ||||||||||| || ||| 
Origi: 301 caatcatgccgacgaccaaatgcacaacgtttcggtatctcaaactattgccaaatttac  
 
                                                                        
Optim: 361 ccccctaatgtgaacaagatcagggaggccctggcgcagacgcacagcgccatcgctgtc  
           || || ||||| ||||| ||  | || ||  |||| || || |||||||| || || ||| 
Origi: 361 ccaccaaatgtaaacaaaattcgtgaagctttggctcaaacccacagcgctattgccgtc  
 
                                                                        
Optim: 421 atcatcggaatcaaggatctggacgcattccggcactatgacgggcgcacaatcatccag  
           || || || ||||| ||| | ||||||||||| || ||||| || || |||||||| ||  
Origi: 421 attattggcatcaaagatttagacgcattccgtcattatgatggccgaacaatcattcaa  
 
                                                                        
Optim: 481 cgcgacaacggataccagccaaactatcacgcggtcaacatcgtgggttactcgaacgcc  
           ||||| || || ||||| |||||||||||||| |||||||| || ||||||   |||||  
Origi: 481 cgcgataatggttaccaaccaaactatcacgctgtcaacattgttggttacagtaacgca  
 
                                                                        
Optim: 541 cagggggtggactactggatcgtgcggaacagttgggacaccaactggggcgacaacggc  
           || || || || || |||||||| || ||||||||||| ||||| ||||| || || ||  
Origi: 541 caaggtgtcgattattggatcgtacgaaacagttgggataccaattggggtgataatggt  
 
                                                                        
Optim: 601 tacggctactttgccgccaacatcgacctgatgatgatcgaagagtacccgtacgtggtg  
           ||||| || ||||| |||||||||||  |||||||||| ||||| || || || || ||  
Origi: 601 tacggttattttgctgccaacatcgatttgatgatgattgaagaatatccatatgttgtc  
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Optim: 661 atcctg 666 
           || || 
Origi: 661 attctc 666 
 
 
Figure 4.5 Comparison of the codon optimized and the original Der p 1 cDNA 
sequences. 
Optim: the codon optimized sequence 
Origi: The original sequence 
Mismatches are where the mutations were introduced 
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  Phe H N S
TTT 20 25 25 
  C 80 75 75  
 
  Lys H N S
AAG 82 0 100
  A 18 100 0 
  Gln H N S 
CAG 88 0 85.7
  A 12 100 14.3  
  Cys H N S 
TGT 32 57.1 28.6 
  C 68 42.9 71.4  
  Asp H N S 
GAT 25 90.9 18.2 
  C 75 9.1 81.8  
  Asn H N S 
AAT 22 52.9 26 
  C 78 47.1 74  
  
GCG 17 0 19.1 
  A 13 23.8 9.5 
  T 17 57.1 19.1 
  C 53 19.1 52.4
Ala H N S 
  
AGG 18 0 20 
  A 10 0 6.7 
CGG  21 0 20 
  A 6 53.3 6.7 
  T 7 40 6 
  C 37 6.7 40
  
CAT 21 50 33.3 
  C 79 50 66.7  
His H N S
  
ATA 5 0 5  
  T 18 60 15   
  C 77 40 80   
  Thr H N S
ACG 15 0 25 
  A 14 9 12.5 
  T 14 50 12.5 
  C 57 37.5 50
  Ser H N S
AGT 10 25 8.3 
  C 34 16.7 33.3
TCG  9 0 8.3 
  A 5 41.7 8.3 
  T 13 8.3 16.6 
  C 28 8.3 25 
  Leu H N  S
TTG 6 55.6  0 
  A 2 22.2  0 
CTG  58 0 66.7
  A 3 0  0 
  T 5 11.1  6 
  C 26 11.1  25 
Ile H N S
Arg H N S 
  
GGG 24 0 22.2 
  A 14 11.1 16.7 
  T 12 72.2 11.1 
  C 50 16.7 50
Gly H N S   Pro H N S
CCG 17 0 12.5 
  A 16 87.5 12.5 
  T 19 0 25 
  C 48 12.5 50
  Tyr H N S
TAT 21 52.9 29.4 
  C 78 47.1 70.6  
  Val H N S
GTG 64 0 64.3
  A 5 14.3 7.1 
  T 7 28.6 7.1 
  C 25 57.1 21.4 
  Glu H N S
GAG 75 0 72.7
  A 25 100 27.3    
 
Table 4.1 Codon usage of highly expressed human (H) genes, the wild type mature 
Der p 1 (N) and the codon optimized mature Der p 1 (S).  Percentage frequencies of 
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individual codons are shown for each corresponding amino acid. The most prevalent 
codon is underlined. Data for highly expressed human genes was derived from Haas J et 
al., 1996. Data for wild type and codon optimized Der p 1 constructs was calculated 
using the sequence information shown in Fig. 4.2 and Fig. 4.4. 
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 Primer Sequence 
1 sDP1/f1   5’ CGCCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAAC 3’ 
2 sDP1/r2 5’ CTTGCGTGCGGCCTCCTCGTCCTCGAAGGTGGCATAGCTCTTGTTGAAGGCTTTCTTG 3’ 
3 sDP1/f3   5’ GAGGAGGCCGCACGCAAGAACTTCCTGGAAAGCGTGAAATACGTCCAGAGCAACGGCGGG 3’ 
4 sDP1/r4   5’ CTTGAACTCGTCCAAAGACAGGTCGGACAGGTGATTGATGGCCCCGCCGTTGCTCTGGAC 3’ 
5 sDP1/f5 5’ TCTTTGGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGCTTTCGAACACCTTAAG 3’ 
6 sDP1/r6   5’ GATGCTGCAGGCGTTGGTCTCCGCGTTGAGATCAAACTGGGTCTTAAGGTGTTCGAAAGC 3’ 
7 sDP1/f7 5’ ACCAACGCCTGCAGCATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG 3’ 
8 sDP1/r8 5’ ACAAGACCCGCAGCCGCCTTGCATGCGGATGGGAGTCACGGTCCTCATCTGGCGCAGATC 3’ 
9 sDP1/f9   5’ GGCGGCTGCGGGTCTTGTTGGGCCTTCTCAGGCGTGGCCGCGACCGAGTCTGCATACCTC 3’ 
10 sDP1/r10 5’ GAGCTCCTGCTCAGCGAGGTCCAGGCTCTGATTCCGATACGCGAGGTATGCAGACTCGG  3’ 
11 sDP1/f11 5’ CTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGATGTCATGGGGATACG 3’ 
12 sDP1/r12 5’ CTGCACGACGCCATTATGCTGGATGTATTCGATACCTCTGGGAATCGTATCCCCATGAC 3’ 
13 sDP1/f13 5’ CATAATGGCGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCCGC 3’ 
14 sDP1/r14 5’ CTGGCAATAGTTGGAAATGCCGAAGCGCTGGGCGTTAGGACGGCGGCAGGACTGCTCCC 3’ 
15 sDP1/f15 5’ ATTTCCAACTATTGCCAGATCTACCCCCCTAATGTGAACAAGATCAGGGAGGCCCTGGCG 3’ 
16 sDP1/r16 5’ ATCCTTGATTCCGATGATGACAGCGATGGCGCTGTGCGTCTGCGCCAGGGCCTCCCTG 3’ 
17 sDP1/f17 5’ ATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATGACGGGCGCACAATCATCCAG 3’ 
18 sDP1/r18 5’ GATGTTGACCGCGTGATAGTTTGGCTGGTATCCGTTGTCGCGCTGGATGATTGTGCGCCC 3’ 
19 sDP1/f19 5’ TATCACGCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGATCGTG 3’ 
20 SDP1/R20 5’ GCCGTAGCCGTTGTCGCCCCAGTTGGTGTCCCAACTGTTCCGCACGATCCAGTAGTCCAC 3’ 
21 sDP1/f21 5’ GGCGACAACGGCTACGGCTACTTTGCCGCCAACATCGACCTGATGATGATCGAAGAGTAC 3’ 
22 sDP1/r22 5’ CCCCCCTCTAGATCACAGGATCACCACGTACGGGTACTCTTCGATCATC 3’ 
Table 4.2 The panel of oligonucleotide primers used to generate the synthetic codon 
optimized Der p 1 sequence. 
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     f1           f3            f5            f7          fn           
        r2           r4            r6           r8           rn           











Codon optimized sequence 
 
 
Figure 4.6 Strategy used to generate synthetic codon optimized sequences. First PCR 
was conducted using partially overlapping oligonucleotides (f1, r2, f3, r4…, f21, r22). 
Second PCR was conducted using oligonucleotides f1 and r22. 
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M Mature Dp1 
 
κ leader Mature Dp1LM 
 
Mature Dp1κ leader Pro-regionLPM 
 
κ leader Humanized mDp1LHM 
 
 
Figure 4.7 Schematic representation of the constructs used in this chapter. Please 
refer to Figure 4.2 for detailed sequence information of the nucleotides encoding the pro-
region and mature peptide (Mature Dp1) of Der p 1; Figure 4.3 for mouse Igκ chain 
leader sequence (κ leader); and Figure 4.4 for codon optimized mature Der p 1 sequence 
(Humanized mDp1). 
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                                              1        2         3        4       5        6 
 
Figure 4.8 Agarose gel electrophoresis analysis of M, LM, LPM, and LHM plasmid 
DNA (lane 2 to lane 5, respectively) stained by Ethidium Bromide. Lane 1 is a 1 kb DNA 
ladder. Lane 6 is the pVAX1 vector. Please refer to Fig. 4.7 for a schematic 
representation of the constructs. 
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Figure 4.9 Schematic representation the immunization regiment for evaluation of Der 
p 1 DNA constructs. 
DNA: DNA immunization was performed intramuscularly on day 0 and day 7 with 
electroporation. 50 µg of each DNA plasmid was used for both immunizations. 
Protein: Protein boost was performed intraperitoneally on day 14 with 25 µg native Der 
p 1 emulsified in 4 mg alum. 
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4.3 Results  
 
4.3.1 Evaluation of the heterologous prime-boost protocol 
 
The strategy of using modified vector and a heterogeneous prime-boost protocol (Fig. 
4.9) was adopted in all the experiments described in this Chapter. As demonstrated in the 
previous Chapter, DNA constructs without signal peptide (designated as leaderless 
constructs) failed to elicit significant antibody responses in mice (Fig. 3.15), despite 
similar levels of in vivo antigen expression (Fig. 3.16). One possible explanation for the 
lack of antibody response induced by the leaderless construct could be due to the fact that 
the magnitude of response was too low to be detectable. To further address the 
importance of the signal peptide in construct design, a leaderless construct was designed 
by inserting gene fragment encoding mature Der p 1 without any signal peptide sequence 
into the pVAX1 vector. The resultant leaderless construct containing only the mature Der 
p 1 sequence (designated as M) or a pVAX1 vector control (V) was used to immunize 
Balb/cJ mice intramuscularly at a dose of 50 µg with electroporation on days 0 and 7. 
Mice were then boosted intraperitoneally with 25 µg of native Der p 1 emulsified in 4 mg 
alum hydroxide, or alum alone, on day 14. Sera were collected from the immunized mice 
weekly and assayed for Der p 1 specific antibodies. As shown in Fig. 4.10A, mice 
immunized with pVAX1 vector control (V) and boosted with Der p 1 did not show 
significant production of Der p 1-specific IgG2a. The lack of IgG2a is expected, given 
the Th2 skewing property of alum. Mice immunized with construct M without further 
protein boost also did not produce significant level of Der p 1 specific IgG2a, which is 
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consistent with the results observed for the leaderless constructs observed in the previous 
chapter (Fig. 3.15). In contrast, mice immunized with construct M and boosted with alum 
emulsified Der p 1 protein induced significant amount of Der p 1 specific IgG2a. The 
kinetics of Der p1 specific IgG1 production was similar to that of IgG2a (Fig. 4.10B), and 
there was no detectable IgE (Fig. 4.10C). Given the Th2 skewing property of alum, the 
lack of IgE even in the vector control mice is a surprise. It could be related to the dose of 
Der p 1 used in the immunization protocol (The relationship between Der p 1 dose and 
the induced immune response will be studied in more details in Chapter 5). These results 
demonstrated that the leaderless construct was capable of inducing a Th1 skewed immune 
response, which could be further boosted by protein immunization. It is clear that the 
prime-boost protocol revealed that the leadless construct was capable of priming some 
but low levels of immune responses (undetectable in the previous studies) which could be 
boosted by the subsequent protein immunization.  
 
4.3.2 Evaluation of the effect of leader sequence 
 
As indicated in Chapter 3, the DNA construct containing a signal peptide sequence from 
Der p 5 cDNA induced much higher levels of immune responses than the leaderless 
construct. It was, therefore, reasoned that a signal peptide sequence that works in the 
mammalian system should be as efficient as, if not more efficient than, the Der p 5 
leader, to enhance the magnitude immune response. A DNA construct was prepared by 
inserting a mouse Igκ chain signal peptide sequence in front of the gene encoding the 
mature Der p 1. This construct, designated as LM, was then used to immunize Balb/cJ 
 135
  Chapter 4 Optimization 
mice with the same prime-boost protocol described in Fig. 4.9. The leaderless construct 
(M) was used as a control for this comparative study. As shown in Fig. 4.11, both 
constructs LM and M induced similar kinetics of Der p 1 specific IgG2a production. 
However, the magnitude of the antibody response induced by construct LM was 
significantly higher than that induced by construct M, suggesting that the inclusion of the 
mouse Igκ signal peptide could indeed enhanced the  antigen specific  humoral responses. 
No Der p 1 specific IgE was detected in mice immunized by either constructs.  
 
4.3.3 Evaluation of the necessity of Pro-enzyme sequence 
 
It is well established that the pro-enzyme sequence of Der p 1 is critical for the proper 
folding of the mature protein that is enzymatically active (Shinde U and Inouye M, 1993). 
The exclusion of this sequence in Der p 1 DNA vaccine design could avoid the possible 
in vivo expression of enzymatically active Der p 1, thus making the DNA vaccine safer 
for clinical applications. It was demonstrated in the previous Chapter that the DNA 
construct containing Der p 1 gene sequence without its proenzyme sequence could induce 
significant Der p 1 specific immune responses. To further investigate the advantages or 
disadvantages of excluding the pro-enzyme sequence in the Der p 1 DNA constructs, 
mice were immunized with a construct containing  pro-sequence (designated as LPM) or 
without the pro-sequence (designated as LM) using the same protocol described in the 
previous sections (shown also in Fig. 4.9), and the antibody responses were compared 
(Fig. 4.12). No Der p 1 specific IgE was detected in mice immunized by either construct.  
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There was some minor differences in the kinetics of IgG2a production induced by LPM 
and LM constructs, with IgG2a levels induced by the LPM construct peaked earlier at 
around day 28 and remained as plateau levels followed by a gradual decline. Construct 
LM induced a significantly higher level of IgG2a as compared to that of LPM (Fig. 
4.12A). The levels of LPM induced IgG1 were peaked at day 35 and gradually declined 
but maintained at relatively high levels up to day 84. On the contrary, Der p 1 specific 
IgG1 levels were lower in the LM immunized mice (Fig. 4.12B). The reversed antibody 
profile in LPM immunized mice (higher G1 Vs. lower G2a) could be due to the 
production and circulating of Der p 1 protein, which is structurally similar to native Der p 
1 allergen, in the presence of the pro-enzyme region. The natively folded Der p 1, 
containing structural IgE epitopes, could possibly skew the immune response towards 
Th2.  
 
Taken together, the data suggest that the exclusion of the pro-enzyme sequence of Der p1 
in the DNA construct may represent a good strategy to up-regulate the more desirable 
IgG2a production (i.e., Th1 Skewed responses) in the immunized mice and it may also 
help to improve the safety of the vaccine by reducing the risk of Der p 1 sensitization of 
the immunized host by circulating Der p 1 protein expressed in vivo. 
 
4.3.4 Evaluation of the codon optimization strategy 
 
As another additional strategy to further improve the magnitude of immune responses 
induced by the LM construct, a codon-optimized Der p 1 gene sequence was synthetically 
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made by silent mutation technique, and the comparison of the wild type and codon 
optimized Der p 1 sequences are shown in Table 4.1 and Fig. 4.5. This strategy aimed at 
enhancing in vivo Der p 1 protein expression by increasing its mRNA translation 
efficiency. The DNA construct containing the codon-optimized Der p1 gene (or referred 
to as the humanized construct, designated as LHM), was used to immunize Balb/cJ mice 
using the same protocol described in Fig. 4.9, and the humoral immune response was 
then compared to that induced by LM (Fig. 4.13A). LHM induced significantly higher (2 
fold) Der p 1 specific IgG2a than that induced by LM, demonstrating the feasibility of 
this strategy. No Der p 1 specific IgE was detected in mice immunized by either 




To further characterize the phenotype of the immune responses induced by construct 
LHM, in vitro T cell cultures were set up and the responses were examined by cytokine 
profiling. Immunized mice were sacrificed on day 84; splenocytes were then cultured 
with native Der p 1 protein for 10 days. The enriched Der p 1-specific CD4+ T cells were 
analysed by intracellular staining for cytokine production profiles (Fig. 4.13C). Averages 
of the percentages of IFN-γ secreting CD4+ T cells and IL-4 secreting CD4+ T cells were 
calculated and shown in Fig. 4.13D and Fig. 4.13E, respectively, and the ratio of IFN-γ 
secreting cells to IL-4 secreting cells were calculated and shown in Fig. 4.13F. It was 
observed that significantly higher percentage of IFN-γ secreting CD4+ T cells were 
present in LHM immunized mice (Fig. 4.13D), as compared to the control mice, which 
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resulted in a higher ratio of IFN-γ secreting cells to IL-4 secreting cells (Fig. 4.13F), 
demonstrating a Th1 skewed phenotype. 
 139






























































































  Chapter 4 Optimization 
 
Figure 4.10 Heterogeneous prime-boost protocol magnified the differences between 
the leaderless construct (M) and the vector control (V). Balb/cJ mice, 5 in each group, 
were immunized intramuscularly with the leaderless construct (M) or the vector control 
(V) on day 0 and day 7. Mice were boosted intraperitoneally with 25 µg native Der p 1 
emulsified in 4 mg alum hydroxide, or alum alone on day 14. Sera were collected from 
the immunized mice sequentially and assayed by ELISA for Der p 1 specific IgG2a (A), 
IgG1 (B), and IgE (C). The differences between M and V are statistically significant from 
day 28 onwards, as determined by Student t test. 
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Figure 4.11 Mouse Igκ chain leader sequence enhanced the Th1 skewed immune 
response. Balb/cJ mice, 5 in each group, were immunized intramuscularly with the 
construct containing mouse Igκ chain leader sequence (LM) or the leaderless construct 
(M) on day 0 and day 7. All mice were then boosted intraperitoneally with 25µg native 
Der p 1 emulsified in 4 mg alum hydroxide on day 14. Sera were collected from the 
immunized mice sequentially and tested by ELISA for the presence of Der p 1 specific 
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IgG2a (A) and IgG1 (B). The difference between M and LM are statistically significant 





















































Figure 4.12 The pro-enzyme sequence is not necessary for Der p 1 construct. Balb/cJ 
mice, 5 in each group, were immunized intramuscularly with the construct containing Der 
p 1 pro-enzyme sequence (LPM) or the LM construct which does not contain the pro-
enzyme sequence (LM) on day 0 and day 7. All mice were then boosted intraperitoneally 
with 25µg native Der p 1 emulsified in 4 mg alum hydroxide on day 14. Sera were 
collected from the immunized mice sequentially and tested by ELISA for the presence of 
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Figure 4.13 Codon optimization increased the immunogenicity of DNA vaccines. 
Balb/cJ mice, 5 in each group, were immunized intramuscularly with the codon 
optimized construct (LHM) or the LM construct which contains the native Der p 1 
sequence on day 0 and day 7. All mice were then boosted intraperitoneally with 25µg 
native Der p 1 emulsified in 4 mg alum hydroxide on day 14. Sera were collected from 
the immunized mice sequentially and tested by ELISA for the presence of Der p 1 
specific IgG2a  (A) and IgG1(B). LHM or PBS primed mice were boosted with native 
Der p 1 as in (A) and sacrificed on day 84. Specific CD4+ T cells was enriched by in 
vitro culture with Der p 1 and intracellular staining was performed to determine the 
percentages of IFN-γ secreting cells and IL-4 secreting cells. Representative flow pictures 
were shown in panel C (C1 and C2 from DNA vaccinated mice, C3 and C4 from PBS 
mock immunized mice). Average percentages of IFN-γ secreting cells and IL-4 secreting 
cells were shown in panel D and E, respectively, and the calculated the ratio of IFN-γ 
secreting cells to IL-4 secreting cells as compared to that in the control mice was shown 
in panel F. Data was presented as Mean + SEM. *, p<0.05. 
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4.4 0Discussion 
 
In this chapter, it was demonstrated that the immunogenicity of DNA vaccination can be 
further improved by various modifications of the DNA constructs and the adoption of 
mixed modality prime-boost immunization protocol.  
 
All the constructs studied in this chapter were prepared using the plasmid backbone of 
pVAX1 vector, which is designed according to FDA regulations for use in human 
protocols. pVAX1 was derived from the parent vector pcDNA3.1, the eukaryotic DNA 
sequences of pVAX 1 vector are limited to those required for antigen expression, so that 
the possibility of chromosomal integration is limited. A kanamycin resistance gene, 
instead of ampicillin resistance gene, is employed in this vector for selection in E. coli to 
avoid allergic responses in human. pVAX1 vector has been used in several clinical trials 
and proved to be safe (Todorova K et al., 2005; Pavlenko M et al., 2004; Morishita R et 
al., 2004). 
 
To facilitate the study of the phenotypes of the immune responses induced by a panel of 
different DNA constructs, the isotypes, magnitudes and kinetics of the Der p 1-specific 
antibody production were used as convenient readout parameters to determine the type of 
immune responses. As has been discussed in Chapter 1 Section 1.1.2 and Chapter 5, 
Section 5.1, induction of allergen specific IgE is a hallmark of allergic sentization by 
allergen and the production of such IgE is tightly regulated by Th2 cytokines such as IL-4 
and IL-13. In the mouse system, the production of IgG2a is highly dependent on Th1 
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cytokine IFN-γ (DeKruyff RH et al., 1993), and it is the antibody isotype that is 
indicative of Th1-skewed immune responses. Thus, the magnitude of Der p 1 specific 
IgG2a was used in this study as an indicator of the magnitude of Th1 skewed immune 
response for the screening of the best construct for further development. It is to be noted 
that the regulation of IgG1 production is more complicated than that of IgE or IgG2a. 
IgG1 was often being referred to as a Th2 antibody because it was found that its primary 
production was dependent on Th2 cytokines (DeKruyff RH et al., 1993). However, its 
secondary response could be stimulated by both Th1 and Th2 cytokines (DeKruyff RH et 
al., 1993). Furthermore, it was recently recognized that IL-12-dependent IgG1 production 
mechanism exists in the mouse system (Faquim-Mauro EL et al., 1999). Therefore, IgG1 
could be an indicator of the magnitude of the general immune response, but it is not a 
good indicator for determining the type of the immune response. In the experiments 
described in this chapter, DNA immunization always induced high levels of antigen 
specific IgG1 responses despite the existence of strong Th1 responses as indicated by T 
cell cytokines profiling data (Fig. 4.13). 
 
For the immunization protocol, a mixed modality DNA-primed and protein boost 
approach was used throughout the study described in this chapter to evaluate the various 
constructs. My data showed that such approach could efficiently increase the magnitude 
of immune responses and magnified the differences between different constructs (Fig. 
4.10). The effect of the heterologous prime-boost strategy on antibody production is 
consistent with the previous observations reported by other researchers (Barnett SW et 
al., 1997; Mossman SP et al., 1999; Nyika A et al., 2002). Although the underlying 
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mechanisms for the improved responses have not been fully understood, the boosting 
effects are consistent and significant. Furthermore, the prime-boost protocol was fully 
exploited in this study to facilitate the evaluation of the various constructs on the basis of 
the magnitude of immune responses.  For example, the difference in magnitude of 
immune responses induced by the leaderless construct and the vector control, which was 
previously undistinguishable and undetectable using the single modality immunization 
protocol (Fig. 3.15), could be easily differentiated as the low level of DNA primed 
responses could be magnified by the protein boost (Fig. 4.10). 
 
Three modification strategies were employed in this study to improve the 
immunogenicity of the DNA constructs. Firstly, a mouse Igκ chain signal peptide 
sequence was inserted in front of the Der p 1 gene to target the in vivo expressed antigen 
to the secretory pathway. This is to increase the availability of Der p 1 in vivo and 
enhance the activation of CD4+ T cells. It has been observed that an efficient signal 
peptide sequence could significantly increase the in vitro expression of HIV-2 envelop 
protein gp 140 (Locher CP et al., 2002) and in vivo immunogenicity of HIV pol 
(Casimiro DR et al., 2002). It was proven in our study that the use of mouse Igκ chain 
signal peptide sequence could also enhance the immune response to Der p 1 significantly. 
Furthermore, the enhanced immune responses were Th1 skewed as demonstrated by the 
lack of Der p 1 specific IgE and the induction of IgG2a antibodies. It is clear in this study 
that manipulation of the leader sequence has not altered the type of immune response 
induced by DNA vaccination. However, it should be noted that the benefits of 
incorporating a strong signal peptide sequence in DNA vaccine for allergy should be 
 150
  Chapter 4 Optimization 
tested for each individual allergen as the nature of allergen may have a profound 
influence on the outcomes of the DNA immunization. It was recently observed in our 
laboratory that inclusion of a strong signal peptide in a DNA construct encoding another 
major allergen Der p 2 resulted in priming of a mixture of Th1 and Th2 responses, with 
induction of low levels of Der p 2 specific IgE in DNA immunized mice (personal 
communications). This observation could be due to the unique properties of Der p 2, 
which is structurally similar to LPS-binding protein MD-2 that are essential for TLR4 
signaling (Gruber A et al., 2004; Ichikawa S et al., 2005). Wider distribution of Der p 2 
resulted from manipulating the signal peptide sequence might interfere with the host 
innate immune system and alter the subsequent Th1/Th2 differentiation. Although such 
properties could be unique to Der p 2 and other related Group 2 mite allergens, it is 
advisable that the inclusion of signal peptide should be used with care to avoid the 
possibility of undesirable sensitization. 
 
Secondly, the feasibility of exclusion of the pro-enzyme sequence of Der p 1 was further 
verified in this chapter. The data confirmed the previous observation the pro-enzyme 
sequence is not necessary for the induction of Der p 1 specific immune responses. The 
data also suggested that the deletion of the pro-enzyme sequence had some enhancing 
effects on the Th1 skewed immune response induced by DNA vaccination. It was 
observed that lower level of Der p 1 specific IgG2a and higher level of IgG1 was induced 
in LPM immunized mice, as compared to the LM immunized mice (Fig. 4.12). It is 
possible that LPM expressed more of the secretory form of Der p 1 protein, which is 
structurally similar to native Der p 1 allergen, because of the presence of the pro-enzyme 
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region. The natively folded Der p 1, containing structural IgE epitopes, could possibly 
skew the immune response towards Th2. It is clear that T cell cytokine profiles and 
adoptive transfer experiments could provide more conclusive evidences. It has been 
suggested by homologue study and structural data that the pro-region of Der p 1 serves as 
an intramolecular chaperon, and is essential for the proper structure and enzymatic 
activity of Der p 1 (Shinde U and Inouye M, 1993; Meno K et al., 2005). Therefore, 
excluding the pro-region not only could avoid in vivo production of enzymatically active 
Der p 1, but also could abolish IgE epitopes which requires conformational structure 
(Greene WK et al., 1991; Lombardero M et al., 1990). 
 
Thirdly, the codon usage of Der p 1 gene was optimized according to human codon usage 
bias by silent mutations. The resultant DNA sequence encodes the same amino acid 
sequence of Der p 1, but the usage of synonymous codons was changed to increase the 
level of protein expression in mammalian cells. Although the exact mechanisms could be 
more complicated, it is believed that codon optimized constructs could make better use of 
the cognate tRNAs in the host cells, and the effectiveness of this strategy to enhance 
protein expression has been demonstrated by various groups (Buell G et al., 1985; Devlin 
PE et al., 1988; Brinkmann U et al., 1989; Del Tito BJ Jr et al., 1995). Codon 
optimization has also been used to enhance expression of mite allergens in mammalian 
cells (Lim LH et al., 2004; Massaer M et al., 2001). It is, therefore, reasonable to deduce 
that the enhancement of immune responses by the LHM over the LM construct could be 
attributed to increased levels of Der p 1 expression in vivo.  
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It is evident that combination of these optimization strategies enormously increased the 
magnitude of Th1 skewed immune responses as compared to the results previously 
described in Chapter 3. The resultant construct, LHM, containing the mouse Igκ chain 
leader sequence and the codon optimized Der p 1 DNA sequence was, therefore, chosen 
for performing the preclinical efficacy evaluation as detailed in Chapter 6. Preclinical 
evaluation of the preventive and therapeutic efficacies against allergic asthma was 
performed with a Der p 1 specific experimental mouse model for allergic asthma.  The 
development of this mouse model will be discussed in the next chapter. 
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DEVELOPMENT OF AN ALLERGIC ASTHMA MOUSE 
MODEL 
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5.1 Introduction 
 
It has been demonstrated in the previous chapter that an optimized construct, LHM, could 
induce high magnitude of Th1 skewed immune response. To facilitate the preclinical 
evaluation of this DNA construct for its potential applications in prevention and treatment 
of Der p 1-induced allergic responses and the subsequent airway inflammation and 
airway heperrresponsiveness (AHR), an experimental mouse model for allergic asthma 
was being established and described in this chapter.   
 
Animal models of allergic asthma have been established in guinea pigs, monkeys, dogs, 
rats, pigs, and mice to provide insights into the pathogenesis of this disease and to 
evaluate the efficacy of various therapeutic agents (Miyamoto T et al., 1968; Underwood 
S et al., 1995; Haczku A et al., 1995; Itoh K et al., 1996; Cui ZH et al., 1997; Redman 
TK et al., 2001; Turner DJ et al., 2002; Watremez C et al., 2003). The mouse model has 
been particularly valuable because of the similarity of its immune system to human, the 
detailed knowledge of the mouse genome, the availability of multiple technologies and 
reagents to manipulate and characterize the murine system, the availability of over 200 
well-characterized inbred strains, and the relative low cost and ease to handle a large 
number of mice. These apparent advantages of a mouse model plus the fact that all the 
DNA immunization work described in this thesis were done in mice had prompted us 
establish a Der p 1-specific experimental allergic asthma model in mice.   
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The biphasic protocol is the most frequently used one for the establishment of mouse 
allergic asthma model. It consists of a systemic sensitization followed by an airway 
challenge (van Halteren AG et al., 1997; Renz H et al., 1994; Herz U et al., 1998). 
Systemic sensitization could be established by intraperitoneal injection of relevant 
allergen or model allergen emulsified in Alum Hydroxide, which is a commonly Th2 
skewing adjuvant. Local airway challenge could then be achieved by nebulized allergen 
aerosol inhalation. Systemic T cell response, allergen specific IgE, and airway 
hyperresponsiveness were commonly used parameters to evaluate the success of this 
model.  
 
In the establishment of such a model, systemic sensitization to induce allergen specific 
IgE is probably the key step, because of the critical role of IgE in the pathogenesis of 
allergic asthma. Multiple mechanisms, including genetic factors, immunological factors 
and environment factors, could influence IgE induction. In the first part of this study, 
optimized dosage of Der p 1 for sensitization was systematically determined using four 
strains of mice with different genetic background. In the second part, the experimentally 
determined  Der p 1 dosage optimized for sensitization was used to immunization the  
Balb/cJ mice to establish a Der p 1 allergic mouse asthma model. 
 
IgE antibody plays a critical role in allergic reactions. Upon allergen exposure, cross-
linking of IgE bound to its high affinity Fc receptor (FcεRI) on tissue mast cells or blood 
basophils triggers immediate onset of symptoms characteristic of asthma, rhinitis, 
eczema, and other allergic diseases (Gould HJ et al., 2003). Der p 1 is a major allergen 
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from house dust mite Dermatophagoiodes pteronyssinus, with specific IgE present in 
more than 70% mite allergic sera (Greene WK et al., 1991). Exposure to Der p 1 has been 
shown to be related to increased level of sensitization and asthma symptoms (Peat JK et 
al., 1996). It is believed that Der p 1 could regulate specific IgE production partly 
because of its unique biochemical properties as a cysteine protease (Hewitt CR et al., 
1995; Chua KY et al., 1988). On the other hand, timing and dose of exposure could also 
play an important role (Erwin EA et al., 2005). The information generated from this 
study might also help in a more rational design of immunotherapies to avoid 
immunotherapy induced sensitization and its related side effects. 
 
Th2 cytokines IL-4 and IL-13 can activate ε germline gene transcription (GLT) in B cells, 
and initiate IgE class switch recombination (CSR) in the presence of CD40L stimulation, 
while Th1 cytokine IFN-γ can inhibit IgE production by either repressing ε GLT in B 
cells, or inhibiting Th2 cell development and reducing the amount of IL-4 and IL-13 
(Geha RS et al., 2003). IL-4 and IL-13 are not only produced by CD4+ Th2 cells, but 
also by CD8+ Tc2 cells (Vukmanovic-Stejic M et al., 2001). Therefore, the effect of Der 
p 1 sensitization dose on IgE induction, if any, could be related to its effect on T cell 
polarization in terms of Th1/Th2 and Tc1/Tc2.  
 
CD4+ CD25+ regulatory T cell population is of intense research in the recent years, with 
more and more evidence pointing to their role in maintaining the homeostasis of the 
immune system. These regulatory T cells have also been implicated in the regulation of 
Th2 immune response as well as IgE production (Curotto de Lafaille MA et al., 2002; 
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Curotto de Lafaille MA et al., 2004). It remains to be seen whether the dose of allergen 
exposure, or more specifically the dose of Der p 1 sensitization, could have any effect on 
the development of CD4+ CD25+ regulatory T cells, which could possibly affect T cell 
polarization as well as IgE induction. 
 
This chapter describes the immunization protocol, characterization of the allergen-
induced Th2-skewed immune responses and the physiopathology of the allergen 
challenged lungs in the Der p 1-sensitized mice.  Additionally, dose effect on T cell 
phenotypes, such as T cell polarization and regulatory T cell development were also 
being explored. 
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5.2 Materials and Methods 
 
5.2.1 Purification of native Der p 1 by monoclonal antibody affinity 
chromatography 
 
Native Der p 1 was purified from spent mite media by mAb 4C1 affinity chromatography 
as described in Chapter 2, Section 2.2.2. Briefly, spent mite media extracts were passed 
through tandem 4C1 columns and the columns were washed with TBS until the OD280nm 
had reached zero. The bound native Der p 1 was eluted with 10 mM Glycine, 50% 
ethylene glycol, pH 10. The eluents were neutralized with 1 M Tris-HCl, pH 6.5 and 
dialysed immediately against PBS and quantitated by comparison with a protein standard 
using a colorimetric assay (BioRad, Hercules, CA, USA). The purity and identity of Der 
p 1 was confirmed by SDS-PAGE and Western blot. 
 
5.2.2 Mice immunization 
 
Female 6 to 8 weeks old mice [C3H/HeJ (H-2k), CBA/J (H-2k), Balb/cJ (H-2d), and AKR 
(H-2k)] were purchased from the Laboratory Animals Center (LAC, Sembawang) 
Singapore, and housed at the National University of Singapore Animal Holding Unit and 
cared for under institutional guidelines for the care and use of laboratory animals. Please 
see Figure 5.1 for the pictures of the mice. For the study of Der p 1 dose effect on IgE 
production, groups of 4-6 mice were primed intraperitoneally with specified amount of 
Der p 1 emulsified in 4 mg Alum on day 0, and boosted in the same way on day 10, and 
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day 20 (see Fig. 5.2 for a schematic representation). For establishment of Der p 1 allergic 
asthma model, Balb/cJ mice were systemically sensitized by intraperitoneal injection of 1 
µg native Der p 1 protein emulsified in 4 mg alum on day 0 and day 7. Airway allergen 
exposures with aerosolized Der p 1 protein were performed on days 22, 25, and 28. 
Airway hyperresponsiveness was performed on day 29 (see Fig. 5.3 for a schematic 
representation). Animals were bled periodically in the whole experimental procedure. 
 
5.2.3 Airway allergen exposure by aerosol 
 
Airway exposures of Der p 1 to mice were performed by generating Der p 1 aerosol via 
an ultrasonic nebulizer (model UltraNEB 99, DeVilbiss Health Care, Sommerset, PA; 
Fig. 2.4) from 0.1 mg/ml solution of Der p 1 in PBS. The mice were kept unrestrained in 
a desiccator chamber with continual flow of aerosol for 30 mins. 
 
5.2.4 Non-invasive measurement of airway hyperresponsiveness 
 
Approximately 24 h after the last aerosol challenge, airway responsiveness was assessed 
in conscious, unrestrained mice by the whole-body plethysmography (model PLY3211, 
Buxco Electronics Inc., Troy, New York, USA) as described in chapter 2, section 2.2.19. 
Briefly, measurements of methacholine responsiveness were obtained by exposing mice 
to an aerosol of PBS (baseline readings), and cumulative increased doses (5 to 40 mg/ml) 
of aerosolized methacholine. The signals were recorded for the subsequent 5 mins. The 
interval between each dose was 1 min.  
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5.2.5 Detection of serum antibody level by ELISA 
 
The levels of Der p 1-specific IgE was determined by ELISA as described in Chapter 2, 
Section 2.2.9. Briefly, mouse sera were incubated in duplicate with the Der p 1 coated 
wells for overnight at 4°C. Biotin-conjugated monoclonal rat anti-mouse IgE (R19-15) 
was used for detection and followed by addition of ExtrAvidin-alkaline phosphatase. 
Signals were developed by addition of p-Nitrophenylphosphate substrate. ELISA index 
unit was defined as the OD405nm reading corresponding to the reading of 1 ng/ml of 
purified mouse IgE in a sandwich ELISA with anti-mouse Igκ as the capture antibody in 
the same plate. All the antibodies used were purchased from Pharmingen (Pharmingen, 
San Diego, CA). 
 
5.2.6 T cell study in vitro 
 
T cell studies were performed as described in chapter 2, section 2.2.11. Briefly, For in 
vitro stimulation of total splenocytes, cells were cultured in 96 well U-bottom plates with 
or without the presence of 20 µg/ml Der p 1 for 72 hours. Supernatants were collected for 
cytokine ELISA assay. For characterization of CD8+ T cell cytokine profile, CD8+ T 
cells were purified from splenocytes by AutoMACS (Miltenyi Biotec) using Biotin-
conjugated Rat anti Mouse CD8β antibody (Pharmingen, San Diego, CA) and Avidine-
conjugated magnetic beads (Miltenyi Biotec), and stimulated with immobilized anti-CD3 
(5µg/ml) and soluble anti-CD28 (2µg/ml) (PharMingen, San Diego, CA) in 96 well U-
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bottom plates for 72 hours. Supernatants were collected for cytokine ELISA assay. For 
characterization of CD4+ CD25+ T cells, splenocytes were cultured with 10 µg of Der p 
1 in 6-well plates. Recombinant IL-2 was added to the cell culture on day 3, day 5 and 
day 7. On day 10, cells were harvested. Live T cells were enriched by Ficoll Gradient 
Centrifugation (Amersham Pharmacia) and stained with anti-CD3, anti-CD4, and anti-
CD25 antibodies (PharMingen, San Diego, CA) for FACScan analysis. 
  
5.2.7 Detection of cytokine concentration by sandwich ELISA 
 
Antibodies used for detection of IL-10 and IL-13 in the cultured supernatant were 
purchased from R&D (R&D systems, Minneapolis, USA). Antibodies used for detection 
of other cytokines were from Pharmingen (PharMingen, San Diego, CA). Sandwich 
ELISA was performed as described in Chapter 2, Section 2.2.10. 
 
5.2.8 Collection of broncheoalveolar lavage and cytospin preparation for 
differential cell counts 
 
Mice were anesthetized by intraperitoneal injection with a lethal dose of a mixture 
containing 1.25 mg/ml midazolam, 2.5 mg/ml fluanisone and 0.079 mg/ml fentanyl 
citrate. The trachea was cannulated by tracheotomy (20G cannula) and lung was lavaged 
with 0.8 ml of ice-cold Hank’s balanced salt solution (HBSS) without calcium and 
magnesium for four times. Cells were centrifuged at 1,200 rpm for 10 min and 
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resuspended in PBS with 1% BSA. Cytospin was prepared by centrifugation of 1 x 105 
cells in 100 µl at 600 rpm for 10 minutes using Cytospin® 3 (Shandon Lipshaw) 
(Cytospin, Runcorn, Cheshire, U.K.). The cells were stained with the Liu stain (Riu CH, 
1953). Cells were identified and differentiated into macrophages, lymphocytes, 
neutrophils, and eosinophils based on standard hematological characteristics under the 
light microscope. For each slide, 500 cells were counted and the percentage of each cell 
type was calculated. 
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Figure 5.1 Four mouse strains used in this study. 
 164
  Chapter 5 Animal model 
A 
 S  S   S 
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                Periodical Bleeding for antibody assay by ELISA 
        
B 
S   S  S 
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 T cell study 
 
S, Systemic sensitization by intraperitoneal injection of 1 µg or 10 µg native Der p 1 
protein emulsified in 4 mg alum 
 
Figure 5.2 Schematic representation of the immunization regime for evaluation of the 
effects of Der p 1 dose on specific IgE production (A), and T cell cytokine profile (B). 
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S, Systemic sensitization by intraperitoneal injection of 1 µg native Der p 1 protein 
emulsified in 4 mg alum 
Aerosol, Airway allergen exposure with aerosolized native Der p 1 at days 22, 25 and 28 
AHR, measurement of airway hyper-responsiveness 
 
Figure 5.3 Schematic representation of the immunization regime for establishment of 
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5.3   Results  
 
5.3.1  Antigen dose dependent induction of Der p 1 specific IgE 
 
5.3.1.1 Effect of Der p 1 dose on the induction of specific IgE 
 
To determine the best sensitizing dose of Der p 1 for the induction of Der p 1 specific 
IgE, Balb/cJ, AKR, CBA/J, and C3H/HeJ mice, 4 in each group, were immunized by 
intraperitoneal injection of 1 µg or 10 µg of Der p 1, emulsified in 4 mg alum, at days 0, 
10, and 20 (see Fig. 5.2 for the protocol). Sera were collected periodically for Der p 1 
specific IgE assays by ELISA (Fig. 5.4). Despite the apparent difference in levels of Der 
p 1 specific IgE in different strains of mice, with significantly higher levels of specific 
IgE induced in C3H/HeJ mice, the kinetics of IgE production was similar, and the dose 
dependent IgE production was identical. Data revealed that the low dose (i.e., 1 µg) of 
Der p 1 could consistently induce significantly higher levels of Der p 1 specific IgE in all 
these mouse strains tested, regardless of their genetic background. 
 
5.3.1.2 Cytokine profile of CD4+ T cells induced by different doses of Der p 1 
 
Since the highest level of Der p 1 specific IgE was induced in C3H/HeJ mice, and the 
dosage effects on IgE production was also most apparent in this strain of mice, 
subsequent further characterization of the immune responses were focused on these mice. 
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It is well established that IgE production by B cells is dependent on the help from type 
two CD4+ T cells, which produce type two cytokines, such as IL-4 and IL-13, both of 
which are critical regulators of IgE (Geha RS et al., 2003). To examine the T cell 
responses induced in sensitized  C3H/HeJ mice, splenocytes from 1 µg, 10 µg, or 0 µg 
(alum alone) of Der p 1 immunized C3H/HeJ mice were cultured in vitro with medium 
containing 20 µg/ml Der p 1 to stimulate CD4+ T cells or medium alone as control. 
Supernatants were taken for cytokine assays by ELISA (Fig. 5.5). Upon in vitro 
exogenous antigen stimulation, splenocytes from mice primed by 1 µg of Der p 1 
produced significantly higher levels of type two cytokines, including IL-4, IL-5, IL-10 
and IL-13. There were no significant differences in the levels of IFN-γ produced by 
splenic T cells obtained from mice in each group. The cytokine profile data indicate that a 
more Th2 skewed immune response had been induced mice immunized with lower dose 
of Der p 1.  
 
5.3.1.3 Cytokine profile of CD8+ T cells induced by different doses of Der p 1 
 
CD8+ T cells is another cell population that could play a role in the regulation of IgE 
production, especially those with a type two cytokine profile, designated as Tc2 cells. To 
examine the phenotype of the CD8+ T cells, purified CD8+ T cells from splenocytes of 
mice immunized with different doses of Der p 1 were stimulated in vitro with anti-CD28 
and anti-CD3 antibodies. 72 hours later, supernatants were taken for cytokine assays by 
ELISA (Fig. 5.6). The levels of the type two cytokines, including IL-4, IL-5, IL-10, IL-
13, were consistently higher in the low dose (1 µg) immunized group, while the levels of 
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type one cytokine IFN-γ were similar for both groups of mice. The data suggest that the 
induction of Tc2 cells in mice primed with low dose Der p 1 and they may play a role in 
the induction of IgE. 
 
5.3.1.4 Percentage of CD4+CD25+ T cells induced by different doses of Der p 1 
 
As seen in the previous section, mice immunized with low dose (1 µg) of Der p 1 induced 
a more Th2 and Tc2 skewed immune response as compared to that of mice immunized 
with a higher dose (10 µg) of Der p 1. It was hypothesized that the less type 2 skewed 
phenotype induced in higher dose immunized mice could be due to some immune 
deviation mechanisms from Th2/Tc2 to Th1/Tc1. To determine whether CD4+CD25+ 
regulatory T cells play a role in this dosage effect on Th2 responses, splenocytes from 
different groups of mice were cultured in vitro with Der p 1 and IL-2. IL-2 has recently 
been shown to help in the generation and maintenance of CD4 CD25 double positive 
regulatory T cells (Malek TR et al., 2002; Bayer AL et al., 2005; Furtado GC et al., 
2002). Therefore, such an in vitro culture condition probably favors the proliferation of 
the regulatory T cell population. After ten days in vitro culture, similar numbers of T 
cells were harvested, and the percentages of CD4+CD25+ T cells from different groups 
of mice were analyzed by Flow Cytometry (Fig. 5.7). For this particular study, an 
additional group of mice immunized with 50 µg of Der p 1 was also included for 
analysis. It was found that the reduction in level of IgE was correlated with increasing 
immunization dosage of Der p 1. The percentage of CD4 CD25 double positive T cells 
was 29.7%, 8.9%, and 3.5% for mice immunized with 50 µg, 10 µg, and 1 µg, 
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respectively. These data suggest that the CD4 CD25 double positive T cells may play a 
regulatory role in specific IgE production. Further studies are required for more in-depth 
understanding of the implication of this phenomenon.  
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5.3.2 Establishment of Der p 1-induced allergic asthma mouse model 
 
5.3.2.1 Induction of Der p 1 specific IgE 
 
It is clear from the above study that low dose of Der p 1 preferentially induced Th2 
skewed phenotypes, which resulted in a higher magnitude of Der p 1 specific IgE. 
Therefore, the low dose Der p 1 immunization protocol was further employed to develop 
the Der p 1 allergic mouse asthma model. Although C3H/HeJ mice showed the highest 
IgE production, this strain of mice was known to be resistant to airway 
hyperresoponsiveness and is not suitable for the establishment of an asthma model (Ewart 
S et al., 1995; Ewart S et al., 1996; Duguet A et al., 2000). CBA/J mice have similar 
problem as an airway hypo-responsive strain (Drazen et al., 1999), and the airway 
responsiveness of AKR mice is not stable (Held HD and Uhlig S, 2000). On the other 
hand, Balb/c mice have been frequently used to establish asthma models, and its price 
and ease of handling offer further advantages. Consequently, a biphasic protocol, 
comprising a low dose sensitization and an airway challenge, was used to establish the 
Der p 1-induced allergic asthma model in Balb/cJ mice. 
 
Mice were sensitized by intraperitoneal injection of 1 µg native Der p 1 emulsified in 4 
mg Alum Hydroxide on day 0 and day 7. Aerosol challenge was performed on days 22, 
25 and 28 with nebulized Der p 1 using 10 ml of PBS containing 0.1 mg Der p 1 protein. 
Sera were collected sequentially for detection of Der p 1 specific antibodies by ELISA 
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(see Fig. 5.3 for a schematic representation of the protocol). As shown in Fig. 5.8A, Der p 
1 specific IgE was successfully induced by this protocol. It peaked around day 14 and 
then decreased gradually (Fig. 5.8A). Significant amount of Der p 1 specific IgG1 could 
also be detected (Fig. 5.8B). On the contrary Der p 1 specific IgG2a was not detectable, 
clearly indicated the induction of a systemic Th2 response to Der p 1. 
 
5.3.2.2 Systemic sensitization demonstrated by T cell cytokine profile 
 
To confirm the induction of Th2 phenotype at the T cell level, sensitized mice were 
sacrificed at day 30, and spelenocytes were cultured with Der p 1 in vitro to stimulate 
antigen specific CD4+ T cells. 72 hours later, supernatants were collected for cytokine 
ELISA to determine the levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ. It was observed 
that the levels of the Th2 cytokines, IL-4, IL-5, IL-10 and IL-13, were significantly 
higher in the Der p 1 sensitized group (Fig. 5.9A, B, C, D). In contrast, the Th1 cytokine 
IFN-γ was similar to that of the naïve mice (Fig. 5.9E). Therefore it is evident that the 
sensitization protocol had successfully induced a prominent Der p 1 specific Th2 
response. 
 
5.3.2.3 Establishment of Airway Hyperresponsiveness (AHR) 
 
Non-specific airway hyperresponsiveness (AHR) is the hallmark of allergic asthma. 
Therefore it is necessary to test whether local airway challenge following the systemic 
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sensitization could recruit the established Th2 cells and other inflammatory cells to the 
site of allergen challenge and subsequently resulting in airway hyperresponsiveness. 
Balb/cJ mice were sensitized and challenged using the same protocol as described in Fig. 
5.3, and AHR was tested on day 29 (about 24 hours after the last aerosol challenge) by 
non-invasive whole body plethysmography. It is shown in Fig. 5.10 that the sensitized 
mice responded to increasing dose of methacholine with significantly higher Penh values 
(enhanced pause), indicating a higher airway responsiveness. Therefore the sensitization 
protocol had successfully induced a systemic Th2 response to Der p 1 and high levels of 
Der p 1 specific IgE. Upon airway exposure to Der p 1, these sensitized mice could 
develop local allergic reactions resulting in non-specific airway hyperresponsiveness. 
 
5.3.2.4 Induction of airway inflammation 
 
Asthma has been recognized as a chronic inflammatory disease (Djukanovic R et al., 
1990). Therefore, airway inflammation is another key feature of an asthma model. To 
determine whether airway inflammation could be established in the sensitized and 
challenged mice, BAL fluid was obtained from anesthetized mice two days after the last 
aerosol challenge. Cytospin slides of the BAL fluid were stained with Liu stain (Riu CH, 
1953) to differentiate cell types. Macrophages, lymphocytes, neutrophils, and eosinophils 
could be identified based on standard hematological characteristics under the light 
microscope. For each slide, a total of 500 cells were counted. It was observed in the 
control naïve mice that more than 90% of the airway resident cells are macrophages and 
the rest are mainly composed of lymphocytes (Table 5.1, Fig. 5.11, Fig. 5.12). In 
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contrast, when the mice were sensitized and challenged with Der p 1, a significant 
increase in lymphocytes and other inflammatory cells were observed (Table 5.1, Fig. 
5.11, Fig. 5.12). The infiltration of large number of lymphocytes, neutrophils and 
eosinophil into the challenged airway clearly indicate the establishment of a local airway 
inflammation in the sensitized mice.  
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Figure 5.4 Antigen dose dependent induction of Der p 1 specific IgE in 4 strains of 
mice. Balb/cJ (panel a), AKR mice (panel b), CBA mice (panel c) and C3H/HeJ mice 
(panel d), 5 in each group, were sensitized by intraperitoneal injection of 1 µg or 10 µg 
Der p 1, emulsified in 4 mg alum, at days 0, 10, and 20. Sera were collected every 10 
days for Der p 1-specific IgE assay by ELISA. Each point in the graph represents mean 
IgE concentration + SEM in sera from 5 mice. Statistical differences were measured by 
Student t test. 
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Figure 5.5 Splenocytes from 1 µg Der p 1 sensitized mice produce more Th2 
cytokines upon in vitro stimulation. C3H/HeJ mice, 5 in each group, were sensitized by 
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intraperitoneal injection of 1 µg or 10 µg Der p 1, emulsified in 4 mg alum, at days 0, 10 
and 20. On day 24, mice were sacrificed; splenocytes were then cultured in vitro with 
medium containing 20 µg/ml Der p 1 or medium alone. 72 hours later, supernatants were 
taken and stored in -20C until cytokine assays by ELISA. Each point in the graph 
represents mean cytokine concentration ± SEM. Statistic differences were measured by 
Student t test. 
 177
  Chapter 5 Animal model 
































































































Figure 5.6 CD8 T cells from low dose Der p 1 sensitized mice produce more type two 
cytokines. C3H/HeJ mice, 5 in each group, were sensitized by intraperitoneal injection of 
1 µg, 10 µg or 50 µg Der p 1, emulsified in 4 mg alum, at days 0, 10 and 20. On day 24, 
mice were sacrificed; CD8+ T cells were purified from splenocytes by autoMACS, and 
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stimulated in vitro with anti CD28 and anti CD3 antibodies. 72 hours later, supernatants 
were taken and stored in -20C until cytokine assays by ELISA. Each point in the graph 
represents mean cytokine concentration ± SEM. Statistic differences were measured by 
student t test. 
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Figure 5.7a   (Alum control)                                                       Figure 5.7b (1 µg Der p 1) 
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 Figure 5.7 Higher percentage of CD4+CD25+ T cells in mice sensitized with higher 
dose of Der p 1. C3H/HeJ mice, 5 in each group, were sensitized by intraperitoneal 
injection of 0 µg (alum control), 1 µg, 10 µg or 50 µg of Der p 1, emulsified in 4 mg 
alum, at days 0, 10 and 20. On day 24, mice were sacrificed; splenocytes were then 
cultured in vitro with 20 µg/ml Der p 1 for 10 days. The cultures were replenished with 
IL-2 at days 3, 5 and 7.  On day 10, Live T cells were enriched by Ficoll gradient. The 
percentage of CD4+CD25+ T cells was analyzed by flowcytometry. Figures 4 a-d  show 
the representative results for mice receiving 0, 1 , 10, 50 ug of Der p1, respectively; the 
histograms in Figure 4e represent the results express as mean ± SEM in each group. 
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Figure 5.8 Induction of Der p 1 specific IgE and IgG1. Four Balb/cJ mice were 
immunized intraperitoneally with 1 µg native Der p 1 emulsified in 4 mg Alum 
Hydroxide on day 0 and day 7. Aerosol challenge was performed on day 22, 25 and 28 
with nebulized Der p 1 from 10ml PBS containing 0.5 mg Der p 1 protein. Sera were 
collected sequentially for detection of Der p 1 specific IgE (A) and IgG1 (B) by ELISA. 
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Figure 5.9 T cell cytokine profile after sensitization. Balb/cJ mice, 4 in each group, 
were kept naïve throughout, or immunized intraperitoneally with 1 µg native Der p 1 
emulsified in 4 mg Alum Hydroxide on day 0 and day 7. Aerosol challenge was 
performed on day 22, 25 and 28 with nebulized Der p 1 from 10ml PBS containing 0.5 
mg Der p 1 protein. Mice were sacrificed on day 30, and spelenocytes were cultured with 
Der p 1 in vitro to stimulate antigen specific CD4+ T cells or with medium control. 72 
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hours later, supernatants were collected for cytokine ELISA to detect the levels of IL-4 
(A), IL-5 (B), IL-10 (C), IL-13 (D), and IFN-γ (E). 
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Figure 5.10 Non-specific airway hyperresponsiveness (AHR) after sensitization and 
challenge. Balb/cJ mice, 4 in each group, were kept naïve throughout, or were immunized 
intraperitoneally with 1 µg native Der p 1 emulsified in 4 mg Alum Hydroxide on day 0 
and day 7. Aerosol challenge was performed on day 22, 25 and 28 with nebulized Der p 1 
from 10ml PBS containing 0.5 mg Der p 1 protein. AHR was tested on day 24 hours after 
the last aerosol challenge by non-invasive whole body plethysmography. The differences 
between sensitized mice and naïve mice are statistically significant at Mch doses 10, 20 
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Mouse No. Macrophage Lymphocyte Neutrophil Eosinophil Total 
1 255 137 108 0 500 
2 233 162 83 22 500 
3 146 95 202 57 500 
4 186 111 178 25 500 
5 471 28 1 0 500 
6 461 39 0 0 500 
7 481 19 0 0 500 
8 488 12 0 0 500 
 
 
Table 5.1 Induction of airway inflammation. Balb/cJ mice (mice 1-4) were 
immunized intraperitoneally with 1 µg native Der p 1 emulsified in 4 mg Alum 
Hydroxide on day 0 and day 7. Aerosol challenge was performed on day 22, 25 and 28 
with nebulized Der p 1 from 10ml PBS containing 0.5 mg Der p 1 protein. On day 30, 
BAL fluid was obtained from anesthetized mice and cells within the BAL were stained, 
identified, and differentiated into macrophages, lymphocytes, neutrophils, and 
eosinophils based on standard hematological characteristics under the light microscope. 
For each slide, 500 cells were counted. Mice 5-8 were control naïve mice. 
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Figure 5.11 Induction of airway inflammation. Balb/cJ mice, 4 in each group, were 
treated as described in Table 5.1 and Fig. 5.3). Cells in BAL were determined in 
individual mouse and the percentage of each cell type was plotted. Each bar in the graph 
represents mean of cell percentage + SEM. Statistic differences were measured by 
student t test. Significant differences could be detected in lymphocytes and neutrophils. *, 
p<0.05. 
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           A                                                                 B 
       
 
          C                                                                   D 
       
 
Figure 5.12 The hematological characteristics of the infiltrating cells in BAL fluid. 
The slides were prepared by cytospin and stained by Liu stain. Each panel represents the 
BAL from one individual mouse. Panels A and B are from naïve mice. Panels C and D 
are from sensitized mice. 
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5.3 Discussion 
 
Der p 1 specific IgE plays a critical role in the pathogenesis of asthma and other allergic 
diseases. It is important to determine the factors that contribute to the induction of Der p 
1 specific IgE. In a previous study, Stewart et al. demonstrated that Der p 1 specific IgE 
could be generated in C3H/HeJ, AKR, Balb/c, C57BL/6, and CBA mice, by a single 
intraperitoneal injection of Der p 1 absorbed to alum. CBA and C57BL/6 strains were 
shown to be high IgE responders, while C3H, AKR, and Balb/c were considered as poor 
responders, suggesting the importance of genetic factors in IgE regulation (Stewart GA 
and Holt PG, 1987). Here I performed similar experiments with different doses of Der p 1 
(1 µg or 10 µg) using four different strains of mice, namely C3H/HeJ, CBA, AKR, 
Balb/cJ. Although significant difference of IgE production did exist between strains, in 
contrast to the study reported by Steward et al., C3H/HeJ mice were shown to be the 
highest IgE responder in my study, followed by CBA, AKR and Balb/cJ. The result 
discrepancy between this study and that of Stewart et al. could be due to differences in 
immunization protocols. Besides genetic factors, the dose of antigen exposure was shown 
to be another critical factor for determining specific IgE level. Regardless of the 
differences in their genetic background, low dose of Der p 1 immunization (1 µg) 
consistently induced significantly higher levels of specific IgE in all four strains of mice 
tested. 
 
IgE is produced by B cell derived plasma cells, which require help from CD4+ T cells to 
mount a specific and efficient response. Multiple signals from CD4+ T cells can 
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influence antibody isotype and its magnitude. It is logical to deduce that difference in IgE 
levels could be directly related to the differentiation of different subsets of CD4+ T cells. 
However, this hypothesis was not supported by the study of Arps et al. (Arps V et al., 
1998). By immunizing CBA mice with different doses of KLH (Keyhole Limpet 
Hemocyanin), the authors also observed significant difference in specific IgE production, 
with higher IgE levels in lower dose immunized mice. Nevertheless, no significant 
difference in the cytokine profile of CD4+ T cells, in terms of IL-4, IL-13, and IFN-γ 
secretion, was observed, indicating that the antigen dose does not have a significant effect 
on CD4+ T cell polarization and the mechanisms of the dose effect on IgE induction 
remains elusive. In my experiments, using house dust mite allergen Der p 1 as an 
immunogen, we observed a clear cut Th2 skewed phenotype in low dose antigen 
immunized mice, demonstrated by higher production levels of IL-4, IL-5, IL-10, and IL-
13 by CD4+ T cells. The discrepancy between my data and that of Arps V et al. could 
have resulted from the differences in antigens and experimental systems. However, the 
effect of antigen dose on T cell polarization is not likely to be specific for Der p 1. The 
phenomena that CD4+ T cell polarization could be influenced by antigen dose has also 
been observed by other researchers using OVA, collagen, and bee venom phospholipase 
A2, in either in vitro or in vivo systems (Boonstra A et al., 2003; Hosken NA et al., 1995; 
Carballido JM et al., 1992; Pfeiffer C et al., 1991). It has been suggested that antigen 
dose could affect the signals transmitted via TCR and the subsequent duration and 
magnitude of calcium influx, which could possibly influence helper T cell polarization by 
(Constant S et al., 1995; Grakoui A et al., 1999). Given the distinct effects of the Th1 and 
Th2 cytokines on ε germline gene transcription and IgE class switch recombination, we 
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propose that effects of Der p 1 sensitizing dose on CD4+ T cell polarization and on IgE 
regulation are likely to be related.  
 
Small amount of exogenous antigen can be presented via MHC class I molecule to 
activate CD8+ T cells (Carbone ER and Bevan MJ, 1990; Kovacsovics-Bankowski M 
and Rock KL, 1995), which has been shown to play a regulatory role in IgE production 
possibly through cytokines they produce (Vukmanovic-Stejic M et al., 2001; Kemeny 
DM, 1998). Similar to CD4+ T cells, CD8+ T cells could also differentiate into distinct 
effector populations with different cytokine profile. To examine whether Der p 1 
sensitization dose could also affect CD8+ T cell differentiation, we further characterized 
CD8+ T cells by cytokine profiling. CD8+ T cells from lower dose immunized mice 
secreted higher amounts of type 2 cytokines, including IL-4, IL-5, IL-9, IL-10, and IL-13, 
than those from higher dose immunized mice. Although, Tc1 and Tc2 derived in vitro 
were both shown to be able to suppress IgE induction, the effect of Tc2 is weaker 
(Thomas MJ et al., 2002). It could be postulated that with CD8+ T cells differentiated to 
a more Tc2 polarized phenotype, which is less powerful in keeping IgE level at bay, the 
low dose Der p 1 immunized mice could then mount higher IgE levels. Although it is still 
possible that the Der p 1 dose dependent polarization of CD8+ T cells is a separate 
phenomena that is unrelated to IgE induction.   
 
Regulatory T cells that co-express CD4 and CD25 are powerful inhibitors of T cell 
activation both in vivo and in vitro (Shevach EM, 2002). Unlike conventional T cells, 
which up-regulate CD25 transiently (within several days after activation), these cells 
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maintain their expression of CD25 (Bluestone JA et al., 2003; Bujdoso R et al., 1993). 
Although new cell surface markers, such as CTLA-4, GITR, CD45RBlow, indicative of 
regulatory T cells are continuously being identified, CD25 remains to be the most 
specific, possibly because of the involvement of this receptor and its ligand in regulatory 
T cell development (Sakaguchi S et al., 2004; Nishimura E et al., 2004). It was observed 
in my experiments that after 10 days of in vitro culture, a remarkably small percentage of 
CD4+ T cells co-expressing CD25 in the low dose group (1 µg). The involvement of 
CD4+CD25+ T cells in dose dependent IgE regulation has not been previously reported. 
Although more complicated mechanisms could be involved, one possible interpretation is 
that lower dose Der p 1 immunization actively inhibited the development of 
CD4+CD25+ regulatory T cells, and helped the effector T cells to escape their 
suppressive effect, which in turn favors the polarization of type 2 skewed immune 
response and hence higher IgE production. On the other hand, high dose allergen 
exposure could possibly favor regulatory T cell development. Recent epidemiological 
evidence suggests that high dose of cat allergen exposure decreases sensitization and the 
involvement of regulatory T cells in this observation is under investigation (Woodfolk 
JA, 2005). It has been shown that different doses of antigen are preferentially presented 
by different types of antigen presenting cells, with low dose antigen more efficiently 
presented by B cells (Lanzavecchia A, 1985; Malynn BA et al., 1985). Signals from 
antigen presenting cells can then influence the subsequent T cell differentiation (Secrist H 
et al., 1995). Detailed functional assays are being carried out currently to further explore 
the inter-relationship between antigen dose, antigen presentation cells, regulatory T cell 
development, and Th2/Tc2 differentiation. 
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In summary, this study demonstrated low dose antigen immunization (1 µg of Der p 1) 
consistently induced significantly higher levels of specific IgE in C3H/HeJ, Balb/cJ, 
CBA, and AKR mice, regardless of the differences in their genetic background. The 
higher levels of IgE induction in lower dose immunized mice was associated with more 
type 2 skewed phenotypes of CD4+ and CD8+ T cells. Furthermore down-regulation of 
CD4+CD25+ T cells was observed in low dose Der p 1 immunized mice. It remains to be 
determined whether the dose effect on this regulatory T cell population is specific for Der 
p 1 or represents a general mechanism underlying the dose dependent regulation of 
immune responses. The role of CD4+CD25+ T cells in the regulation of IgE induction 
and allergy development deserves further investigation. 
 
Based on the above findings, an experimental mouse asthma model was established on 
Balb/cJ mice using the low dose sensitization protocol. Systemic sensitization with 1 µg 
Der p 1 successfully induced Der p 1 specific Th2 response characterized by IgE 
production and the Th2 skewed phenotype of CD4+ T cells. Subsequent airway challenge 
further induced local allergic reaction and airway hyperresponsiveness. It should be noted 
that the airway eosinophilia is evident but not as significant as that observed in human 
asthma patients or the OVA allergic models (Tomkinson A et al., 2002; Gong PH et al., 
2005). Instead, lymphocytes and neutrophils were responsible for the majority of the 
inflammatory cells recruited to the airway. The recruitment of lymphocytes and 
neutrophils was also observed by other researchers in Der p 1-induced mouse asthma 
models (Lee YL et al., 1999). However, it has to be emphasized there are differences 
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between human and mouse, and the limitations of animal models, as has been pointed out 
by many investigators (Pabst R, 2002-2003; Isenberg-Fieg H et al., 2003; Canning BJ, 
2003; Kips JC et al., 2003). Nevertheless, mouse asthma model is still a powerful 
research tool for the efficacy evaluation of DNA vaccines or other form of allergen 
specific vaccines.   
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PRECLINICAL EVALUATION OF DER P 1 DNA VACCINE 
IN A MOUSE ASTHMATIC MODEL 
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6.1 Introduction 
 
House dust mites are the most important source of indoor allergens responsible for 
sensitization and development of allergic diseases. The prevalence of allergic asthma 
related to house dust mite allergy is high and keeps increasing worldwide (Weiss KB et 
al., 2000). Der p 1 is a major house dust mite allergen from Dermatophagoides 
pteronyssinus. More than 70% of sera from mite allergic individuals showed IgE 
reactivity to Der p 1. It has been suggested that exposure and sensitization by the major 
mite allergens may facilitate the sensitization to other less prevalent minor allergens 
resulting in polysensitization by multiple allergens (Silvestri M et al., 1999). Therefore 
Der p 1 is commonly being targeted as one of the key candidate molecules for vaccine 
development against mite allergy and allergic asthma.  
 
Since Der p 1 is a cysteine protease with demonstrated proteolytic activity (Chua KY et 
al., 1988; Hewitt CR et al., 1995; Wan H et al., 1999; Schulz O et al., 1998B), prolonged 
endogenous synthesis in a vaccinated host may have unpredictable effects. It has been 
reported that the pro-enzyme peptide of cysteine proteases serves as an intramolecular 
chaperon, and is essential for correct folding of the mature protein (Shinde U and Inouye 
M, 1993). Therefore, it was hypothesized that the exclusion of the native cDNA 
sequences encoding for the pre-pro-regions of Der p 1 in the Der p1 DNA construct is a 
feasible strategy to produce immunogenic but enzymatically inactive Der p 1 in vivo. 
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In study described in chapter 3, I have proven the concept that  intramuscular injection of 
a DNA construct containing cDNA fragment encoding for mature Der p 1 only was 
capable of priming Der p 1- specific Th1 skewed immune responses in mice, but the 
magnitude of the immune responses was low. Thus, the focus of the study described in 
chapter 4 was on the optimization strategy aiming to increase the magnitude of DNA-
induced immune responses. The results showed that the combination of using an efficient 
mouse Igκ light chain signal peptide sequence and a codon-optimized Der p 1 gene 
sequence greatly increased the immunogenicity of DNA construct that was designated as 
LHM. In this chapter, I will describe the preclinical evaluations of construct LHM for 
prophylactic and therapeutic applications using an experimental allergic asthma mouse 
model detailed in chapter 5. It is to be noted the evaluation was mainly focused on the 
efficacy potential of the immune responses induced by the injected DNA constructs 
without any subsequent boosting with protein. Inhibition of Der p 1 specific IgE, 
reduction of Th2 cytokine production by Der p 1 specific T cells, and attenuation of 
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6.2 Materials and Methods 
 
6.2.1 Generation of codon optimized Der p 1 construct 
 
The generation of the LHM construct has be detailed in chapter 4, section 4.2.1. Briefly, 
partially overlapping oligonucleotides spanning the mature part of Der p 1 coding 
sequence were synthesized and used to generate the codon optimized DNA fragment 
(hmDerp1) in a two-step PCR amplification (Massaer M et al., 2001). A mouse Ig κ light 
chain signal sequence (mk) was tagged in-frame to the 5’ end of the hmDer p1 by PCR 
and subsequently the entire DNA fragment were cloned into the pVAX1 expression 
vector and DNA sequence confirmed (Fig. 6.1, Fig. 6.2). The prophylactic and 
therapeutic potentials of the resulting construct, pVAX1-mk-hmDerp1 (LHM), were 
evaluated with the Der p 1 allergic mouse asthma model developed in Chapter 5. 
 
6.2.2 DNA immunization and in vivo electroporation 
 
DNA immunization and in vivo electroporatioin was performed on six to eight weeks old 
female Balb/cJ mice as described in chapter 2, section 2.2.15. Briefly, anesthetized mice 
were then immunized by intramuscular injection of 50 µl of naked DNA (1 µg/µl) in the 
left anterior tibialis using a 1 ml insulin syringe and a 27 G needle, followed by 
immediate electroporation with an ECM 830 apparatus (BTX, Genetronics, San Diego, 
CA). Mice were boosted the same way in the other leg 7 days later. Sera were collected 
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before (day 0) and sequentially after immunization. Detailed immunization protocols 
were shown in Fig. 6.3 and Fig. 6.4, and described in section 6.2.4. 
 
6.2.3 Purification of native Der p 1 by monoclonal antibody affinity 
chromatography 
 
Native Der p 1 was purified from spent mite media by mAb 4C1 affinity chromatography 
as described in chapter 2, section 2.2.2. Briefly, spent mite media extracts were passed 
through tandem 4C1 columns and the columns were washed with TBS until the OD280nm 
had reached zero. The bound native Der p 1 was eluted with 10 mM Glycine, 50% 
ethylene glycol, pH 10. The eluents were neutralized with 1 M Tris-HCl, pH 6.5 and 
dialysed immediately against PBS and quantitated by comparison with a protein standard 
using a colorimetric assay (BioRad, Hercules, CA, USA). The purity and identity of Der 
p 1 was confirmed by SDS-PAGE and Western blot. 
 
6.2.4 Airway allergen exposure by aerosol 
 
Airway exposures of Der p 1 to mice were performed by generating Der p 1 aerosol via 
an ultrasonic nebulizer (model UltraNEB 99, DeVilbiss Health Care, Sommerset, PA; 
Fig. 2.4) from 0.1 mg/ml solution of Der p 1 in PBS. The mice were kept unrestrained in 
a desiccator chamber with continual flow of aerosol for 30 mins. Please see Fig. 6.5 for 
the nebulizer and the chamber used in this study. 
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6.2.5 Experimental mouse models 
 
Six to eight weeks old female BALB/cJ mice were purchased from Laboratory Animals 
Centre (Sembawang, Singapore) and housed in the Animal Holding Unit facility in 
National University of Singapore under institutional guidelines for the care and use of 
laboratory animals. Immunization was done according to the regiments shown in Figure 
6.3 and Figure 6.4.  
 
For evaluation of prophylactic efficacy (Fig. 6.3), DNA immunization was carried out by 
injection of 50 µg of LHM (in 50 µl PBS) intramuscularly, followed by in vivo 
electroporation (see 6.2.2). Mice were immunized with LHM twice on day 0 and day 7, 
and then challenged with the sensitization protocol developed in Chapter 5. Briefly, for 
sensitization challenge, mice were injected intraperitoneally with 1 µg of Der p 1 
emulsified with 4 mg alum as adjuvant, on day 14 and 21. On day 36, 39, and 42, airway 
allergen exposures were performed by inhalation of Der p 1 (100 µg/ml native Der p 1 in 
PBS) using an ultrasonic nebulizer (DeVilbiss Health Care, Sommerset, PA; see section 
6.2.4 and Fig. 6.5). For half of the mice (Fig. 6.3A), blood samples were collected every 
week until day 77 for detection of Der p 1 specific antibodies by ELISA (6.2.6). For the 
other half of the mice (Fig. 6.3B), AHR was measured on day 43 (please see section 6.2.7 
for AHR measurement method). One day after the AHR measurement (day 44), mice 
were sacrificed, spleens were taken for T cell study (section 6.2.8), and BAL was 
collected for inflammation study (section 6.2.9). This protocol is to mimic the situation 
where the patient is vaccinated with allergen gene first and subsequently subject to 
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allergen sensitization, so as to evaluate the effect of DNA vaccination on future allergen 
challenge. 
 
For evaluation of therapeutic efficacy (Fig. 6.4), Der p 1 allergic mouse asthma model 
was first established by the biphasic protocol developed in chapter 5. Briefly, mice were 
injected intraperitoneally with 1 µg of Der p 1 emulsified with 4 mg alum as adjuvant, on 
day 0 and 7. On day 22, 25, and 28, airway allergen exposures were performed by 
inhalation of Der p 1 (100 µg/ml native Der p 1 in PBS) using an ultrasonic nebulizer 
(DeVilbiss Health Care, Sommerset, PA; see section 6.2.4 and Fig. 6.5). DNA 
immunization with LHM construct was then carried out on day 35 and day 42. Mice were 
exposed again to Der p 1 allergen intraperitoneally (1 µg in 4 mg Alum) on day 77 and 
via airway (section 6.2.4) on day 83. Blood samples were collected on day 56 (two weeks 
after the second DNA immunization) and day 84 (one week after the last intraperitoneal 
injection) for detection of Der p 1 specific antibodies by ELISA (section 6.2.6). AHR was 
measured on day 84, which is 24 hours after the last airway allergen exposure (please see 
section 6.2.7 for AHR measurement method). One day after the AHR measurement (day 
85), mice were sacrificed, spleens were taken for T cell study (6.2.7), and BAL was 
collected for inflammation study (section 6.2.9). This protocol is to mimic the situation 
where the patient is sensitized to allergen and then treated with DNA immunization, and 
subsequently exposed to allergen again, so as to evaluate the effect of DNA 
immunization on established allergic asthma status. 
 
6.2.6 Detection of Der p 1 specific mouse immunoglobulin responses 
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The levels of Der p 1 specific IgE, IgG1, and IgG2a were determined by ELISA as 
described in chapter 2, section 2.2.9. Briefly, mouse sera were incubated in duplicate with 
the Der p 1 coated wells for overnight at 4°C. Biotin-conjugated monoclonal rat anti-
mouse IgE (R19-15), anti-mouse IgG1 (G1-1.5) and anti-mouse IgG2a (R35-92) were 
used for detection and followed by addition of ExtrAvidin-alkaline phosphatase. Signals 
were developed by addition of p-Nitrophenylphosphate substrate. ELISA index unit was 
defined as the OD405nm reading corresponding to the reading of 1 ng/ml of purified mouse 
IgE, IgG1, or IgG2a in a sandwich ELISA with anti-mouse Igκ as the capture antibody in 
the same plate. All the antibodies used were purchased from Pharmingen (Pharmingen, 
San Diego, CA). 
 
6.2.7 Non-invasive measurement of airway hyperresponsiveness 
 
Approximately 24 h after the last aerosol challenge, airway responsiveness was assessed 
in conscious, unrestrained mice by the whole-body plethysmography (model PLY3211, 
Buxco Electronics Inc., Troy, New York, USA; Fig. 2.5) as described previously 
(Hamelmann E et al., 1997). This system calculates a dimensionless parameter known as 
enhanced pause (Penh) reflecting the changes in waveform of the chamber pressure, 
measured with a transducer (model TRD5100) connected to preamplifier modules (model 
MAX2270) and analyzed by BioSystem XA software (model SFT 1410, all from Buxco 
Electronics). Measurements consisted of respiratory rate, tidal volume, pause (PEF/PIF), 
and Penh ((Te/RT-1) x PEF/PIF), where PEF = peak expiratory flow (ml/s), PIF = peak 
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inspiratory flow (ml/s), Te = expiratory time, and RT = relaxation time. Measurements of 
methacholine responsiveness were obtained by exposing mice to an aerosol of PBS 
(baseline readings), and cumulative increased doses (5 to 40 mg/ml) of aerosolized 
methacholine. The aerosol was generated by a portable ultrasonic nebulizer (model 
5500D, DeVilbiss Health Care, Sommerset, PA) and drawn through the chamber for 3 
mins with the Bias Flow Supply (model PLY1040). The signals were recorded for the 
subsequent 5 mins. The interval between each dose was 1 min. This whole-body 
plethysmographic method for measurement of airway responsiveness has been validated 
by direct comparison with the conventional invasive measurement (Hamelmann E et al., 
1997). 
 
6.2.8 T cell cytokine profiling 
 
T cell cytokine profiling was performed as described in chapter 2, section 2.2.11. Briefly, 
single-cell suspensions were prepared from spleen and red blood cell lysis was 
performed.  Splenocytes (4x105 cells /well) were cultured in the presence or absence of 
20 µg/ml of Der p 1 in 96-well round-bottomed plates (Costar, Corning, NY) containing 
RPMI 1640 medium supplemented with 10% heat-inactivated bovine calf serum 
(StemCell Technologies Inc.), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml 
penicillin and 100 µg/ml streptomycin (Hyclone Laboratories, Logan, UT) and 5.5 ×10-2 
mM 2-mercaptoethanol (Life technology, Grand Island, NY). After 72 h, culture 
supernatants were collected, stored at -20oC and assayed in duplicate for the presence of 
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the cytokines IL-4, IL-5, IL-13, IFN-γ, and IL-10, by sandwitch ELISA as described in 
chapter 2, section 2.2.10. 
 
6.2.9 Collection of broncheoalveolar lavage and cytospin preparation for 
differential cell counts 
 
Mice were anesthetized with intraperitoneal injection with a lethal dose of a mixture 
containing 1.25 mg/ml midazolam, 2.5 mg/ml fluanisone and 0.079 mg/ml fentanyl 
citrate. The trachea was cannulated by tracheotomy (20G cannula) and lung was lavaged 
with 0.8 ml of ice-cold Hank’s balanced salt solution (HBSS) without calcium and 
magnesium for four times. Cells were centrifuged at 1,200 rpm for 10 min and 
resuspended in PBS with 1% BSA. Cytospin was prepared by centrifugation of 1 x 105 
cells in 100 µl at 600 rpm for 10 mins using Cytospin® 3 (Shandon Lipshaw) (Cytospin, 
Runcorn, Cheshire, U.K.). The cells were stained with the Liu stain (Riu CH, 1953). 
Cells were identified and differentiated into macrophages, lymphocytes, neutrophils, and 
eosinophils based on standard hematological characteristics under the light microscope. 
For each slide, 500 cells were counted and the percentage of each cell type was 
calculated.
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Mouse Igκ chain leader sequence: 
atg gag aca gac aca ctc ctg cta tgg gta ctg ctg ctc tgg gtt cca ggt tcc  
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S  
act ggt gac gcg gcc 
 T   G   D   A   A 
 
Codon optimized mature Der p 1 DNA sequence: 
   1 Accaacgcct gcagcatcaa cggcaatgcc cccgctgaga ttgatctgcg ccagatgagg     
  61 accgtgactc ccatccgcat gcaaggcggc tgcgggtctt gttgggcctt ctcaggcgtg  
 121 gccgcgaccg agtctgcata cctcgcgtat cggaatcaga gcctggacct cgctgagcag  
 181 gagctcgttg actgcgcctc ccaacacgga tgtcatgggg atacgattcc cagaggtatc  
 241 gaatacatcc agcataatgg cgtcgtgcag gaaagctatt accgatacgt agctagggag  
 301 cagtcctgcc gccgtcctaa cgcccagcgc ttcggcattt ccaactattg ccagatctac  
 361 ccccctaatg tgaacaagat cagggaggcc ctggcgcaga cgcacagcgc catcgctgtc  
 421 atcatcggaa tcaaggatct ggacgcattc cggcactatg acgggcgcac aatcatccag  
 481 cgcgacaacg gataccagcc aaactatcac gcggtcaaca tcgtgggtta ctcgaacgcc  
 541 cagggggtgg actactggat cgtgcggaac agttgggaca ccaactgggg cgacaacggc  
 601 tacggctact ttgccgccaa catcgacctg atgatgatcg aagagtaccc gtacgtggtg  
 661 atcctgTGA  
 
 
Figure 6.1 Nucleotide sequence encoding the signal peptide of mouse Igκ chain (upper 
panel; the encoded amino acids were indicated below), and the codon optimized DNA 
sequence encoding mature Der p 1 (lower panel) 
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Figure 6.2 Schematic representation of the LHM construct. Please refer to Figure 6.1 
for detailed sequence information of mouse Igk chain leader and the codon optimized 
mature Der p 1 sequence. These two sequences were directly linked together and inserted 
into the Bam HI and Xba I sites of pVAX1 vector. The map of pVAX1 vector was 
adapted from Invitrogen website. 
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Figure 6.3 Schematic representation of the immunization regiments for evaluation of 
preventive efficacy. For half of the mice, blood samples were collected until day 77 for 
detection of Der p 1 specific antibodies by ELISA (A). For another half of the mice, AHR 
was measured on day 43, and the mice were sacrificed on day 44 for T cell study (B). 
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S S D/C D/CAerosol   S   Aerosol 
 
 84    85 0 7 Day 14 21 28 35 42 49 56 63 70 77 
Bleeding 
 
  Bleeding    T cell  
  AHR           BAL  
 
S, Systemic sensitization by intraperitoneal injection of 1 µg native Der p 1 protein 
emulsified in 4 mg alum, on day 0, 7, and 77 
D, DNA immunization with LHM DNA construct, on day 35 and 42 
C, PBS control 
Aerosol, Airway allergen exposure with aerosolized native Der p 1 on day 22, 25, 28, 
and 83 
AHR, measurement of airway hyper-responsiveness on day 84 
 
Figure 6.4 Schematic representation the immunization regiments for evaluation of 
herapeutic efficacy.  
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Figure 6.5 Pictures of Ultrasonic nebulizer (A), desiccator chamber with a mouse 
inside (B), and the connection of the two devices (C) for airway allergen exposure (see 










Figure 6.6 Whole-body plethysmography (model PLY3211, Buxco Electronics Inc., 
Troy, New York, USA). Mice were individually kept in the chambers shown at the left 
hand side in the upper picture pictures, and the breath of mice were monitored and 
recorded by a computer. The lower picture shows a mouse kept in one of the chamber for 
AHR measurement. This system calculates a dimensionless parameter known as 
enhanced pause (Penh). Penh = ((Te/RT-1) x PEF/PIF), where PEF = peak expiratory 
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flow (ml/s), PIF = peak inspiratory flow (ml/s), Te = expiratory time, and RT = relaxation 
time. 
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6.3 Results 
 
6.3.1 Prophylactic evaluation of DNA immunization 
 
6.3.1.1 Prophylactic effect of DNA vaccine on Der p 1 specific IgE 
 
The humanized mature Der p 1 gene was tagged with a strong leader sequence from 
mouse Igκ chain, and inserted into pVAX1 expression vector (Fig. 6.2). The resulting 
construct, pVAX1-mk-hmDerp1 (LHM), was shown to induce significantly higher levels 
of immune responses as compared to other constructs as described in chapters 3 and 4. I 
have also demonstrated that by adopting DNA primed – protein boost approach, the 
magnitude of the DNA primed immune responses could be further up-regulated. 
However, in order to gain further understanding on the efficacy potential of the immune 
responses exclusively induced by DNA immunization, the mixed modality prime-boost 
immunization strategy was not used in this study. The strategy used to assess the 
prophylactic efficacy of LHM DNA immunization is shown schematically in Fig. 6.3. 
Mice were pre-immunized with 50 µg of LHM DNA at days 0 and 7, followed by 
systemic sensitisation with Der p 1 in alum intraperitoneally on day 14 and 21 (Fig. 
6.3A). It was observed that Der p 1 specific IgE production in DNA vaccinated mice was 
significantly down-regulated (Figure 6.7A), and the difference is statistically significant 
ever since significant Der p 1 specific IgE was induced in the control mice on day 28. On 
the contrary, both IgG2a and IgG1 levels were greatly boosted in DNA immunized mice 
after intraperitoneal Der p 1/alum challenge (Figure 6.7B, C). Given the different 
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regulation of IgE and IgG2a by Th2 and Th1 cells, respectively, these data indicated that 
Der p 1 gene immunization induced Th1 skewed immune responses, which mediated the 
attenuation of Th2 responses and inhibition of IgE production upon subsequent allergen 
challenge. 
 
6.3.1.2 Prophylactic effect on DNA vaccine on T cell polarization 
 
Allergen specific Th2 skewed immune response is critical for the development of allergic 
asthma (Wills-Karp M, 1999). Studies have shown that Th2 cytokines also have direct 
effects on the pathogenesis of this disease (Cohn L et al., 2004). To confirm the 
suppression of Th2 response by DNA vaccination, we further examined the cytokine 
profile of spleen T cells upon in vitro stimulation with Der p 1. Mice that were 
immunized and challenged as shown in prophylactic regiment (Fig. 6.3B) were sacrificed 
on day 44 and in vitro culture of splenocytes was carried out with or without Der p 1. As 
shown in Fig. 6.8, the levels of Th2 cytokines IL-4, IL-5, IL-10, and IL-13 were 
significantly decreased in DNA vaccinated mice, while the Th1 cytokine IFN-r levels 
were boosted. The ratios of IL-4 to IFN-r were also significantly decreased from 2.5 in 
control mice to 1 in DNA vaccinated mice, which confirmed the significant suppression 
of Th2 responses concurrent with a shift to Th1 response.  
 
6.3.1.3 Prophylactic effect of DNA vaccine on AHR 
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The suppression of Der p 1 specific IgE and Th2 polarization by DNA vaccination 
prompted us to further test whether airway hyperresponsiveness (AHR), which is a 
hallmark of the asthma symptom, could also be attenuated by DNA immunization. The 
protocol for this assessment is shown in Fig. 6.3B. Mice were immunized and challenged 
as described in Figure 6.3B. AHR was measured with whole-body plethysmography on 
day 43, which is 24 hours after the last aerosolized allergen challenge. AHR was 
successfully established in Der p 1 sensitized and challenged mice. On the contrary, Der 
p 1 DNA immunized mice showed attenuation in AHR as indicated by the reduced Penh 
values (Fig. 6.9) after methacholine challenge. 
 
6.3.1.4 Prophylactic effect of DNA vaccine on airway inflammation 
 
Airway inflammation is another key feature of allergic asthma (Djukanovic R et al., 
1990). To determine whether DNA vaccination could have any effect on airway 
inflammation, mice were immunized with the same protocol as described in Fig. 6.3B, 
and BAL fluid was obtained on day 44 before the mice were sacrificed for T cell study. 
Cells within the BAL were stained with Liu stain (Riu CH, 1953). Cells were then 
identified and differentiated into macrophages, lymphocytes, neutrophils, and eosinophils 
based on standard hematological characteristics under the light microscope. For each 
slide, a total of 500 cells were counted. It was observed in the naïve mice that more than 
90% of the airway resident cells are macrophages and the rest are mainly composed of 
lymphocytes (Table 6.1, Fig. 6.10, Fig. 6.11). When the mice were mock immunized, 
sensitized and challenged with Der p 1, significant increase in lymphocytes, neutrophils, 
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and eosinophils were observed (Table 6.1, Fig. 6.10, Fig. 6.11). In contrast, if the mice 
were vaccinated with LHM DNA construct before sensitization, the numbers of 
neutrophils and eosinophils decreased tremedously as compared to the mock immunized 
mice (Table 6.1, Fig. 6.10, Fig. 6.11). 
 
6.3.2 Therapeutic evaluation of DNA immunization  
 
6.3.2.1 Therapeutic effect of DNA vaccine on Der p 1 specific IgE 
 
To evaluate the therapeutic effects of DNA vaccination with LHM construct, 
experimental asthmatic mouse model was established and treated with LHM 
immunization regiment as shown in Figure 6.4. The Der p 1 specific IgE levels were 
compared on day 56 and day 84, two weeks after the second DNA immunization and one 
week after the final Der p 1 challenge, respectively (Please refer to chapter 5 for the 
kinetics of antibody response in sensitized mice). At both time points, the Der p 1 
specific IgE levels in the LHM treated mice were significantly lower than that in the 
control group (Figure 6.12A). On the other hand, Der p 1 specific IgG2a levels, but not 
the IgG1 levels, were significantly higher in the vaccinated group on day 84 (Figure 
6.12B and 6.12C).  
 
6.3.2.2 Therapeutic effect of DNA vaccine on T cell polarization 
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To confirm the suppression of Th2 response in the T cells level, cytokine profiles of Der 
p 1 specific T cells were tested. Mice that were sensitized, and subsequently treated with 
DNA immunization, and challenged again as shown in the therapeutic regiment (Fig. 6.4) 
were sacrificed on day 85 and in vitro culture of splenocytes was carried out with or 
without Der p 1. However, although the T cell cytokines profiling showed a slight 
increase of IFN-γ and decrease in IL-13 in DNA treated mice, there was no significant 
difference between the DNA treated and non-treated mice in terms of cytokine 
production (Fig. 6.13 A-E).  
 
The above data indicated that treatment with plasmid DNA immunization inhibited Der p 
1 specific IgE and boosted IgG2a production, implicating that the LHM DNA was still 
capable of inducing Der p 1-specifc Th1 skewed humoral responses in the sensitized 
mice with dominant pre-existing Th2 skewed responses. However, T cell cytokines 
profiles data revealed that two administrations with LHM DNA were insufficient to 
suppress the pre-existing Th 2 cells (Fig. 6.13).  
 
6.3.1.3 Therapeutic effect of DNA vaccine on AHR 
 
Nevertheless, I went on to examine whether the inhibition of IgE by DNA immunization 
could result in any attenuation of airway hyperresponsiveness. AHR was measured with 
whole-body plethysmography 24 hours after the last aerosolized allergen challenge on 
day 83. AHR was established in Der p 1 sensitized and challenged mice. DNA 
immunization after the initial Der p 1 sensitization reduced the Penh values only slightly 
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Figure 6.7 Prophylactic efficacy on the inhibition of Der p 1 specific IgE. Balb/cJ 
mice, 4 in each group, were mock immunized or immunized with codon optimized Der p 
1 DNA construct intramuscularly with electroporation on days 0 and 7. Der p 1 
sensitization was done by systemic immunization intraperitoneally on day14 and day 21 
followed by three airway exposure with aerosolized Der p 1 challenges on days 36, 39, 
and 42 (Fig. 6.3A). Blood samples were collected weekly and the titer of Der p 1 specific 
IgE, IgG1 and IgG2a in serum was determined by ELISA. Results are shown as Mean + 
SEM. *: p < 0.05. 
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Figure 6.8 Prophylactic efficacy on the Der p 1 specific T cell cytokine profiles. Four 
Balb/cJ mice were immunized with DNA vaccine and challenged with Der p 1 the same 
way as described in Figure 6.3B (grey bar). Mice that were sensitized with Der p 1 
protein alone (black bar), or received DNA vaccination alone (open bar), 4 in each group, 
were included as controls. Two days after the last airway allergen challenge, mice were 
sacrificed and the splenocytes were cultured in RPMI with or without Der p 1. The 
concentration of IL-4 (A), IL-5 (C), IL-10 (E), IL-13 (D), and IFN-r (B) were measured 
from the culture supernatants with ELISA. *: p < 0.05. 
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Figure 6.9 Prophylactic efficacy on the reduction of airway hyper-responsiveness 
(AHR). Balb/cJ mice, 4 in each group, were immunized and challenged the same way as 
described in Figure 6.3B. AHR was measured with whole-body plethysmography 24 
hours after the last aerosolized allergen challenge. AHR was successfully established in 
Der p 1 sensitized and challenged mice (control group, filled square). DNA immunization 
before the Der p 1 sensitization reduced the Penh values significantly (vaccinated group, 
open square). The differences between vaccinated group and the control group at Mch 
doses 20, 40 mg/ml are statistically different, p<0.05. 
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Mouse No. Macrophage Lymphocyte Neutrophil Eosinophil Total 
1 471 28 1 0 500 
2 461 39 0 0 500 
3 481 19 0 0 500 
4 488 12 0 0 500 
5 396 163 34 7 500 
6 237 216 12 35 500 
7 450 47 3 0 500 
8 295 199 4 2 500 
9 194 118 82 106 500 
10 146 86 218 50 500 
11 190 93 186 31 500 
12 205 80 198 17 500 
 
Table 6.1 Attenuation of airway inflammation by DNA vaccination. Mice 1-4 were 
naïve mice. Mice 9-12 were mock immunized on day 0 and day 7, subsequently 
sensitized intraperitoneally with 1 µg native Der p 1 emulsified in 4 mg Alum on day 14 
and day 21, and exposed to aerosolized Der p 1 on day 36, 39, and 42. Mice 5-8 were 
immunized with LHM on day 0 and 7, and the subsequent treatments are the same as 
mice 9-12 described above. On day 30, all mice were anesthetized, BAL fluid was 
obtained, and cells within the BAL were stained, identified, and differentiated into 
 225
  Chapter 6 Preclinical evaluation 
macrophages, lymphocytes, neutrophils, and eosinophils based on standard hematological 
characteristics under the light microscope. For each slide, 500 cells were counted.  
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Figure 6.10 Prophylactic efficacy on airway inflammation. Balb/cJ mice were treated 
the same way as described in Table 6.1. Cells in BAL were determined in individual 
mouse and the percentage of each cell type was plotted. Each bar in the graph represents 
mean of cell percentage + SEM. Statistic differences were measured by student t test. 
Significant differences could be detected in the number of neutrophils. *, p<0.05. 
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Figure 6.11 The hematological characteristics of the infiltrating cells in BAL fluid. 
The slides were prepared by cytospin and stained by Liu stain. Each panel represents the 
BAL from one individual mouse. Panel A and B are from naïve mice. Panel C and D are 
from sensitized mice (see Fig. 6.3B for the sensitization protocol). Panel E and F are from 
mice immunized with DNA and then sensitized. 
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Figure 6.12 Therapeutic efficacy on the attenuation of Der p 1 specific IgE. Balb/cJ 
mice, 4 in each group, were systemically sensitized by intraperitoneal injection of native 
Der p 1 intraperitoneally with alum, followed by aerosol allergen challenge on day 21, 
22, 23. On days 35 and 42 mice were either treated with DNA immunization (vaccinated, 
grey bar) or PBS (control, black bar). On day 77, mice were challenged with Der p 1 
intraperitoneally again (Figure 6.4). Blood were collected on days 56 and 84 and titers of 
Der p 1 specific IgE (A), IgG2a (B) and IgG1 (C) were determined by ELISA. Results 
are shown as Mean ± SEM. *: p < 0.05. 
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Figure 6.13 Evaluation of therapeutic efficacy on T cell cytokine profiles. Four 
Balb/cJ mice were sensitized with Der p 1, immunized with DNA vaccine, and then 
challenged with Der p 1 the same way as described in Figure 6.4 (Black bar). Mice that 
were sensitized and challenged with Der p 1 protein without DNA vaccine treatment 
(gray bar) and the naïve mice (open bar), 4 in each group, were included as controls. Two 
days after the last airway allergen challenge (on day 83), mice were sacrificed and the 
splenocytes were cultured in RPMI with or without Der p 1. The concentration of IL-4 
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(A), IL-5 (B), IL-10 (C), IL-13 (D), and IFN-r (E) were measured from the culture 
supernatants with ELISA. 
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Figure 6.14 Evaluation of therapeutic efficacy on the reduction of airway hyper-
responsiveness (AHR). Balb/cJ mice, 4 in each group, were immunized and challenged 
the same way as described in Figure 6.4. AHR was measured with whole-body 
plethysmography 24 hours after the last aerosolized allergen challenge on day 83. AHR 
was established in Der p 1 sensitized and challenged mice (control group, filled square). 
DNA immunization after the initial Der p 1 sensitization reduced the Penh values slightly 
on Mch doses 5 and 20 mg/ml (vaccinated group, open square). However the differences 
were not statistically significant as determined by Student t test. 
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6.4 Discussion 
 
In this chapter, pre-clinical evaluation was performed with the LHM construct, which 
was designed by linking an efficient leader sequence from mouse Igκ chain with the 
codon optimized sequence of mature Der p 1. Codon optimization has been shown to 
enhance the expression of mite allergens in mammalian cells by our lab and other 
researchers (Lim LH et al., 2004; Massaer M et al., 2001), and was used to enhance the 
efficiency of plasmid DNA vaccines encoding Listeria monocytogenes, tetanus, HIV, 
malaria, and mycobacterial antigens (Uchijima M et al., 1998; Stratford R et al., 2000; 
Deml L et al., 2001; Narum DL et al., 2001; Ko HJ et al., 2005). On the other hand, an 
efficient leader sequence could help the Der p 1 protein that is produced in vivo after 
intramuscular injection of DNA to be secreted and taken up by the antigen presenting 
cells more efficiently. As it was shown in Chapter 3 and Chapter 4, the choice of leader 
sequence did make a difference in the subsequent immune response. Therefore both 
strategies could potentially enhance the DNA vaccine induced immune response and 
achieve better efficacy.  
 
The preclinical efficacy was evaluated on a Der p 1 allergic mouse asthma model that 
was developed in Chapter 5. A biphasic protocol was employed to establish the asthma 
model in Balb/cJ mice. Mice were first systemically sensitized by intraperitoneal 
injection of Der p 1 protein emulsified in a Th2 skewing adjuvant - Alum, and 
subsequently challenged with aerosol to establish local inflammation and airway 
hyperresponsiveness, which are hallmarks of allergic asthma. For the evaluation of 
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prophylactic efficacy, mice were pre-immunized with the LHM construct, and then 
sensitized and challenged with the above mentioned biphasic protocol. The effects of pre-
immunization of LHM on Der p 1 specific IgE production, T cell cytokine profile, airway 
inflammation, and airway hyperresponsiveness were subsequently tested. For the 
evaluation of therapeutic efficacy, mice were treated with the biphasic protocol to 
establish the asthma model first, and then treated with DNA immunization. Mice were 
then challenged with Der p 1 again. This is to mimic the provocation phase of asthma 
patients. Similarly, Der p 1 specific IgE, T cell cytokine production and AHR were used 
as parameters to study the effect of DNA immunization. 
 
It is clearly demonstrated in our experiments that pre-immunization of the optimized 
construct LHM could effectively inhibit Der p 1 specific IgE production, down-regulate 
Th2 cytokines, and attenuate airway hyperresponsiveness and airway inflammation upon 
subsequent allergen challenge. Given the critical roles of IgE and Th2 cytokines in the 
pathogenesis of allergic asthma, the control of these two factors are likely to be the 
prerequisites of its effects on down stream asthma symptoms such as AHR. The clear-cut 
prophylactic efficacy in animal models indicates the great potential of DNA vaccination 
for prevention of allergic response to Der p 1 and other allergens in human, which needs 
to be further demonstrated in clinical trials.  
 
The therapeutic efficacy of DNA immunization was also evaluated. It was shown that 
Der p 1 specific IgE production induced by the biphasic sensitization protocol could be 
effectively inhibited. The inhibition of Der p 1 specific IgE was also evident upon a 
 237
  Chapter 6 Preclinical evaluation 
second allergen challenge (the provocation phase). In contrast, Der p 1 specific IgG2a 
could be boosted by LHM immunization. These results indicated the induction of Th1 
response in the pre-existing Th2 environment. However, the attenuation of the existing 
Th2 response is not evident in terms of T cell cytokine production. It is known that 
established Th2 cells are very difficult, if not impossible, to change their phenotype 
(Mosmann TR et al., 1986). In this study, a strong Th2 environment was established by 
low dose Der p 1 sensitization in the presence of a Th2 skewing adjuvant - alum. DNA 
immunization was performed only twice without further boosting. The mice were 
exposed to another round of systemic and local sensitization about one month after the 
DNA treatments. There are two weaknesses in this therapeutic protocol. Firstly, the DNA 
primed Th1 response was not further boosted by extra immunizations or the mixed 
modality protocol developed in chapter 4. Secondly, the second round systemic 
sensitization on day 77 might not be necessary, because it does not happen to patients in 
the real world, and the airway allergen exposure on day 83 alone might be sufficient to 
mimic the provocation phase. Therefore, in this strong Th2 skewing protocol, twice DNA 
immunizations were not effective in attenuation of the Th2 cytokines and airway 
hyperresponsiveness. Nevertheless, the inhibition of IgE and boosting of IgG2a in this 
strong Th2 skewed environment, clearly demonstrating the potential of DNA 
immunization for treatment of allergic asthma with further modifications. 
 
Extra immunizations with DNA constructs might help to boost the therapeutic Th1 
immune responses. It is also possible that a stronger Th1 skewing and more immunogenic 
construct, or immunization protocol, such as the heterologous prime-boost protocol, is 
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required. Furthermore, development of strategies to attenuate the established memory 
Th2 response, possibly through the induction of regulatory T cells, used in combination 
with DNA immunization, could probably provide a better therapeutic approach. DNA 
vaccine design using T cell epitopes could also potentially induce a stronger immune 
response (Kwon SS et al., 2001). Recently, Jarman et al. reported significant therapeutic 
effect of a plasmid DNA encoding T cell epitope of Der p 1 spanning residues 111-139, 
on the reduction of Th2 cytokines levels and suppression of airway eosinophilia (Jarman 
ER and Lamb JR, 2004). However, due to the concern about the complexity and 
polymorphic nature of human MHC genes, full length Der p 1 gene was used in our 
vaccine design to achieve a broader spectrum of protective immunity for clinical use. 
Therefore further modifications to achiever higher efficiency and better efficacy, as 
described in the following chapters, is still based the full length strategy.  
 
In the next chapter, the feasibility of using lysosome targeting sequence in DNA vaccine 
design to target the in vivo expressed Der p 1 to a MHC II compartment, and the prime-
boost strategy to further improve the efficiency of DNA vaccination will be explored. 
 
The clear-cut prophylactic efficacies, observed for the optimized Der p 1 encoding DNA 
construct (LHM) in animal models, also prompted us to explore the strategy of multi-
gene immunization using constructs encoding several major allergens from house dust 
mites that are of local importance. The aim of multi-gene vaccination was to achieve a 
more complete protective and therapeutic efficacy in the allergic population. The results 
will be discussed in Chapter 8. 
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7.1 Introduction 
 
Data in chapter 6 showed that the established Th2 skewed phenotype in Der p 1 
presensitized mice could not be down regulated by treatment with two injections of LHM 
plasmid DNA without boosting despite a significant inhibition of specific IgE. The 
airway hyper-responsiveness of the DNA treated mice was not attenuated. The current 
chapter describes two additional strategies explored aiming to improve the efficacy of 
Der p 1 DNA vaccine. 
 
Firstly, I investigated the feasibility of lysosome targeting to enhance the immunogenicity 
of DNA vaccines. The lysosome targeting sequence from Lysosome Associated 
Membrane Proteins (LAMP) has been shown to direct the encoded protein to the MHC II 
compartment, and enhance the activation of CD4+ T cells (Wu TC et al., 1995; Ruff AL 
et al., 1997; Raviprakash K et al., 2001). In addition, results from Dr. Lip Nyin Liew in 
our lab with another allergen Blo t 5 showed that LAMP targeting could also specifically 
enhance Th1 skewed immune response (unpublished data). Therefore, Plasmid constructs 
containing genes of house dust mite allergen Der p 1, with the LAMP targeting sequence 
attached to the 3 prime end was tested in the animal model and described in this chapter.  
 
Secondly, I examined the heterogeneous prime-boost protocol in more detail. It has been 
shown in chapter 4 that the DNA primed Th1 skewed immune response could be 
significantly boosted by intraperitoneal immunization with native Der p 1 protein 
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emulsified in Alum Hydroxide. The boosting effect on the magnitude of the immune 
response and the maintenance of Th1 skewed phenotype indicate that DNA prime-protein 
boost could be a feasible modality for allergic asthma treatment. Since intraperitoneal 
injection is not clinically acceptable for human subjects, we tested the feasibility of 
boosting the DNA primed Th1 immune response via subcutaneous injection and 
intratracheal instillation (i.e. mimicking the natural exposure to allergen via airway). The 
effect of protein boost was examined in terms of antibody responses and T cell responses. 
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7.2 Materials and methods 
 
7.2.1 Construction of Der p 1 plasmids 
 
The construction of plasmids was carried out by conventional molecular cloning 
techniques (Ausubel FM et al., Current Protocols in Molecular Biology). Briefly, the 
lysosome targeting sequence was amplified from the pVAX/hTPA/Myc/MCS/TMCYD 
construct containing DNA sequences encoding the transmembrane domain and the 
cytoplasmic domain of mouse Lysosome Associated Membrane Protein 1 (LAMP1) 
provided by Professor J. Thomas August from Johns Hopkins Singapore International 
Medical Center. It was tagged in-frame to the 3’ end of LHM to make the LHML 
construct (see Fig. 7.1 for the sequence information of the lysosome targeting sequence 
from LAMP1 and Fig. 7.2 the schematic representation). 
  
7.2.2 DNA immunization and in vivo electroporation 
 
DNA immunization and in vivo electroporatioin was performed on six to eight weeks old 
female Balb/cJ mice as described in chapter 2, section 2.2.15. Briefly, anesthetized mice 
were then immunized by intramuscular injection of 50 µl of naked DNA (1 µg/µl) in the 
left anterior tibialis using a 1 ml insulin syringe and a 27 G needle, followed by 
immediate electroporation with an ECM 830 apparatus (BTX, Genetronics, San Diego, 
CA). Mice were boosted the same way in the other leg 7 days later. 
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7.2.3 Preparation of native Der p 1 by monoclonal antibody chromatography 
 
Native Der p 1 was purified from spent mite media by mAb 4C1 affinity chromatography 
as described in chapter 2, section 2.2.2. The purity and identity of Der p 1 was confirmed 
by SDS-PAGE and western blot. 
 
7.2.4 Purification of recombinant Der p 1 fragments 
 
E. coli clones producing GST fused recombinant Der p 1 fragments spanning residueds 1-
56, 15-94, 53-99, 57-130, 98-140, 131-187, and 188-222 were grown in LB medium 
containing 100 µg/ml of ampicillin and induced for 3 h with 0.5mM IPTG.  The bacteria 
were pelleted and resuspended in TBS with 1 mM PMSF, 20 µg/ml of Dnase I, 20 µg/ml 
of Lysozyme, and Tween 20 to 1% of the cell suspension. The bacteria were disrupted by 
sonication on ice, and the supernatant was collected after centrifugation. The peptides 
were purified by passage over a column of glutathione agarose beads preequilibrated in 
TBS, and elution of the bound material with 10mM reduced glutathione in 50 mM Tris 
HCl pH 8 buffer. The concentration of recombinant peptide was quantified by a 
colorimetric assay, and the purity of Der p 1 was confirmed by SDS-PAGE (Fig. 7.12). 
 
7.2.5 Detection of specific mouse immunoglobulin responses 
 
The levels of Der p 1 specific IgE, IgG1, and IgG2a were determined by ELISA as 
described in chapter 2, section 2.2.9. Briefly, mouse sera were incubated in duplicate with 
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the Der p 1 coated wells for overnight at 4°C. Biotin-conjugated monoclonal rat anti-
mouse IgE (R19-15), anti-mouse IgG1 (G1-1.5) and anti-mouse IgG2a (R35-92) were 
used for detection and followed by addition of ExtrAvidin-alkaline phosphatase. Signals 
were developed by addition of p-Nitrophenylphosphate substrate. ELISA index unit was 
defined as the OD405nm reading corresponding to the reading of 1 ng/ml of purified mouse 
IgE, IgG1, or IgG2a in a sandwich ELISA with anti-mouse Igκ as the capture antibody in 
the same plate. All the antibodies used were purchased from Pharmingen (Pharmingen, 
San Diego, CA). 
 
7.2.6 Non-invasive measurement of airway hyperresponsiveness 
 
Approximately 24 h after the last aerosol challenge, airway responsiveness was assessed 
in conscious, unrestrained mice by the whole-body plethysmography (model PLY3211, 
Buxco Electronics Inc., Troy, New York, USA; Fig. 2.5) as described in chapter 2, 
section 2.2.19. Briefly, measurements of methacholine responsiveness were obtained by 
exposing mice to an aerosol of PBS (baseline readings), and cumulative increased doses 
(5 to 40 mg/ml) of aerosolized methacholine. The signals were recorded for the 
subsequent 5 mins. The interval between each dose was 1 min.  
 
7.2.7 T cell cytokine profiling 
 
T cell cytokine profiling was performed as described in chapter 2, section 2.2.11. Briefly, 
single-cell suspensions were prepared from spleen and red blood cell lysis was performed.  
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Splenocytes (4x105 cells /well) were cultured in the presence or absence of 20 µg/ml of 
Der p 1 in 96-well round-bottomed plates (Costar, Corning, NY) containing RPMI 1640 
medium supplemented with 10% heat-inactivated bovine calf serum (StemCell 
Technologies Inc.), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 
100 µg/ml streptomycin (Hyclone Laboratories, Logan, UT) and 5.5 ×10-2 mM 2-
mercaptoethanol (Life technology, Grand Island, NY). After 72 h, culture supernatants 
were collected, stored at -20oC and assayed in duplicate for the presence of the cytokines 
IL-4, IL-5, IL-13, IFN-γ, and IL-10, by sandwitch ELISA as described in chapter 2, 
section 2.2.10. 
 
7.2.8 Determination of cell proliferation by Thymidine Incorporation Assay 
 
Splenocytes were isolated as described in 2.2.11.1 and cultured with medium control, 20 
µg/ml native Der p 1, or equal molar amount of recombinant Der p 1 fragments in 96-
well U bottom plate (Nunc, Roskilde, Denmark) at a density of 4x105 cells/200 µl 
medium/well. Cells were pulsed with 1 µCi of [3H]-thymidine (Amersham Bioscience, 
UK) for the remainder 16 hrs of culture and harvested at 96 hrs on to glass filters 
(Skatron instruments AS, Lier, Norway) using a cell harvester. The amount of [3H]-
thymidine incorporation was determined using a liquid scintillation counter. Cell 
proliferation was presented as counts per min (cpm). 
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Lysosome targeting sequence from LAMP1: 
 
ttg atc ccc att gct gtg ggc ggt gcc ctg gca ggg ctg atc ctc atc gtc ctc  
 L   I   P   I   A   V   G   G   A   L   A   G   L   I   L   I   V   L    
att gcc tac ctc att ggc agg aag agg agt cac gcc ggc tat cag acc atc tag  




Figure 7.1 Nucleotide sequences encoding the lysosome targeting sequence of LAMP1 
with encoded amino acid sequence indicated below. The full length LAMP1 sequence 
could be found in Genbank with accession number NM 010684. 
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Figure 7.2 Schematic representation of the LHML construct. Please refer to Fig. 4.3 
for detailed sequence information of mouse Igk chain leader, Fig. 4.4 for codon 
optimized mature Der p 1 sequence, and Fig. 7.1 for lysosome targeting sequence from 
LAMP1. These three sequences were linked together and inserted into the Bam HI and 
Xba I sites of pVAX1 vector. The map of pVAX1 vector was adapted from Invitrogen 
website. 
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Day 42 49 56 63352821147 0  
 
Weekly Bleeding for antibody assays 
 
DNA: DNA immunization was performed intramuscularly on day 0 and day 7 with 
electroporation. 50 µg of each DNA plasmid was used for both immunizations. 
Protein: Protein boost was performed on day 14 with 25 µg native Der p 1 emulsified in 
4 mg alum intraperitoneally, or with PBS dissolved Der p 1 (25 µg) intratracheally 
 
Figure 7.3 Schematic representation of the immunization regiment for comparison of 
humoral immune responses induced by LHM and LHML, or for the comparison of 
boosting effects of intraperitoneal injection and intratracheal instillation. 
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 D S S  D  AHR on day43 
   Aerosol 
 
0 7 14 21 28 35 42 44 
 
                Bleeding for IgE assay                          T cell study 
        
 
D, DNA immunization with LHM DNA construct 
S, Systemic sensitization by intraperitoneal injection of 1 µg native Der p 1 protein 
emulsified in 4 mg alum 
Aerosol, Airway allergen exposure with aerosolized native Der p 1 at day 36, 39 and 42  
AHR, measurement of airway hyper-responsiveness 
 
Figure 7.4 Schematic representation of the immunization regiments for evaluation of 
preventive efficacy of LHM and LHML. Blood samples were collected on day 28 for 
detection of Der p 1 specific IgE by ELISA. AHR was measured on day 43, and the mice 
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A 
 Protein ProteinDNA DNA
 
 Day 0 7 70 77 84 14 21 28 35 42 49 56 63
 








Day 0 7 70 77 84 14 21 28 35 42 49 56 63
 
 
                                Mice sacrificed for T cell proliferation study
 
DNA: DNA immunization was performed intramuscularly on day 0 and day 7 with 
electroporation. 50 µg of each DNA plasmid was used for both immunizations. 
Protein: Protein boost was performed intraperitoneally or subcutaneously, on day 14 and 
day 28, with 100 µg native Der p 1 emulsified in 4 mg alum. 
 
Figure 7.5 Schematic representation of the immunization regiment for comparison of 
boosting effects of intraperitoneal injection and subcutaneously injection. 
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7.3  Results  
 
7.3.1 Evaluation of lysosome targeting strategy  
 
To investigate whether lysosome targeting could further improve the efficiency of the 
optimized DNA vaccine construct LHM developed in chapter 4, the lysosome targeting 
sequence from Lysosome Associated Membrane Protein 1 (LAMP1) was tagged to the 3 
prime end of LHM, resulting in a new construct LHML (Fig. 7.2). The immunogenicity 
of this LHML construct was then tested using the same platform described in chapter 4. 
Balb/cJ mice were immunized intramuscularly with 50 µg of LHML or LHM on day 0 
and day 7. All mice were then boosted intraperitoneally with 25 µg native Der p 1 
emulsified in 4 mg alum hydroxide on day 14 (Fig. 7.3). Sera were collected from the 
immunized mice sequentially and tested for the presence of Der p 1 specific antibodies. It 
is observed that the 2 constructs induced similar kinetics of Der p 1 specific IgG2a (Fig. 
7.6A). However, the magnitude induced by the new construct LHML was much lower 
than the LHM construct which did not contain the lysosome targeting sequence (Fig. 
7.6A).  
 
The prophylactic efficacy evaluation using the same protocol described in chapter 6 was 
performed. Mice were immunized with LHML or LHM first and then challenged with the 
sensitization protocol developed in chapter 5 (see Fig. 7.4 for the immunization protocol). 
Der p 1 specific IgE was tested on day 28 and it is observed that both LHM and LHML 
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could efficiently suppress IgE production induced by the sensitization protocol (Fig. 
7.6B).  
 
Mice were sacrificed on day 44, and splenic T cells from immunized mice were 
stimulated in vitro with Der p 1 and the culture supernatants were collected for detection 
of IL-4 and IFN-γ by ELISA and the ratio of IL-4 to IFN-γ was calculated (Fig. 7.7). As 
shown in Fig. 7.7C, low dose (i.e. 1 µg) of Der p1 sensitization induced a significant Th2 
skewed phenotype, which was effectively inhibited by DNA immunizations with either 
LHM or LHML. Data also revealed that the inhibitory effect on Th2 response was more 
prominent in the LMHL immunized group, and the difference between the LHML 
immunized group and the LHM immunized group was statistically significant. 
Interestingly, although the LHML construct was more efficient in attenuating the Th2 
phenotype, no significant effect of this construct on attenuation of AHR was observed 
(Fig. 7.8).   
 
7.3.2 Evaluation of heterogeneous prime-boost protocol 
 
Protein boost has been shown to efficiently enhance the DNA primed Th1 skewed 
immune response in chapter 4. However, intraperitoneal injection is unacceptable for 
human usage. Here we tested the feasibility of intratracheal instillation and subcutaneous 
injection as alternative routes for protein boost strategies. Intratracheal instillation is 
particularly attractive, because if airway allergen exposure proves to be sufficient to 
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boost the DNA primed immune response, it follows that an extra protein injection might 
not be necessary in the real world, since we are constantly being exposed to inhalant 
aeroallergens. To test this possibility, Balb/cJ mice were primed on day 0 and day 7 with 
the LHM construct, and then boosted on day 14 with either Alum emulsified Der p 1 (25 
µg) intraperitoneally (IP route) or PBS dissolved Der p 1 intratracheally (IT route), and 
antibody concentration in sera was monitored (see Fig. 7.3 for the immunization 
protocol). As shown in Fig. 7.9, intratracheal instillation of native Der p 1 protein could 
boost the DNA primed antibody production, but the level is much lower than that can be 
achieved by intraperitoneal injection. The results are not surprising as the boosting via IT 
route was performed locally without any adjuvant whereas boosting with IP route was 
more systemic in the presence of a strong adjuvant. 
 
Another strategy used for protein boost was subcutaneous (SC) injection. Subcutaneous 
injection is frequently used in the conventional immunotherapies for allergic diseases. To 
examine the effects of boosting via SC route, mice were immunized with LHM construct 
on day 0 and day 7 and then boosted with 100 µg Der p 1 emulsified in alum on day 14 
and day 28 either intraperitoneally or subcutaneously (see Fig. 7.5A for the immunization 
protocol). The subcutaneously injected mice were further divided into 2 subgroups, with 
one subgroup injected with Der p 1 emulsified in alum and another injected with just 
native Der p 1. As shown in Fig. 7.10, although subcutaneous injection with protein 
without alum did not significantly boost up the antibody levels, subcutaneous injection 
with alum emulsified Der p 1 significantly boosted the antibody response, with higher 
magnitude of Der p 1 specific IgG2a than that observed in the intraperitoneally injected 
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group (Fig. 7.10A), indicating the importance of using adjuvant for boosting of immune 
responses. Interestingly, the Der p 1 specific IgG1 levels were lower in the 
subcutaneously injected group (Fig. 7.10B). 
 
The above data indicated that subcutaneous injection and intraperitoneal injection both 
could be feasible methods to boost the DNA primed immune responses in mice, and the 
inclusion of adjuvant such as alum is essential to boost the magnitude of responses. 
 
It is then of interest to examine the impacts of the protein boost on the specific T epitopes. 
Mice were immunized on day 0 and day 7 with the LHM construct, and then boost with 
100 µg protein on day 14 and day 28 either intraperitoneally or subcutaneously (see Fig. 
7.5B). On day 35, mice were sacrificed and splenocytes were cultured with 7 different 
fragments spanning different regions of Der p 1 (Fig. 7.11; Greene et al., 1991). The 
mapping of the T-epitopes was performed by cell proliferation assay on CD4+ T cells 
upon in vitro stimulation of Der p 1 or its derived peptides (Fig. 7.11). As shown in Fig. 
7.13A, splenic T cells from mice immunized with DNA vaccine alone responded to the 
fragments similarly with a counting around 2000 CPM. Surprisingly, if the mice were 
further boosted with extreme high dose (100 µg) protein intraperitoneally or 
subcutaneously, the T cell responses was significantly suppressed instead of boosted, and 
no significant difference could be detected between responses to different fragments (Fig. 
7.13B, Fig. 7.13C). The general suppression of T cell response was in sharp contrast to 
the boosting effect on antibody production. 
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Figure 7.6 LHML induced lower level of Der p 1 specific IgG2a but was still 
effective in IgE inhibition. A. Balb/cJ mice, 4 in each group were immunized 
intramuscularly with 50 µg of LHML or LHM on day 0 and day 7. All mice were then 
boosted intraperitoneally with 25 µg native Der p 1 emulsified in 4 mg alum hydroxide 
on day 14 (Fig. 7.3). Sera were collected from the immunized mice sequentially and 
tested for the presence of Der p 1 specific IgG2a. B. Mice were immunized with LHM or 
LHML construct intramuscularly on days 0 and 7. Der p 1 sensitization was done by 
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systemic immunization intraperitoneally with 1 µg Der p 1 emulsified in 4 mg alum on 
day 14 and day 21, followed by three aerosolized Der p 1 challenges on days 36, 39, and 
42 (See Fig. 7.4). Blood samples were collected on day 28 and the titer of Der p 1 
specific IgE was determined by ELISA. Results are shown as Mean + SEM. *: p < 0.05. 
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Figure 7.7 LHML inhibited Th2 response more significantly than LHM. Balb/cJ mice, 
4 in each group, were immunized with LHM or LHML construct intramuscularly on days 
0 and 7. Der p 1 sensitization was done by systemic immunization intraperitoneally on 
day14 and day 21 followed by three aerosolized Der p 1 challenges from days 35-42 (Fig. 
7.4). Two days after the last airway allergen challenge, mice were sacrificed and the 
splenocytes were cultured in RPMI with or without Der p 1. The concentration of IL-4 
(A), IFN- γ (B) were measured from the culture supernatants with ELISA, and the ratio 
of IL-4 to IFN-γ was calculated (C). *: p < 0.05. 
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Figure 7.8 The lysosome targeting construct did not attenuate airway 
hyperresponsiveness in mouse asthma model. Balb/cJ mice, 4 in each group, were 
immunized with LHM or LHML construct intramuscularly on days 0 and 7. Der p 1 
sensitization was done by systemic immunization intraperitoneally on day14 and day 21 
followed by three aerosolized Der p 1 challenges from days 35-42 (Fig. 7.4). AHR was 
measured with whole-body plethysmography 24 hours after the last aerosolized allergen 
challenge. AHR was successfully established in Der p 1 sensitized and challenged mice 
(Sensitized, yellow line). LHM immunization before the Der p 1 sensitization reduced the 
Penh values significantly (LHM vaccinated group, pink line). LHML immunization 
before the Der p 1 sensitization did not have significant effect on the Penh values (LHML 
vaccinated group, blue line). 
 
 260






















































Figure 7.9 Intratracheal protein inoculation could boost DNA primed immune 
response but the level is much lower than intraperitoneal boosting. Balb/cJ mice, 4 in 
each group, were primed on day 0 and day 7 with the LHM construct, and then boosted 
on day 14 with either Alum emulsified Der p 1 intraperitoneally (I.P., blue line) or PBS 
dissolved Der p 1 intratracheally (I.T. pink line), and Der p 1 specific IgG2a (A) and 
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IgG1 (B) concentration in sera was monitored (see Fig. 7.3 for immunization protocol. 
Results are shown as Mean + SEM. 
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Figure 7.10 Subcutaneous protein injection effectively boosted the Th1 skewed 
immune response primed by DNA immunization. Balb/cJ mice, 4 in each group, were 
immunized on day 0 and day 7 with the LHM construct, and then boost with 100 µg 
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protein on day 14 and day 28 either intraperitoneally (I.P., yellow line) or subcutaneously 
(see Fig. 7.5A for immunization protocol). The subcutaneously injected mice were 
further divided into 2 subgroups, with one subgroup injected with protein emulsified in 
alum (S.C. with alum, pink line) and another injected with just native protein (S.C. no 
alum, blue line). Der p 1 specific IgG2a (A) and IgG1 (B) concentration in sera were 
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Figure 7.11 Der p 1 fragments used in proliferation assays. Peptides 17, 14, 65, 18, 63, 
19, 20 were produced as GST fusion proteins from E.coli, and purified using Glutathione-
Sepharose beads. The top line represents the full length Der p 1 which contains 222 
amino acids. 
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Figure 7.13 High dose protein boost inhibited T cell response to Der p 1. Balb/cJ mice, 
4 in each group, were immunized on day 0 and day 7 with the LHM construct, and then 
boost with 100 µg protein emulsified in alum on day 14 and day 28 either 
intraperitoneally (B) or subcutaneously (C) (see Fig. 7.5B for the immunization protocol). 
On day 35, mice were sacrificed and splenocytes were cultured with 7 different fragments 
spanning different regions of Der p 1 (Fig. 7.11). Proliferation assay was performed to 
examine the proliferation rate of the CD4+ T cells upon in vitro stimulation of Der p 1 or 
its fragments. Results are shown as Mean + SEM. 
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7.4 Discussion 
 
In this Chapter, two strategies were examined to further improve the efficiency of DNA 
vaccination for allergic asthma. The first strategy tested is lysosome targeting, that is to 
target the in vivo expressed protein to the lysosome where processed peptides were 
assembled with MHC II molecules. This strategy is to restrict the in vivo expressed 
antigen within the cell and at the same time stimulate the CD4+ T cell response. Data 
shows that the LHML construct, which contains the lysosome targeting sequence, could 
effectively induce Th1 skewed immune response, and inhibited the Th2 phenotype upon 
subsequent challenge more significantly than the LHM construct. However, the antibody 
production induced by this LHML construct is not as high as that induced by LHM. 
Furthermore attenuation of airway hyperresponsiveness was not achieved by this 
lysosome targeting construct.  
 
It should be noted that the mechanisms of T cell priming for the LHML construct is 
different from that of LHM. LHM encodes secretable Der p 1, which is present as 
exogenous antigens in vivo. The exogenous Der p 1 is then taken up by professional 
antigen presenting cells, processed and presented in MHC class II pathway. On the 
contrary, Der p 1 expressed from the LHML construct was restricted within the 
transfected cells (myocytes or APCs), and it enters the MHC class II pathway by being 
targeted to lysosome. Clearly, the cells involved in antigen processing and presentation 
for LHM could be more diverse than that for LHML. The fact that attenuation of AHR 
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was observed in LHM immunized mice but not in LHML immunized mice, might imply 
the importance of priming a particular cell type by extracellular Der p 1 and that this 
particular cell type is not stimulated in LHML immunized mice. More studies are 
required to address this phenomenon. 
 
The lack of attenuation of AHR could also be due to the lower availability of 
extracellular Der p 1 in vivo, which resulted in lower magnitude of humoral immune 
response. As Der p 1 specific IgG2a antibodies might serve as blocking antibodies, as has 
been described as one of the mechanisms of conventional immunotherapy (Garcia BE et 
al., 1993; Jutel M et al., 2003), the lower magnitude of antibody production could be a 
another possible explanation for the lack of protection against AHR.  
 
Nevertheless, the stronger Th1 skewing property and the ability to limit the in vivo 
expressed protein within the cell could potentially make this construct a better and safer 
DNA vaccine, provided that an efficient method to boost the magnitude of the primed 
immune response could be developed. The safety aspect of the lysosome targeting 
strategy could be particularly important for some of the allergens, such as Der p 2. It was 
recently observed in our lab that inclusion of a leader sequence in a DNA construct 
encoding another major allergen Der p 2, to make the in vivo expressed protein secretable, 
resulted in a mixture of Th1 and Th2 responses, with low level of Der p 2 specific IgE 
induced (personal communications). This observation could be due to the unique 
properties of Der p 2, which is structurally similar to LPS-binding protein MD-2 that are 
essential for TLR4 sigaling (Gruber A et al., 2004; Ichikawa S et al., 2005). Wider 
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distribution of Der p 2 resulted from manipulating the leader sequence might interfere 
with the host innate immune system and alter the subsequent Th1/Th2 differentiation. It 
could be postulated that the lysosome targeting strategy, which could limit the in vivo 
expressed Der p 2 within the cell, may help avoid sensitization. 
 
The second strategy we studied in more detail is the heterogeneous prime-boost 
immunization protocol. It was demonstrated that the DNA primed antibody response 
could be boosted by protein immunization by means of intratracheal inoculation, 
intraperitoneal injection or subcutaneous injection, with intratracheal to be the least 
efficient. The efficient boosting effect on antibody production by intraperitoneal and 
subcutaneous injections prompted us to test the boosting effect in terms of epitope 
preferences. However, suppression rather than enhancing of the T cell responses was 
observed by high dose (100 µg, twice) protein boost. The suppression of T cell response 
could possibly be attributable to the induction of regulatory T cells by high dose repeated 
protein immunizations, as observed in Chapter 5. On the other hand, boosting on 
antibody production could be due to direct stimulation of allergen specific B cells. If this 
is true, high dose protein immunization used in combination with DNA vaccination could 
be a feasible method to inhibit Der p 1 specific Th2 response, and provide a more 
effective therapeutic approach, although the potential therapeutic efficacy of this method 
was not studied in this thesis due to time constraint. Further functional studies of the 
DNA primed and high dose protein boosted T cells could be conducted to test the 
inhibitory effect both in vitro and in vivo. These studies could probably provide a better 
understanding of the heterologous prime-boost strategy, which could be more 
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complicated that it has been expected. Such study will also shed some light on the basic 
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8.1 Introduction 
 
It has been demonstrated in Chapters 6 and 7 that an optimized construct, LHM, could 
efficiently inhibit Der p 1 specific IgE production, down-regulate Th2 cytokines and 
eventually attenuate airway hyperresponsiveness in the prophylactic mouse asthma 
model. Construct LHM represents a good prototype for developing Der p 1 DNA vaccine 
for prophylactic application in humans. The main aim of the study describes in this 
chapter is to determine whether LHM can be used as a basic plasmid backbone to make a 
DNA construct containing three individual allergen genes encoding for Der p 1, Der p 2 
and Blo t 5,  respectively. 
 
The need for making a construct containing multiple allergens derived from the 
observation that it is common for mite allergic asthma patients to be allergic to multiple 
mite allergens. It has been shown that dual sensitization to Blomia tropicalis and 
Dermatophagoides pteronyssinus is common in tropical countries and subtropical 
countries (Yeoh SM et al., 2003; Kuo IC et al., 1999), and Der p 1, Der p 2 and Blo t 5 
are the most important sensitizing allergens in both tropical and subtropical regions. It 
has been estimated that there are more than 1 billion of the world population are 
sensitized by the major allergens from these two mite species (Holt PG et al., 2005). 
  
It is therefore important to develop multi-gene DNA constructs for a more complete 
protection against mite allergy worldwide. In this cChapter, I will describe the strategy 
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for making the multi-gene construct, and the data on the evaluation of the 
immunogenicity of the construct by using DNA prime – protein boost strategy will be 
discussed.  
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8.2 Materials and methods 
 
8.2.1 Construction of Der p 1 plasmids 
 
The construction of plasmids was carried out by conventional molecular cloning 
techniques (Ausubel FM et al., current protocols in molecular biology). In general, codon 
optimized DNA sequences encoding Der p 1, Der p 2 and Blo t 5 was designed based on 
codon preference of highly expressed human transcripts (Please refer to Fig. 4.4, Fig. 8.2, 
Fig. 8.5 for the optimized sequences of Der p 1, Der p 2 and Blo t 5). Partially 
overlapping oligonucleotides spanning the Der p 1, Der p 2, or Blo t 5 coding sequences 
were synthesized (Table 4.1, Table 8.1, Table 8.2) and used to generate the codon 
optimized DNA sequences (hDer p 1, hDer p 2, and hBlo t 5) in a two-step PCR 
amplification (Massaer M et al., 2001), as described in Fig. 4.6. The original sequences 
of Blo t 5 and Der p 2 were shown in Fig. 8.1 and Fig. 8.4. Fig. 8.3 and Fig. 8.6 show the 
comparison between original sequences of Blo t 5 and Der p 2, with the codon optimized 
sequences. A mouse Igκ light chain signal sequence (mκ; see Fig. 4.3 for sequence 
information) was tagged in-frame to the 5’ end of the hDer p 1, hDer p 2, hBlo t 5 
chimeric sequence (with linker sequences between the allergen genes), by PCR and 
subsequently the entire DNA fragment were cloned into the pVAX1 expression vector, to 
make the construct L152 (see Fig. 8.7 for a schematic representation of the L152 
construct). 
 
8.2.2 DNA immunization and in vivo electroporation 
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DNA immunization and in vivo electroporatioin was performed on six to eight weeks old 
female Balb/cJ mice as described in chapter 2, section 2.2.15. Briefly, anesthetized mice 
were then immunized by intramuscular injection of 50 µl of naked DNA (1 µg/µl) in the 
left anterior tibialis using a 1 ml insulin syringe and a 27 G needle, followed by 
immediate electroporation with an ECM 830 apparatus (BTX, Genetronics, San Diego, 
CA). Mice were boosted the same way in the other leg 7 days later. 
 
8.2.3 Preparation of native Der p 1 by monoclonal antibody affinity 
chromatography 
 
Native Der p 1 was purified from spent mite media by mAb 4C1 affinity chromatography 
as described in chapter 2, section 2.2.2. The purity and identity of Der p 1 was confirmed 
by SDS-PAGE (Fig. 8.8). 
 
8.2.4 Purification of recombinant Der p 2 
 
Recombinant Der p 2 protein was produced from the P. pastoris yeast expression system 
(Kuo IC et al., 1999). Yeast transformant carrying the Der p 2 cDNA was grown in 5ml 
of buffered glycerol-complex medium (1% yeast extract, 2% peptone, 1.34% yeast 
nitrogen base with ammonium sulfate, 1% glycerol, 0.4 mg/l biotin, and 0.1 M potassium 
phosphate, pH 6.0) and subsequently transferred to a final of 2 liters culture until the 
OD600nm = 6. Cells were harvested by centrifugation at 1000 g and gently suspended in 
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400 ml of buffered methanol-complex medium containing 0.5% methanol. The cells were 
cultured for another 2 days to induce the protein production and methanol was 
replenished to 0.5% final concentration every 24 hours. The yeast media containing the 
recombinant Der p 2 was applied to an SP-Sepharose column equilibrated with 10 mM 
sodium acetate, pH 5.5. Bound proteins were eluted with 600 ml of a linear sodium 
chloride gradient from 0 to 500 mM. The purity and identity of recombinant Der p 2 was 
confirmed by SDS-PAGE (Fig. 8.8). 
 
8.2.5 Purificaiton of recombinant yeast Blo t 5 
 
Recombinant yeast Blo t 5 proteins were produced from the P. pastoris yeast expression 
system (Kuo IC et al., 1999). The yeast transformant carrying the Blo t 5 cDNA was 
grown in 5ml of buffered glycerol-complex medium (1% yeast extract, 2% peptone, 
1.34% yeast nitrogen base with ammonium sulfate, 1% glycerol, 0.4 mg/l biotin, and 0.1 
M potassium phosphate, pH 6.0) and subsequently transferred to a final of 2-liters culture 
until the OD600nm = 6. Cells were harvested by centrifugation at 1000 g and gently 
suspended in 400 ml of buffered methanol-complex medium containing 0.5% methanol. 
The cells were cultured for another 2 days to induce the protein production and methanol 
was replenished to 0.5% final concentration every 24 hours. The yeast media containing 
Blo t 5 was applied to a Q-Sepharose column equilibrated with with 10 mM Tris-HCl, pH 
7.5. Bound proteins were eluted with 600 ml of a linear sodium chloride gradient from 0 
to 500 mM. The purity and identity of recombinant Blo t 5 was confirmed by SDS-PAGE 
(Fig. 8.8). 
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8.2.6 Detection of specific mouse immunoglobulin responses 
 
The levels of Der p 1, Der p 2, Blo t 5 specific IgE, IgG1, and IgG2a were determined by 
ELISA. Mouse sera were incubated in duplicate with the Der p 1, Der p 2, or Blo t 5 
coated wells for overnight at 4°C. Biotin-conjugated monoclonal rat anti-mouse IgE 
(R19-15), anti-mouse IgG1 (G1-1.5) and anti-mouse IgG2a (R35-92) were used for 
detection and followed by addition of ExtrAvidin-alkaline phosphatase. Signals were 
developed by addition of p-Nitrophenylphosphate substrate. ELISA index unit was 
defined as the OD405nm reading corresponding to the reading of 1 ng/ml of purified mouse 
IgE, IgG1, or IgG2a in a sandwich ELISA with anti-mouse Igκ as the capture antibody in 
the same plate. All the antibodies used were purchased from Pharmingen (Pharmingen, 
San Diego, CA). 
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    1 aaaacactca caatccacaa actcaaacaa caatgaagtt cgccatcgtt cttattgcct 
   61 gctttgccgc ttcggttttg gctcaagagc acaagccaaa gaaggatgat ttccgaaacg 
  121 aattcgatca cttgttgatc gaacaggcaa accatgctat cgaaaaggga gaacatcaat 
  181 tgctttactt gcaacaccaa ctcgacgaat tgaatgaaaa caagagcaag gaattgcaag 
  241 agaaaatcat tcgagaactt gatgttgttt gcgccatgat cgaaggagcc caaggagctt 
  301 tggaacgtga attgaagcga actgatctta acattttgga acgattcaac tacgaagagg 
  361 ctcaaactct cagcaagatc ttgcttaagg atttgaagga aaccgaacaa aaagtgaagg 
  421 atattcaaac ccaataaaaa tttagaattg tacaatttta catttttgat atgattaaat 





Figure 8.1 cDNA sequence of full length Blo t 5. Nucleotides 33-83 encode the 
signal peptide of Blo t 5. Nucleotides 84-434 encode the mature Blo t 5. This nucleotide 
sequence has been deposited to Genbank with accession number U59102. 
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   1 caggagcaca agcccaagaa ggacgacttc aggaacgagt tcgaccactt gctgatcgag 
  61 caggctaacc acgcgatcga aaagggggag catcaactgc tctacctgca gcaccagctc  
 121 gacgagctga atgagaacaa gagcaaggaa ctgcaggaga aaatcatccg cgagcttgat  
 181 gtggtctgcg ccatgatcga aggcgcccag ggcgccctgg agcgcgagct gaancggacg  
 241 gacctcaaca tcctggagcg ctttaactac gaagaggccc agactctctc caagatcctg  




Figure 8.2 Codon optimized mature Blo t 5 DNA sequence without stop codon.  This 
optimized sequence was prepared by introduction of silent mutations. Therefore, it 
encodes the same amino acid sequence as the original sequence (for the original sequence, 
see Fig. 8.2, nucleotides 84-434; for a comparison, see fig. 8.5). Partially overlapping 
oligonucleotides spanning the mature part of the optimized Blo t 5 encoding sequence 
were synthesized (see table 8.1 for detailed sequence information) and used to generate 
the codon optimized DNA sequence in a two-step PCR amplification. The correct 
sequence was confirmed by DNA sequencing. 
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Optim: 1   caggagcacaagcccaagaaggacgacttcaggaacgagttcgaccacttgctgatcgag  
           || ||||||||||| |||||||| || ||| | ||||| ||||| |||||| |||||||  
Origi: 1   caagagcacaagccaaagaaggatgatttccgaaacgaattcgatcacttgttgatcgaa  
 
                                                                        
Optim: 61  caggctaaccacgcgatcgaaaagggggagcatcaactgctctacctgcagcaccagctc  
           ||||| ||||| || ||||||||||| || |||||| |||| ||| |||| ||||| ||| 
Origi: 61  caggcaaaccatgctatcgaaaagggagaacatcaattgctttacttgcaacaccaactc  
 
                                                                        
Optim: 121 gacgagctgaatgagaacaagagcaaggaactgcaggagaaaatcatccgcgagcttgat  
           |||||  ||||||| ||||||||||||||| |||| ||||||||||| || || |||||| 
Origi: 121 gacgaattgaatgaaaacaagagcaaggaattgcaagagaaaatcattcgagaacttgat  
 
                                                                        
Optim: 181 gtggtctgcgccatgatcgaaggcgcccagggcgccctggagcgcgagctgaancggacg  
           || || ||||||||||||||||| ||||| || ||  |||| || ||  |||| || ||  
Origi: 181 gttgtttgcgccatgatcgaaggagcccaaggagctttggaacgtgaattgaagcgaact  
 
                                                                        
Optim: 241 gacctcaacatcctggagcgctttaactacgaagaggcccagactctctccaagatcctg  
           || || |||||  |||| || || |||||||||||||| || ||||||  ||||||| || 
Origi: 241 gatcttaacattttggaacgattcaactacgaagaggctcaaactctcagcaagatcttg  
 
                                                              
Optim: 301 ctcaaggacctgaaggagaccgagcagaaagtgaaggacattcagacccag 351 
           || |||||  ||||||| ||||| || ||||||||||| ||||| ||||| 
Origi: 301 cttaaggatttgaaggaaaccgaacaaaaagtgaaggatattcaaacccaa 351 
 
Figure 8.3 Comparison of the codon optimized DNA sequence and the original Blo t 
5 cDNA sequence. 
Optim: codon optimized sequence 
Origi: The original sequence 





  Chapter 8 multigene 
 
 Primer Sequence 
1 sBlot5/f1 5’ GCCTCGAGCCACCATGAAGTTCGCCATCGTGCTGATCGCCTGCTTTGCCGCCTCCGTGCT 3’ 
2 sBlot5/r2 5’ TGCCGCCTCCGTGCTGGCCCAGGAGCACAAGCCAAAGAAGGATGATTTCAGAAACGAGTT 3’ 
3 sBlot5/f3 5’ TTTCAGAAACGAGTTCGATCACCTGCTGATCGAGCAGGCCAACCACGCCATCGAGAAGGG 3’ 
4 sBlot5/r4 5’ CGCCATCGAGAAGGGCGAGCACCAGCTGCTGTACCTGCAGCACCAGCTGGACGAGCTGAA 3’ 
5 sBlot5/f5 5’ GCTGGACGAGCTGAATGAGAACAAGAGCAAGGAGCTGCAGGAGAAGATCATCAGAGAGCT 3’ 
6 sBlot5/r6 5’ GATCATCAGAGAGCTGGATGTGGTGTGCGCCATGATCGAGGGCGCCCAGGGCGCCCTGGA 3’ 
7 sBlot5/f7 5’ CCAGGGCGCCCTGGAGCGGGAGCTGAAGAGAACCGATCTGAACATCCTGGAGAGATTCAA 3’ 
8 sBlot5/r8 5’ CCTGGAGAGATTCAACTACGAGGAGGCCCAGACCCTGAGCAAGATCCTGCTGAAGGATCT 3’ 
9 sBlot5/f9 5’ CCTGCTGAAGGATCTGAAGGAGACCGAGCAGAAGGTGAAGGATATCCAGACCCAGGGAAG 3’ 
10 sBlot5/r10 5’ GATATCCAGACCCAGGGAAGCGGAGGAGGAGGAAGCGGAGGAGGAGGAAGCGGATCCAA 3’ 
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    1 cacaaattct tctttcttcc ttactactga tcattaatct gaaaacaaaa ccaaacaaac 
   61 cattcaaaat gatgtacaaa attttgtgtc tttcattgtt ggtcgcagcc gttgctcgtg 
  121 atcaagtcga tgtcaaagat tgtgccaatc atgaaatcaa aaaagttttg gtaccaggat 
  181 gccatggttc agaaccatgt atcattcatc gtggtaaacc attccaattg gaagccgttt 
  241 tcgaagccaa ccaaaacaca aaaacggcta aaattgaaat caaagcctca atcgatggtt 
  301 tagaagttga tgttcccggt atcgatccaa atgcatgcca ttacatgaaa tgcccattgg 
  361 ttaaaggaca acaatatgat attaaatata catggaatgt tccgaaaatt gcaccaaaat 
  421 ctgaaaatgt tgtcgtcact gttaaagtta tgggtgatga tggtgttttg gcctgtgcta 
  481 ttgctactca tgctaaaatc cgcgattaaa tcaaacaaaa tttattgatt ttgtaatcac 
  541 aaatgattga ttttctttcc aaaaaaaaaa taaataaaat tttgggaatt c 
 
 
Figure 8.4 cDNA sequence of full length Der p 2. Nucleotides 72-119 encode the 
signal peptide of Der p 2. Nucleotides 120-509 encode mature Der p 2. This nucleotide 
sequence has been deposited to Genbank with accession number AF276239. 
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   1 gatcaggtgg acgtcaagga ctgtgccaac cacgagatca agaaggtgct ggtacctgga  
  61 tgccatggca gcgagccatg catcatccac cgggggaagc ccttccagct cgaggccgtg  
 121 ttcgaagcca accagaacac caagaccgcg aagatcgaaa tcaaagccag catcgacggt  
 181 ctggaggtgg acgtgcccgg catcgacccc aatgcgtgcc actacatgaa gtgccccctg  
 241 gtgaaaggcc agcaatacga cattaagtat acgtggaacg tgccgaagat tgcacctaag  
 301 tccgagaacg tggtcgtcac tgtgaaggtg atgggggatg acggcgttct cgcctgtgct  
 361 atcgccaccc acgctaagat ccgcgacTGA 
 
Figure 8.5 Codon optimized mature Der p 2 DNA sequence with a stop codon in the 
3’ end.  This optimized sequence was prepared by introduction of silent mutations. 
Therefore, it encodes the same amino acid sequence as the original sequence (for the 
original sequence, see Fig. 8.4, nucleotides 120-509; for a comparison, see fig. 8.6). 
Partially overlapping oligonucleotides spanning the mature part of the optimized Der p 2 
coding sequence were synthesized and used to generate the codon optimized DNA 
sequence in a two-step PCR amplification (see Table 8.2 for detailed sequence 
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Optim: 1   gatcaggtggacgtcaaggactgtgccaaccacgagatcaagaaggtgctggtacctgga  
           ||||| || || ||||| || |||||||| || || ||||| || ||  ||||||| ||| 
Origi: 1   gatcaagtcgatgtcaaagattgtgccaatcatgaaatcaaaaaagttttggtaccagga  
 
                                                                        
Optim: 61  tgccatggcagcgagccatgcatcatccaccgggggaagcccttccagctcgaggccgtg  
           ||||||||    || ||||| ||||| || || || || || |||||  | || |||||  
Origi: 61  tgccatggttcagaaccatgtatcattcatcgtggtaaaccattccaattggaagccgtt  
 
                                                                        
Optim: 121 ttcgaagccaaccagaacaccaagaccgcgaagatcgaaatcaaagccagcatcgacggt  
           |||||||||||||| ||||| || || || || || ||||||||||||   ||||| ||| 
Origi: 121 ttcgaagccaaccaaaacacaaaaacggctaaaattgaaatcaaagcctcaatcgatggt  
 
                                                                        
Optim: 181 ctggaggtggacgtgcccggcatcgaccccaatgcgtgccactacatgaagtgccccctg  
            | || || || || ||||| ||||| || ||||| ||||| |||||||| |||||  || 
Origi: 181 ttagaagttgatgttcccggtatcgatccaaatgcatgccattacatgaaatgcccattg  
 
                                                                        
Optim: 241 gtgaaaggccagcaatacgacattaagtatacgtggaacgtgccgaagattgcacctaag  
           || ||||| || ||||| || ||||| ||||| ||||| || ||||| |||||||| ||  
Origi: 241 gttaaaggacaacaatatgatattaaatatacatggaatgttccgaaaattgcaccaaaa  
 
                                                                        
Optim: 301 tccgagaacgtggtcgtcactgtgaaggtgatgggggatgacggcgttctcgcctgtgct  
           || || || || ||||||||||| || || ||||| ||||| || ||| | ||||||||| 
Origi: 301 tctgaaaatgttgtcgtcactgttaaagttatgggtgatgatggtgttttggcctgtgct  
 
                                      
Optim: 361 atcgccacccacgctaagatccgcgactga 390 
           || || || || ||||| |||||||| | | 





Figure 8.6 Comparison of the codon optimized DNA sequence and the original Der p 
2 cDNA sequence. 
Optim: the codon optimized sequence 
Origi: The original sequence 
Mismatches are where the mutations were introduced 
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 Primer Sequence 
1 SDerp2/f1 5’ CCCCCCAAGCTTACCATGGAGGATCAGGTGGACGTCAAGGACTGTGCCAACCACGAGATC 3’ 
2 sDerp2/r2  5’ GCATGGCTCGCTGCCATGGCATCCAGGTACCAGCACCTTCTTGATCTCGTGGTTGGCAC 3’ 
3 sDerp2/f3 5’ CATGGCAGCGAGCCATGCATCATCCACCGGGGgAagCCcTTCCagcTcGagGCCGTgTTC 3’ 
4 sDerp2/r4  5’ TTTGATTTCGATCTTCGCGGTCTTGGTGTTCTGGTTGGCTTCGAACACGGCCTCGAGCTG 3’ 
5 sDerp2/f5 5’ GCGAAGATCGAAATCAAAGCCAGCATCGACGGTCTGGAGGTGGACGTGCCCGGCATCGAC 3’ 
6 sDerp2/r6  5’ GCCTTTCACCAGGGGGCACTTCATGTAGTGGCACGCATTGGGGTCGATGCCGGGCACGTC 3’ 
7 sDerp2/f7 5’ TGCCCCCTGGTGAAAGGCCAGCAATACGACATTAAGTATACGTGGAACGTGCCGAAG 3’ 
8 sDerp2/r8  5’ CATCACCTTCACAGTGACGACCACGTTCTCGGACTTAGGTGCAATCTTCGGCACGTTCC 3’ 
9 sDerp2/f9  5’ GTCACTGTgAagGTgATGGGgGATGacGGcGTTcTcGCCTGTGCTAtcGCcAccCacGC 3’ 
10 sDerp2/r10 5’ CCCCCCGGATCCTCAGTCGCGGATCTTAGCGTGGGTGGCGATAGC 3’ 
 
Table 8.2 Oligonucleotide primers used to generate synthetic codon optimized Der p 
2 sequence. 
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 Mouse Igκ 
leader 
Linker  hDerp2 
sequence 







           
Linker 
Nucleotide sequence: GGAGGGGGCTCCGGAGGGGGCTCCGGAGGG 
Amino acid sequence: GGGSGGGSGG 
 
Figure 8.7 Schematic representation of the L152 construct. Please refer to Figure 4.3 
for detailed sequence information of mouse Igκ chain leader, Fig. 4.4 for codon 
optimized mature Der p 1 sequence (hDerp1); Figure 8.2 for codon optimized mature Blo 
t 5 sequence (hBlot5); and Figure 8.5 for codon optimized mature Der p 2 sequence 
(hDerp2). The linker sequence was shown above. These nucleotide sequences were 
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linked together in the indicated order and inserted into the Bam HI and Xba I sites of 
pVAX1 vector. The map of pVAX1 vector was adapted from Invitrogen website. 
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                                                         1       2       3       4      
 
Figure 8.8 Electrophoresis of purified native Der p 1 (lane 2), recombinant Der p 2 









 Day 0 7 70 77 84 14 21 28 35 42 49 56 63
 
 Weekly Bleeding for antibody assay
 
 
DNA: DNA immunization was performed intramuscularly on day 0 and day 7 with 
electroporation. 50 µg of each DNA plasmid was used for both immunizations. 
Protein: Protein boost was performed intraperitoneally, on day 14, day 21, and day 28, 
with 100 µg each of native Der p 1, recombinant Der p 2, and recombinant Blo t 5 
emulsified in 4 mg alum. 
 
Figure 8.9 Schematic representation of the immunization regiment for evaluation of 
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8.3  Results  
 
8.3.1 Immunogenicity of a DNA construct containing three individual mite 
allergen genes 
 
DNA  construct carrying mouse Igκ chain signal peptide sequence followed by codon 
optimized sequences of mature Der p 1, Blo t 5 and Der p 2, with link sequences inserted 
in between, was constructed and designated as L152 (Fig. 8.7). A DNA-prime-protein 
boost immunization strategy was used for the assessment of the immune responses 
induced construct L152 for each of the three allergens in mice (Fig. 8.9). This construct 
was used to immunize Balb/cJ mice on days 0 and 7. The mice were then boosted 
intraperitoneally with a mixture of 100 µg each of alum emulsified native Der p 1, 
recombinant Blo t 5 and recombinant Der p 2 proteins, on days 14, 21 and 28. Sera were 
collected for the assay of the specific antibody responses against Der p 1, Der p 2 and Blo 
t 5. The control mice were first immunized similarly with pVAX 1 vector DNA and 
subsequently boosted by exactly the same boosting protocol as the experimental groups.   
 
Significant levels of IgG2a and IgG1 specific to Der p 1, Der p 2 and Blo t 5 were 
detected in L152 primed and protein boosted mice, and they were not detectable in mice 
that were immunized with protein mixture alone (Fig. 8.10, Fig. 8.11). These data 
indicate that construct L152 was capable of priming the specific responses for the 
respective individual allergens included in the DNA construct. Furthermore, the DNA 
primed specific responses were boostable by the respective allergen proteins.  
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The allergen-specific IgE production was also tested in the control and experimental mice. 
Significant levels of Blo t 5 specific IgE could be detected in the control mice that were 
primed with pVAX1 vector and boosted with a mixture of three proteins. This result was 
rather unexpected as the mice were boosted with purposively high dose (100 µg) of Blot 
5 protein. The IgE data observed in control mice suggest that 100 µg of Blot 5 emulsified 
in alum was still capable of inducing TH2 skewed responses. Nevertheless, this IgE 
production was greatly attenuated in mice that were preimmunized with the L152 
construct (Fig. 8.12), demonstrating the immune responses induced by L152 multigene 
construct were indeed useful for the suppression of IgE production. There were no 
significant Der p 1 or Der p 2 specific IgE detected in both the DNA immunized mice 
and control mice.   
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Figure 8.10 L152 immunization induced specific IgG2a production to each of the 
encoded allergens. L152 construct or the vector control was used to immunize Balb/cJ 
mice, 4 in each group, on day 0 and day 7. The mice were then boosted intraperitoneally 
with a mixture of native Der p 1, recombinant Blo t 5 and recombinant Der p 2 proteins, 
each 100 µg, emulsified in Alum Hydroxide on days 14, 21 and 28. Der p 1, Der p 2, and 
Blo t 5 specific IgG2a was detected by ELISA. Results are shown as Mean + SEM. 
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Figure 8.11 L152 immunization induced specific IgG1 production to each of the 
encoded allergens. L152 construct or the vector control was used to immunize Balb/cJ 
mice, 4 in each group, on day 0 and day 7. The mice were then boosted intraperitoneally 
with a mixture of native Der p 1, recombinant Blo t 5 and recombinant Der p 2 proteins, 
each 100 µg, emulsified in Alum Hydroxide on days 14, 21 and 28. Der p 1, Der p 2, and 
Blo t 5 specific IgG1 was detected by ELISA. Results are shown as Mean + SEM. 
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Figure 8.12 L152 immunization inhibited Blo t 5 specific IgE production. L152 
construct or the vector control was used to immunize Balb/cJ mice, 4 in each group, on 
day 0 and day 7. The mice were then boosted intraperitoneally with a mixture of native 
Der p 1, recombinant Blo t 5 and recombinant Der p 2 proteins, each 100 µg, emulsified 
in Alum Hydroxide on days 14, 21 and 28. Blo t 5 specific IgE was detected by ELISA. 
Results are shown as Mean + SEM. The difference between L152 and vector is 
statistically significant on day 21, as determined by Student t test. 
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8.3 Discussion 
 
The construct L152, containing codon-optimized genes of three major allergens Der p 1, 
Blo t 5 and Der p 2, was prepared, and the immunogenicity for each individual allergen 
was tested in mice using a DNA primed-protein boost immunization strategy (Fig. 8.9). 
Significant amount of IgG2a antibodies specific for Der p 1, Der p 2 and Blo t 5 were 
successfully induced, demonstrating the apparent Th1 skewed immune response to each 
of the encoded allergens. Data on the specific IgE assay revealed some interesting and 
useful information about the protein dosage for boosting purposes. As shown in Fig. 8.12, 
there were significant levels of Blo t 5 specific IgE being induced in control mice pre-
immunized with vector DNA only, despite the use of a relatively high dose (100 µg) of 
Blot 5 protein for boosting in these mice. On the contrary, unlike Blot 5, 100 µg of Der p 
1 or Der p 2 did not induce any detectable IgE or Th2 responses. The results further 
indicate that the optimal dosage of allergen intended for safe and efficient boosting 
regime has to be determined carefully and independently with each allergen concerned, 
as every allergen could have its unique biological and immunological properties.   
 
Taken together, the data for this feasibility study support the concept that it is to induce 
Th1 skewed immune responses specific to each individual allergen by using a single 
construct containing three unrelated allergen genes. Therefore, vaccination with the 
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Due to time constraint, a number of important questions have not been addressed in this 
preliminary study. I had obtained some data on the humoral responses for each respective 
allergen, but there was no data on the T cell responses induced by the immunization 
strategy. It is important to have a better understand on the effects of boosting the DNA 
immunized mice with high doses of allergens. The T epitopes mapping data presented in 
chapter 7 revealed that boosting with high dose of allergen protein could have some 
suppression on T cell responses. Further understanding of this phenomenon can provide 
useful information on the proper strategy to optimize the effects of protein boost. 
 
More investigations are needed on the design of the multi-gene construct. For example, in 
construct L152, the three allergen genes were linked directly by using linkers and this 
chimeric gene was linked to a single signal peptide. It would be interesting to examine a 
similar construct with each individual gene link to a separate signal peptide instead of 
sharing a single signal peptide. In addition, different types of linkers should be tested to 
achieve optimal specific immune responses. More work should be performed to assess 
the prophylactic and therapeutic effects of construct L152 using an experimental asthma 
mouse model induced by poly-sensitization with Der p 1, Der p 2 and Blot 5. 
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  Chapter 9 General discussion 
The long term goal of the research presented in this thesis is to develop a good DNA 
vaccine for more effective prevention and treatment of mite allergy related allergic 
asthma. The specific aim of this project focused on the design of the DNA constructs and 
optimization of immunization strategy to achieve better vaccine efficacy using an 
experimental mouse allergic asthma model. The model allergen used in this study is a 
major mite allergen from Dermatophagoiodes pteronyssinus mites, designated as Der p 1. 
On the basis of epidemiological data, Der p 1 is being well recognized as one of the most 
important allergens worldwide and therefore it is a good candidate molecule for the 
vaccine development against allergy and related allergic diseases (Warner AM et al., 
1996, O’Brien RM et al., 1994B). However, the unique biochemical and immunological 
properties of Der p 1 have made the development of this vaccine rather problematic. Der 
p 1 DNA vaccine research work started by a number of research groups since the first 
publication of the proof of concept on allergen gene immunization for allergy in 1996 
(Hsu CH et al., 1996A). However, the progress made over the years was slow. It was 
reported that DNA vaccine design using T cell epitopes could potentially overcome the 
biochemical and immunological problems of full length Der p 1 (Kwon SS et al., 2001). 
Recently, Jarman et al. reported significant therapeutic effect of a plasmid DNA encoding 
T cell epitope of Der p 1 spanning residues 111-139, on the reduction of Th2 cytokines 
levels and suppression of airway eosinophilia (Jarman ER and Lamb JR, 2004). 
Immunuzation with T-epitopes approach has some significant limitation as it had been 
indicated by several published work that numerous important human T cell epitopes were 
located throughout the Der p1 molecule (Hale BJ and Thomas WR, 1997; O’Brien RM et 
al., 1994A). Therefore, immunization with a single T epitope will not offer full protection 
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against Der p 1 sensitization. Furthermore, given the complexity and polymorphic nature 
of human MHC genes, DNA vaccine containing the full Der p 1 gene, would offer a 
broader spectrum of protective immunity in the highly heterogeneous human populations. 
Therefore, it was the main aim of this thesis to design and develop a DNA vaccine using 
the full length Der p 1 gene. 
 
Initially, a general DNA immunization protocol was established experimentally (Chapter 
3). BALB/c mice were chosen to be the mouse strain used for DNA immunization 
throughout this study mainly because these mice are readily available locally and they are 
one of the good responders for Der p 1 immunization. Highly purified intact plasmid 
DNA was administered in naked DNA form (without the use of any polymer or viral 
vector) via intramuscular route with the help of in vivo electroporation. It has been well 
established by our laboratory and others that the naked plasmid DNA injected 
intramuscularly induced is the one of best strategies for the induction of Th1-skewed 
immune responses (Feltquate DM et al., 1997; Oliveira SC et al., 1999; Belperron AA et 
al., 1999). Immunization with naked plasmid DNA has being regarded as a safe and 
simple method for vaccine delivery, but the major weakness of this approach is the 
relatively low magnitude of the primed responses. This problem can be overcome to a 
large extent by incorporating the use of in vivo electroporation to increase the transfection 
efficiency of muscle cells during i.m. injection to boost the magnitude of responses. 
Another commonly used DNA delivery method is by biolistic techniques, such as gene 
gun or Biojector 2000. The biolistic methods have the advantage of being highly efficient 
in transfection. It has been shown in mice that approximately 100-fold less DNA is 
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required using gene gun for a comparable antibody response (Fynan EF et al., 1993; 
Bennett AM et al., 1999; Lodmell DL et al., 2001). Nevertheless, the biolistic methods 
were generally believed to favor Th2 responses. In many cases, the same plasmid that 
elicited a Th1 response when given i.m., induced a Th2 response when delivered by gene 
gun (Feltquate DM et al., 1997; Oliveira SC et al., 1999; Belperron AA et al., 1999). 
Therefore, these methods were considered to be not suitable for use in allergic diseases. 
However, in a recent study, using β-galactosidase as a model antigen, it was 
demonstrated that gene gun immunization with pCMV-βGal construct resulted in a mixed 
Th1/Th2 response in BALB/c mice and inhibited IgE production upon subsequent 
challenge by protein sensitization (Ludwig-Portugall I et al., 2004). Given that gene gun 
delivery requires much smaller quantity of DNA to elicit an immune reaction, the 
efficacy and the potential risk of its application in allergic diseases deserve further 
evaluation. 
 
The detailed mechanism of antigen processing and presentation after intramuscular 
injection is not the focus of this thesis. It is generally believed that intramuscular 
injection leads to direct transfection of myocytes (Manam S et al., 2000), which is 
consistent with our findings in chapter 3. The myocyte expressed antigen is then taken up 
by professional antigen presenting cells that process the antigen and present to specific T 
cells. However, the exact identity of the antigen presenting cells and their role in 
polarizing immune response to Th1 phenotype are still elusive. It should be noted that, 
although skeletal muscle lacks detectable MHC expression under physiological 
conditions, more and more evidences show that, under certain conditions, such as injury 
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or inflammation, myoblasts, i.e., skeletal muscle stem cells, can express a surprising 
variety of immunologically important molecules, such as MHC, co-stimulatory molecules 
(Nagaraju K, 2001), cytokines, chemokines, cell adhesion molecules (Figarella-Branger 
D et al., 2003), and Toll Like Receptors (TLRs) (Schreiner B et al., 2005). There is 
growing consensus that muscle cells could perform as antigen presenting cells in some 
situation (Wiendl H et al., 2005). These findings indicated that myoblasts might play a 
more active role in DNA vaccination than just expressing the antigens as originally 
thought. Further study in this field could generate important information for the design of 
future DNA vaccines. 
 
The study on the kinetics of the protein expression in vivo following DNA immunization 
was examined using GFP fusion proteins as readout parameters has contributed some 
useful information for  the understanding and interpretation of some data on construct 
evaluation. For example, the antigen expression data helped to revealed the fact that the 
weak humoral responses by a construct without a good signal peptide was not due to its 
inability to express sufficient protein, as the protein expression data showed that 
construct with or without a signal peptide could express similar levels of protein with 
similar kinetics (Chapter 3, Fig. 3.16).  
 
A systematic approach was used in the design of the DNA constructs used in this study. 
First of all, the full length Der p 1 cDNA sequence, including its pre (leader) and pro 
(pro-enzyme) sequences, was inserted into a mammalian expression vector, and the 
resultant construct was used to immunize Balb/cJ mice intramuscularly. Der p 1-specific 
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IgG2a was subsequently detected in the sera of the immunized mice. The presence of 
IgG2a and the absence of IgE in the immunized mice demonstrated the Th1 skewing 
property of DNA vaccination using the full length Der p 1 construct, but the magnitude of 
response was low (Fig. 3.9).  
 
In the subsequent studies, various strategies were explored to modify the design of the 
construct aiming to enhance the priming ability of the injected DNA. In this regard, the 
pre-sequence of Der p 1 was deleted and replaced by a more efficient signal peptide 
sequence taken from others gene such as Der p 5 gene or mouse Igκ chain, to target the in 
vivo expressed Der p 1 into the secretory pathway so as to stimulate stronger T cell and B 
cell responses.  The pro-sequence of Der p 1 was excluded to abolish the possibility of in 
vivo expression of an enzymatically active Der p 1; and codon optimization approach 
was used to enhance the mRNA translation efficiency. All these modifications resulted in 
a safer and highly immunogenic DNA construct LHM, which was subsequently used for 
the pre-clinical studies in the mouse asthma model as described in chapter 6. The mouse 
Der p 1 allergic asthma model (as described in chapter 5) was established by a biphasic 
protocol, consisting of a systemic sensitization by intraperitoneal injection of alum 
emulsified low dose Der p 1, and then a local airway challenge. Der p 1 specific IgE, Th2 
skewed phenotype of CD4+ T cells, and airway hyperresponsiveness were successfully 
induced in the mouse model. In mice pre-immunized with the LHM construct before the 
sensitization protocol, Der p 1 specific IgE was inhibited, Th2 cytokine production was 
reduced and AHR was attenuated, demonstrating the potential application Der p 1 gene 
immunization for prophylactic vaccination against Der p 1 sensitization.    Der p 1 pre-
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sensitized mice which were subsequently treated with LHM immunizations, reduction of 
Der p 1 specific IgE was also observed, demonstrating that the DNA-induced responses 
are useful for attenuating the pre-existing Th2 response to a certain extent, indicating its 
potential application for therapeutic purposes. 
 
Using construct LHM as a plasmid backbone, construct LHML was made representing 
yet another modification to construct design. Construct LHML contains the lysosome 
targeting sequence in the 3 prime end of Der p 1 gene in construct LHM. This construct 
induced a more Th1 skewed phenotype. The inclusion of the lysosome targeting sequence 
could limit the in vivo expressed protein within the host cell by-passing the conventional 
secretory pathway. The chimeric Der p 1/LAMP protein is recombinant endogenous 
molecules that enter the cell vesicular compartment by endoplasmic reticulum 
translocation signal sequence (the mouse Igκ chain signal peptide), pass through the 
Golgi apparatus, and are directed to lysosomes (MHC II compartment) by tyrosine-based 
carboxy terminal targeting sequence present in LAMP (Bonifacino JS et al., 1999; 
Bonifacino JS et al., 2003). This strategy is aiming at inducing stronger Th1 skewed 
responses and reducing the potential risk to the immunized host by avoiding the 
biodistribution of allergen expressed in vivo to numerous host tissues. These properties 
could be extremely useful for those allergens with biological properties that are potential 
toxic to certain cells or tissues of the host.   
 
The feasibility of using heterogeneous prime-boost protocol to further improve the 
efficiency of DNA vaccination was also investigated. It was observed the DNA primed 
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antibody production could be boosted by subsequent protein immunization by 
intratracheal inoculation, intraperitoneal injection, or subcutaneous injection, with 
intratracheal to be the least efficient possibly due to the lack of any adjuvant. In the cases 
of intraperitoneal injection and subcutaneous injection, alum hydroxide, an adjuvant 
licensed for human use, was employed. Aluminum is capable of inducing Th2-type 
immune response for many antigens in mice, and is particularly effective in stimulating 
IgE production (Mancino D and Ovary Z, 1980). However, when alum was used with 
high dose antigens to boost the DNA primed immune response, no IgE was detected. 
These data indicate that alum could be a useful adjuvant together with boosting protein 
antigen to enhance the immune response without altering the Th1 skewed phenotype 
induced by DNA vaccination. Therefore, it appears that the DNA prime-protein boost 
could be an efficient mixed modality strategy for vaccination against allergic diseases. 
However, there are several questions remain to be answered. Firstly, the effects of the 
protein boost on the T-epitopes prime by DNA immunization to be determined. It is 
unclear whether the subsequent protein boost will preferentially enhance the T epitopes 
originally primed by DNA immunization or the boosting will result in priming for more 
new T- epitopes. It remains to be determined whether the enhanced immune responses 
boosted by the protein immunization have any impact on the protective immunity 
induced by DNA immunization. Secondly, the boosting effect on the antibody production 
might not be related to a boost in T cell response, especially when high dose allergen was 
applied repeatedly, as revealed by data shown in Chapter 7, Fig. 7.13. It seems that there 
was a general suppressive effect on T cells response to Der p 1 antigen. This suppression 
effect could be due to the extremely high dose of Der p 1 that was used for intraperitoneal 
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and subcutaneous injections. It has been observed in chapter 5 that high dose protein 
exposure favors antigen specific regulatory T cells, which are CD4, CD25 double 
positive. Since the induction of antigen specific T cell suppression could be another 
feasible approach to attenuate Th2 responses, it is worthwhile to further investigate this 
phenomenon in more detailed study. Such study may also depend on the advances in the 
field of basic immunology and cell biology. Until such knowledge becomes available, 
heterogeneous prime-boost protocol should be used with care. 
 
As has been discussed previously, therapeutically, the effect of DNA vaccination was less 
satisfactory, although inhibition of IgE was evident. It indicates that inhibition of IgE 
alone might not be sufficient to achieve a satisfactory therapeutic efficacy. Simultaneous 
inhibition of Th2 response is likely to be necessary. It is known that established Th2 cells 
are very difficult, if not impossible, to change their phenotype (Mosmann TR et al., 1986). 
These established memory/effector Th2 cells could possibly interfere with the desired 
DNA induced Th1 response. Therefore the immune response induced by DNA 
vaccination in a strong Th2 environment could be a complicated mixture of Th2, Th1, 
and even Tr (T-regulatory) phenotypes. It could be postulated that we need either a 
stronger Th1 skewing and more immunogenic construct (or immunization protocol), or 
some strategy to attenuate the established Th2 response, possibly through the induction of 
regulatory T cells, used in combination with DNA immunization to achieve better 
therapeutic efficacy. Another reason for the less satisfactory therapeutic efficacy is that 
DNA vaccine alone could not have direct effect on the ongoing airway inflammation and 
airway remodelling. As indicated in Figure 8.1, allergic asthma could be conceptually 
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divided into two phases, the sensitization phase (phase 1) and the manifestation phase 
(chronic inflammation phase, phase 2). DNA vaccination could exert its effects on the 
effectors cells and mediators in phase 1, i.e. to modulate the phenotypes of allergen 
specific T cells, which could potentially stop or attenuate airway inflammation and the 
process of airway remodelling. However it might not be able to reverse the established 
pathological changes, which may lead to the persistence of the disease. In this regard, 
DNA vaccine, used in combination with anti-inflammation agents, is advisable for severe 
late stage asthma patients. 
 
In summary, several Der p 1 DNA constructs were made and evaluated in this study. 
Immunization with construct LHM appears to be very potent for the attenuation of Der p 
1 specific IgE and Th2 responses in both prophylactic and therapeutic models. However, 
such immunization could attenuate AHR prophylactically, but not therapeutically. The 
full therapeutic efficacy of Der p 1 gene vaccination definitely deserves more study.  
Construct LHM is a good candidate for further development into a prophylactic DNA 
vaccine for further evaluation for human clinical trials. 
 
Based on the plasmid framework of construct LHM, another construct containing multi-
allergen genes was designed and designated as L152. Major allergens from House Dust 
Mites, i.e. Der p 1, Der p 2 and Blo t 5, are used as model allergens in this study, since 
they account for the majority of allergic asthma patients. The preliminary data obtained in 
this study have proven the concept that it is feasible to induce specific immune responses 
to multiple allergens with a single DNA construct containing multiple unrelated allergen 
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genes. A poly-sensitization mouse model has been successfully established in our 
laboratory recently, the preclinical efficacy evaluation can be performed accordingly. 
This DNA immunization approach is particularly useful for vaccination of the atopic 
children at high risk to prevent the onset of allergy and subsequent development of 
allergic diseases. The strategies used for the mite allergen genes may also be applicable 
in the design of DNA vaccines for other allergens from peanut, pollen, or mold. 
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Finally, besides further modification of the plasmid construct and vaccination regimens, 
mechanistic study to dissect the detailed antigen processing and presentation pathway 
after DNA vaccination would also have fundamental impacts on DNA vaccine 
development. Given the dominant effect of the antigen processing and presentation on the 
induction and modification of the subsequent adaptive immune responses, such 
mechanism study is particularly important for the design of DNA vaccines aiming at 
allergic diseases, which are immunological in nature. Recent advances in immunology 
have provided more complicated views of antigen presenting cells (mainly dendritic cells) 
and helper T cells (Shortman K and Liu YJ, 2002; Hawrylowicz CM and O’Garra A, 
2005; Randolph DA and Fathman CG, 2006), presenting more options for DNA vaccine 
designers. The possibility of targeting DNA vaccines to a specific subset of dendritic 
cells and induction of allergen specific adaptive regulatory T cells for the treatment of 
allergic diseases could be explored. It should be noted, however, that some 
immunomodulatory factors, such as TGF-β, employed by the immune system are actually 
related to airway remodeling (Maddox L and Schwartz DA, 2002). Therefore, knowledge 
of subsets of regulatory T cells and the mechanisms of their immunomodulation function 
is required before an effective regulatory T cell inducing DNA vaccine could be 
developed. 
 
Clearly, what has been presented in this thesis opened more possibilities and questions 
than it has achieved or answered. As Albert Einstein said, “The most beautiful thing we 
can experience is the mysterious. It is the source of all true art and all science”. Indeed, it 
is the mysterious that makes the scientific exploration so exciting. 
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Abstract
The mite protein Der p 1 is a major trigger of allergy and atopic asthma world-wide, and thus, a good vaccine candidate for allergy
prevention. Since it is a cysteine protease, the catalytic effects of Der p 1 vaccination may be unpredictable. One approach to reduce this
risk is to vaccinate with DNA encoding enzymatically inactive forms of Der p 1. Here we show that Der p 1 DNA without its native pre–pro
sequences potently induced Der p 1-specific antibodies, as long as its pre-sequence was substituted by another leader sequence. Without
any pre–pro sequence, the same DNA fragment was well expressed but failed to induce significant level of anti-Der p 1 antibodies, without
further boosting by protein.
© 2002 Elsevier Science Ltd. All rights reserved.
Keywords: Der p 1; Naked DNA; DNA vaccine
1. Introduction
From an epidemiological point of view, Der p 1, a protein
synthesized by Dermatophagoides pteronyssinus mites, is
one of the top candidates for an allergy vaccine: house dust
mites are major indoor triggers of atopic allergy; the majority
of allergic individuals are sensitized to one or more species
that are common in their environment; D. pteronyssinus is
one of the three most common species of mites in temperate
regions; the majority of mite sensitive patients respond to
group I and group II allergens, and Der p 1 is one of the
prevalent antigens in this mixture [1–4]. The amino acid
sequence is highly conserved among group I allergens of
different mite species. Exposure and initiation of an allergic
process by a major mite allergen may facilitate sensitization
to other less prevalent allergens [5].
Der p 1 protein is a cysteine protease; its full-length cDNA
encodes a precursor of 320 amino acid residues, including
an 18 amino acid signal peptide, a pro-enzyme region of 80
amino acid, and a mature enzyme of 222 amino acid residues
[6]. Like its homologues papain and actinidin, Der p 1 has a
two-domain structure. The left domain (approximately cor-
responding to amino acid sequence 1–116) consists of three
-helix and the right domain (approximately corresponding
∗ Corresponding author. Tel.: +65-874-4345; fax: +65-775-7593.
E-mail address: paecky@nus.edu.sg (K.Y. Chua).
to amino acid sequence 114–222) is largely composed of
-pleated sheets [7].
The synthetic pathway of Der p 1 has imposed limitations
to the production of large quantities of recombinant protein
for immunotherapy or vaccination [8]. The recombinant al-
lergen is trapped as a zymogen inside inclusion bodies. Der
p 1 maturation does not occur naturally in bacterial or in-
sect systems, and therefore the protein has to be solubilized
and renatured. Removal of the pro-sequence by autocataly-
sis was problematic and often resulted in protein degradation
[9,10].
We propose that genetic immunization with Der p 1 gene
is a feasible alternative strategy to develop useful prophy-
lactic and therapeutic reagents for mite allergy [11–18]. In
this case, DNA sequences encoding the T cell epitopes could
be exploited for the vaccine design [19]. However, as indi-
cated by the published data, numerous important human T
cell epitopes that have been mapped were located through-
out the Der p 1 molecule [20,21]. Given the complexity and
polymorphic nature of the MHC genes, vaccine design us-
ing the full Der p 1 gene or large gene fragments would of-
fer a broader spectrum of protective immunity in the highly
heterogenous human populations.
Since Der p 1 is a cysteine protease with demonstrated
proteolytic activity [6,22–24], prolonged endogenous syn-
thesis in a vaccinated host may have unpredictable effects.
Therefore, DNA encoding enzymatically inactive immuno-
genic forms of the allergen may represent a feasible and safer
0264-410X/02/$ – see front matter © 2002 Elsevier Science Ltd. All rights reserved.
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Der p 1 vaccine. It has been reported that the pro-enzyme
peptide of cysteine proteases serves as an intramolecular
chaperon, and is essential for correct folding of the mature
protein [25]. It has been shown that incorrectly folded Der
p 1 lacked enzymatic activity [8,9]. Therefore, we rationale
that excluding the pre–pro-region of Der p 1 in the DNA
construct is a feasible strategy to produce immunogenic but
enzymatically inactive Der p 1 in vivo.
In this study, we evaluated IgG reactivity to native Der
p 1 and antigen expression in vivo after immunization with
Der p 1 gene or gene fragments. Various DNA constructs
encoding either Der p 1 full-length gene or gene fragments,
with or without its own pre–pro sequences, were evaluated.
2. Materials and methods
2.1. Animals
Six to eight-week-old female BALB/cJ mice were pur-
chased from Laboratory Animals Centre (Sembawang, Sin-
gapore). Mice were housed at the National University of
Singapore Animal Holding Unit and cared for under institu-
tional guidelines for the care and use of laboratory animals.
Immunization experiments were performed with groups of
4–10 animals. For DNA immunizations mice were anes-
thetized with a cocktail of Hypnorm plus Midazolam pro-
vided by the Animal Holding Unit, National University of
Singapore.
2.2. Constructs preparation
Fig. 1 shows the Der p 1 variant expression constructs
that were produced: Der p 1 full-length cDNA inserted into
pcDNA3; Der p 5 L/Der p 1(1–116) and leaderless Der p
1(1–116), each encoding the N-terminal half of Der p 1, in-
serted into pEGFP to assess expression or into pCIneo for
immunization; Der p 5 L/Der p 1(1–222) and Der p 1(1–222)
each encoding for the full-length mature protein inserted
also into pEGFP or into pCIneo for the same purposes.
The construction of plasmid pcDNA3-pre–pro-Der p 1
was carried out by insertion of the PCR amplified full-
length cDNA fragment of Der p 1, using oligonucleotide
primers (5′-CCCGGATCCAACATGAAAATTGTTTTGG-
CC-3′ and 5′-GCGCTCGAGTTTAGAG AATGACAACAT-
ATGG-3′) and the gt10RecL3a Der p 1 cDNA as DNA
template, into the BamHI and XhoI sites of mammalian ex-
pression vector pcDNA3 (InvitrogenTM Life technologies).
PCR was used to amplify the sequences of Der p 1 DNA
coding for the N-terminal domain (residues 1–116) and the
full-length mature protein (residues 1–222). The sequences
of the synthetic oligonucleotide primers (Operon, Qiagen,




CA-3′. Each individual primer was engineered to include a
unique restriction endonuclease site at its 5′ terminus for
compatible cloning of the PCR fragment into the pEGFP-N3
(Clontech, Palo Alto, CA) expression vectors. The PCR am-
plification and cloning procedure were performed with stan-
dard protocols as previously described [26]. PCR fragment
were cloned into pCR2.1 vector for sequence confirmation
by automatic sequencing (ABI PRISMTM sequencing kit).
In order to link the Der p 5 signal peptide sequence to
the Der p 1 fragments, the pCR2.1-Der p 1 recombinant
constructs were digested with BspEI and XhoI restriction
endonucleases. The 64-basepairs synthetic oligonucleotides
corresponding to the Der p 5 leader (sense sequence 5′-
TCGAGATCAATCATGAAATTCATCAT TGCTTTCTTT-
GTTGCCA CTTTGGCAGTTATGACTGRTT-3′ and anti-
sense sequence 5′-CCGGAAA CAGCCTAAACTGCCAA-
AGT GGCAACAAAGAAAGCAAT GATGAAT T TCATG-
ATTGATC-3′) were then inserted into the BspEI and XhoI
sites of the 4.7 kb vector to generate pCR2.1-Der p 5 L/Der
p 1(1–116), and pCR2.1-Der p 5 L/Der p 1(1–222). The
resulting plasmids were sequenced using ABI PRISMTM
sequencing kit.
To generate the pEGFP-N3-based expression vectors, the
inserts encoding the Der p 5 L/Der p 1(1–116), and Der p 5
L/Der p 1(1–222) fusion proteins were released from plas-
mids pCR2.1-Der p 5 L/Der p 1(1–116) and pCR2.1-Der p 5
L/Der p 1(1–222) by digestion with XhoI, BamHI and EcoRI.
Subsequently, the agarose gel purified DNA fragments were
extracted from the gel using the QIAEX II kit and inserted
into the XhoI–BamHI gap of pEGFP-N3 vector. The ligated
plasmid DNA was then transformed into the E. coli strain
DH5. Kanamycin resistant transformants were selected by
screening for pDer p 5 L/Der p 1(1–116)-EGFP and pDer p
5 L/Der p 1(1–222)-EGFP DNA, respectively. Subsequent
construction of pCIneo-based Der p 5 L/Der p 1 variant
constructs was carried out by PCR amplification of the
encoding sequences using three specific synthetic oligonu-
cleotide primers and the DNA templates pDer p 5 L/Der p
1(1–116)-EGFP and pDer p 5 L/Der p 1(1–222)-EGFP. The
sequence of these specific primers corresponding to the Der
p 5 signal peptide sequence, the C-terminal sequence of the
N-terminal domain of Der p 1 and the C-terminal sequence
of the C-terminal domain of Der p 1 domain are 5′-GCCT-
CGAGCCACCATGAAATTCATCATTGCT-3′, 5′-GCGG-
AT CCGCGGCCGCT TAGAGAAT GACAACA TAT GG-3′
and 5′-CCGCGGCCGCTAATAGT TTGAGATACCGAAA-
CGTTG-3′, respectively. The PCR products were sub-
cloned into pCR2.1 vector to generate plasmid con-
structs termed pCR2.1-Der p 5 L/Der p 1(1–116) ter and
pCR2.1-Der p 5 L/Der p 1(1–222) ter. The expression con-
structs pCIneo-Der p 5 L/Der p 1(1–116) and pCIneo-Der
p 5 L/Der p 1(1–222) were produced by insertion of the
Der p 5 L/Der p 1 encoding sequences released from
pCR2.1-Der p 5 L/Der p 1(1–116) ter and pCR2.1-Der p 5
L/Der p 1(1–222) ter into the XhoI and NotI sites of the pCI-
neo (Promega, Madison, WI). Similar PCR amplification
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Fig. 1. Schematic representation of the constructs used for immunization.
strategy was employed to generate pCR2.1-Der p 1(1–116)




AATAGTT TGAGATACCGAAACGTTG-3′, the DNA tem-
plates pCR2.1-Der p 5 L/Der p 1(1–116) ter and pCR2.1-Der
p 5 L/Der p 1(1–222) ter. The XhoI–BstXI fragments en-
coding for the Der p 1(1–116) and Der p 1(1–222) fusion
proteins released from the vectors pCR2.1-Der p 1(1–116)
and pCR2.1-Der p 1(1–222) were used to replace the
XhoI–BstXI fragments of pDer p 5 L/Der p 1(1–116)-EGFP
and pDer p 5 L/Der p 1(1–222)-EGFP and resulted in
pDer p 1(1–116)-EGFP and pDer p 1(1–222)-EGFP. To gen-
erate pCIneo-Der p 1(1–116) and pCIneo-Der p 1(1–222)
the BstXI–NotI fragments from pCIneo-Der p 5 L/Der p
1(1–116) and pCIneo-Der p 5 L/Der p 1(1–222) and the
XhoI–BstXI fragments from pDer p 1(1–116)-EGFP and
pDer p 1(1–222)-EGFP were linked together with the XhoI
and NotI sites of pCIneo, respectively.
2.3. Mice immunization
BALB/cJ mice were immunized under anesthesia, by in-
tramuscular injection of 50l of naked DNA (1g/l) in the
left quadriceps using a 1 ml insulin syringe and a 27 G nee-
dle. For immunization with electroporation, the front of the
upper left leg was shaved, and DNA was injected as above,
in the anterior tibialis, followed by immediate electropora-
tion with an ECM 830 apparatus (BTX, Genetronics, San
Diego, CA). Electroporation was performed with a 0.5 cm
2-needle array inserted 2 mm deep in parallel to the muscle
fibers, that delivered four pulses of 20 ms, 80 V each, with
a 200 ms interval. Animals received pEGFP-N3-Der p 1 or
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pCIneo-Der p 1 constructs with or without electroporation.
Serum was collected before (day 0) and sequentially after
immunization.
2.4. Purification of native Der p 1 and Der p 1
recombinant peptides
Spent Mite Media (a gift from CSL Limited, Melbourne,
Australia) was resuspended to 10% (w/v) in a 0.5 M NaCl
in 10 mM Tris–HCl pH 7.5 solution containing 1 mM PMSF
and 1 mM EDTA and the suspension was stirred at 4 ◦C
overnight. The next day the suspension was centrifuged at
12.100 g for 15 min and the supernatant was collected for
purification, using a protocol that was previously described
[27]. Briefly, A monoclonal antibody (4C1) sepharose affin-
ity column was equilibrated with five bed volumes of the
suspension buffer and the supernatant of spent mite medium
was applied to the column, Der p 1 was eluted with 5 mM
glycine in 50% ethylene-glycol pH 10 and the fractions were
collected in tubes containing 100l/ml fraction of 0.2 M
Na2HPO4 pH 7 neutralizing buffer. The peak samples were
pooled, dialyzed immediately against 50 mM NH4HCO3,
and lyophilized. The samples were resuspended in PBS and
quantitated by comparison with a protein standard using a
colorimetric assay (BioRad, Hercules, CA).
E. coli clones producing Der p 1 recombinant pep-
tides GST-(1–116) and GST-(114–222) were grown in LB
medium containing 100g/ml of ampicillin and induced
for 3 h with 0.5 mM IPTG (Calbiochem, LaJolla, CA). The
bacteria were pelleted and resuspended in TBS with 1 mM
PMSF, 20g/ml of Dnase I, 20g/ml of Lysozyme and
Tween 20 to 1% of the cell suspension. The bacteria were
disrupted by sonication on ice, and the supernatant was
collected after centrifugation. The peptides were purified
by passage over a column of glutathione agarose beads
pre-equilibrated in TBS, and elution of the bound material
with 10 mM reduced glutathione in 50 mM Tris–HCl pH
8 buffer. The concentration of recombinant peptide was
quantified by a colorimetric assay (BioRad, Singapore) and
purity was assessed by SDS–PAGE. For Western analysis,
aliquots of the eluted peak were run on 7.5% SDS–PAGE,
transferred to Hybond C nitrocellulose membranes (Amer-
shampharmacia Biotech AB, Malaysia) and probed with
monoclonal antibodies 6BC, specific for 1–116 peptide, and
1BB specific for 114–222 peptide, produced for this purpose.
2.5. Protein expression in cryosections of muscle
Muscle samples from the injection site were collected at 1,
6 h, and 1, 2, 4, 7, 10, 14, 21, and 28 days after injection. The
samples were embedded in O.C.T compound (Tissue-Tek,
Sakura, Torrance, CA) snap frozen in liquid nitrogen and
stored at −20 ◦C. Ten micrometers cryosections were cryo-
statically sectioned and mounted with fluorescence quench-
ing medium (DAKO). Fluorescent images were captured by
confocal microscopy.
For immunostaining, 5m sections were cut and mounted
onto silanized slides, fixed in cold acetone, treated with
0.3% hydrogen peroxide, washed, and blocked with 5%
normal goat serum. Replica slides were then stained with
a 0.3% dilution of irrelevant mouse antiserum, anti-Der p
1 antiserum or 0.1% dilution of ascites containing mon-
oclonal anti-Der p 1 antibodies. The slides were devel-
oped with the VECTASTAIN ABC kit (Vector Labora-
tories Inc., Burlingame, CA) following manufacturer’s
instructions.
2.6. Detection of antisera specific for native Der p 1 and
for recombinant Der p 1-derived peptides by ELISA
Maxisorp Immuno plates (Nalge Nunc Intl, Naperville,
IL) were coated with 5g/ml of native Der p 1 in 0.1 M
NaHCO3 pH 8.3, overnight at 4 ◦C. The plates were then
flicked to remove uncoated antibody and blocked for 1 h
with a solution of 1% BSA in PBS/0.05% Tween 20
(washing buffer). The plates were washed three times with
PBS/Tween 20. Dilutions of sera were added and incubated
overnight at 4 ◦C. Dilutions of standard mouse IgG2a or
mouse IgG1 (PharMingen, San Diego, CA) were added to
each plate onto wells coated with anti-mouse kappa light
chain clone 187.1 (PharMingen). The plates were washed
three times and Biotin conjugated IgG2a- or IgG1-specific
monoclonal antibody (clone LO-MG2a-7 and clone
LO-MG1-2, respectively, Serotec, Oxford, England) were
added for 1 h, followed by alkaline phosphatase conjugated
ExtrAvidin (Sigma–Aldrich) and p-Nitrophenylphosphate
substrate (Sigma–Aldrich). The Antibody Production Units
of antigen-specific antibodies were determined by compari-
son of the plot of absorbance versus dilutions of the sample
to that of the standard versus its concentration.
Similar methods were used for detection of peptide-specific
antibodies, except that the plates were coated with 5g/ml
of purified Der p 1-derived peptides GST-(1–116) or
GST-(114–222) peptides. The amount of peptide coated on
each well was comparable, as determined by binding of
peptide-specific monoclonal antibodies. Replicas of the an-
tisera were tested on plates coated with GST for specificity
control.
3. Results
3.1. Immunogenicity of pcDNA3-pre–pro-Der
p 1 plasmid
To determine whether naked Der p 1 cDNA inserted into
an expression plasmid could induce anti-Der p 1 antibod-
ies, pcDNA3 engineered pre–pro-mature Der p 1 plasmids
were injected into the muscle of BALB/cJ mice. One injec-
tion was insufficient to elicit a detectable humoral response
(data not shown); therefore the animals were boosted with
similar protocol 1 or 2 weeks after priming (Fig. 2). Two
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Fig. 2. Kinetics of the anti-Der p 1 antibody response induced by intra-
muscular injection of pcDNA3-pre–pro-Der p 1 plasmid. (A) Mice were
injected on day 0 and boosted on day 7 (arrows). Sera were collected
weekly and tested by ELISA on plates coated with native Der p 1. (B)
Mice were injected on day 0 and boosted on day 14 (arrows). Sera were
collected and tested as in A. Each line represents the Ig titer of an in-
dividual mouse serum. IgG1 anti-Der p 1 antibodies were not detected
(<10 units).
injections of naked DNA given 1 week apart (Fig. 2A) in-
duced a response peak by the third week after priming that
had almost returned to baseline by day 56. Two injections
of naked DNA given 2 weeks apart (Fig. 2B) induced two
response peaks, the first of very low magnitude between 21
and 28 days after priming, returned to baseline by day 35.
The second peak occurred during the sixth week (day 42
sample), and in this group anti-Der p 1 antibodies could still
be detected by day 70. Spacing the first and second dose by
3 weeks produced similar results, a very low first antibody
peak, followed by a secondary response of higher magni-
tude and even longer duration (data not shown). These re-
sults suggested that two intramuscular doses of whole length
Der p 1 gene could produce antibodies with native Der p
1 specificity. For the following experiments the two doses
were given 2 or 3 weeks apart.
The maximum antibody concentrations observed for
naked DNA injection were low, ranging from 50 to 400 units
of IgG2a in all the experiments. Other isotypes were tested
but not detected (Fig. 2), indicative of predominant Th1
immunity.
3.2. Der p 1-specific antibodies are also induced by
Der p 5 L/Der p 1 plasmids
To limit the possibility of production of enzymatically ac-
tive form of Der p 1 in the vaccinated host, new constructs
were made, where the pro-enzyme sequence, which is neces-
sary for a right conformation of mature Der p 1, was deleted.
It was also of interest to determine if engineering a differ-
ent leader peptide into the expression vector could turn the
plasmid into a more potent immunogen. Previous work had
shown that Der p 5 cDNA could successfully induce a pro-
tective response to the house dust mite allergen Der p 5 [11].
Therefore, the autologous Der p 1 leader was replaced by the
Der p 5 leader. Two plasmids were derived from the pCIneo
vector: Der p 5 L/Der p 1(1–222) encodes the whole mature
Der p 1, and Der p 5 L/Der p 1(1–116) encodes only the first
116 amino acids (Fig. 1). Sera from mice injected with this
plasmid were collected sequentially and tested for the pres-
ence of Der p 1-specific antibodies. As shown in Fig. 3, the
peak anti-Der p 1 IgG2a responses induced by the products
of the pre–pro-Der p 1 plasmid and chimeric Der p 5 L/Der
p 1(1–222) DNA were comparable. These data suggest that
the pro-enzyme sequence is not necessary for the production
of Der p 1-specific antibody, and that substitution of the Der
p 1 leader sequence with the Der p 5 leader sequence does
not result in significant differences in immunogenicity.
For subsequent experiments, electroporation was incor-
porated to the immunization protocol to maximize in situ
transfection of the muscle. Both the frequency of respon-
ders and the general anti-Der p 1 antibody titers increased
(Fig. 4). Der p 5L/Der p 1(1–222) plasmid and the second
chimeric construct, Der p 5L/Der p 1(1–116) are both
Fig. 3. Comparison of the anti-Der p 1 antibody response induced by
intramuscular injection of the pcDNA3-pre–pro-Der p 1 plasmid (left
panel) or the pCIneo-Der p 5 L/Der p 1(1–222) construct (right panel).
Sera were collected weekly. Each dot represents the peak Ig titer response
of an individual sample. Statistically, there was no difference between the
two groups, as determined by the Student’s t-test.
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Fig. 4. Electroporation increases the frequency of responders and the titer
of anti-Der p 1 antibodies. Each panel represents a group of animals
intramuscularly injected with one of the two constructs with Der p 5
leader. The two left panels show the data from animals receiving naked
plasmid by intramuscular injection alone. The two right panels show the
data from animals receiving naked plasmid by intramuscular injection and
electroporation. Each dot represents the serum of an individual mouse. The
statistical significance of differences of means between different groups
were P < 0.05 (Der p 5 L/Der p 1(1–222) with or without electroporation)
and P < 0.01 (Der p 5 L/Der p 1(1–116) with or without electroporation),
as determined by the Student’s t-test.
immunogenic. The long-lasting antibody response induced
by these two plasmids using naked DNA injection with
electroporation is shown in Fig. 5. Anti-Der p 1 antibod-
ies peaked between days 56 and 101 for both constructs.
Detectable circulating antibodies persisted for at least 128
days after the last plasmid injection.
The levels of Der p 1-specific IgG2a and IgG1 antibodies
in animals receiving the chimeric Der p 1 plasmids were
compared. Control vector induced no detectable anti-Der
p 1 antibody response. As shown in Fig. 6, both Der p
5L/Der p 1(1–116) and Der p 5L/Der p 1(1–222) immunization
resulted in a skewed antibody response dominated by IgG2a
antibodies, especially in mice receiving the Der p 5L/Der
p 1(1–222) plasmid. The Der p 5L/Der p 1(1–116) induced
larger amounts of IgG1.
3.3. Leaderless plasmids are poor anti-Der p 1
immunogens for humoral response
To understand whether the leader sequence was neces-
sary at all to induce anti-Der p 1 antibody production, two
leaderless plasmids encoding either the complete mature se-
quence of Der p 1, pCIneo-Der p 1(1–222), or the first 116
amino acids, pCIneo(1–116), were designed as described in
Section 2 (Fig. 1). These plasmids were administered on
Fig. 5. Persistent anti-Der p 1 antibody response after Der p 1 DNA im-
munization. Mice received pCIneo-Der p 5 L/Der p 1(1–116) (dashed line)
or pCIneo-Der p 5 L/Der p 1(1–222) (solid line) i.m. with electroporation
on days 0 and 21. Serum samples were collected periodically and the
titer of Der p 1-specific antibodies in serum was determined by ELISA.
Data is shown as mean ± S.E.M.
days 0 and 21 with electroporation, and the results of this
experiment are shown in Fig. 7. In the absence of a signal
peptide, the anti-Der p 1 antibody response to pCIneo-Der
p 1(1–222) was very low (Fig. 7B), and for pCIneo-Der p
1(1–116) it was below detection levels (Fig. 7A).
The lack of detection of a significant anti-Der p 1 response
in the mice immunized by pCIneo-Der p 1(1–116) could
Fig. 6. Preferential induction of Der p 1-specific IgG2a. The mice received
pCIneo-Der p 5 L/Der p 1(1–116) (A) or pCIneo-Der p 5 L/Der p 1(1–222)
(B) with electroporation on days 0 and 21. Serum samples were collected
on day 101 and assayed by ELISA. The statistical significance of differ-
ences of means between the concentration of Der p 1-specific IgG2a and
IgG1 antibodies was P < 0.02, as determined by the Student’s t-test.
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Fig. 7. Leaderless plasmids do not elicit a significant antibody response. Detection of IgG2a was assayed on Der p 1 coated plates (solid lines), or on
1–116 peptide coated plates (dashed lines). Mice received pCIneo-Der p 1(1–116) (A) or pCIneo-Der p 1(1–222) (B) with electroporation on days 0 and 21.
result from the absence of native epitopes in the expressed
product of this leaderless plasmid. To explore this possi-
bility, a recombinant peptide corresponding to the first half
of Der p 1, amino acid sequence 1–116, was produced and
used to coat plates. Anti-Der p 1 monoclonals specific for
Fig. 8. Time course of pEGFP-Der p 1 expression in the muscle: cryosections from injected muscles were collected at different times after immunization
with electroporation. Panel A: representative section of muscle from mice injected with PBS. Panels B to K: sections of muscle from mice injected with
pDer p 5L/Der p 1(1–116)-EGFP collected 1, 6, 24 h, days 2, 4, 7, 10, 14, 21, or 28 after immunization. Panel L: representative section of muscle from
mice injected with leaderless pDer p 1(1–116)-EGFP collected 4 days after injection.
the 1–116 domain were used to standardize the test. Fig. 7
shows that the anti-peptide response induced by leaderless
plasmids was also insignificant.
These results indicate that a leader sequence is required
to induce antibodies to Der p 1.
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3.4. Similar levels of antigen expression after injection of
Der p 5 L/Der p 1 or leaderless Der p 1 constructs
Next we examined whether the lack of a prominent hu-
moral response to leaderless Der p 1 constructs was due to
a failure to express these proteins in vivo. pEGFP-N3 con-
structs encoding only Der p 1 amino acids 1–116, or the
chimeric Der p 5 L/Der p 1(1–116) were produced and in-
jected as described above (Fig. 1). The Der p 1 sequence was
inserted 5′ of the GFP reporter sequence; therefore lumines-
cence reported Der p 1 fragment translation. Cryosections
of injected muscle were observed by confocal microscopy.
In the absence of electroporation, naked plasmids resulted
in very low frequency of dimly fluorescent cells (data not
shown). Naked DNA injection and electroporation resulted
in marked expression of pEGFP-Der p 5 L/Der p 1(1–116).
The kinetics of fluorescent signal were determined in mus-
cle samples collected on days 1, 2, 4, 7, 10, 14, 21 and 28
after injection. Three animals were examined for every time
point, and representative images are shown in Fig. 8.
Expression of Der p 5 L/Der p 1(1–116)-GFP was consis-
tent, widespread, and frequently intense. It could already be
observed a few hours after immunization and continued to
increase for a week. Expression was maintained at plateau
levels for 7–14 days. Twenty-one days after immunization,
expression was lower and barely detectable on day 28.
Surprisingly, the fluorescence emitted by muscle trans-
fected with leaderless pEGFP-Der p 1(1–116) was just as in-
tense as that observed for animals injected with Der p 5
L/Der p 1(1–116)-GFP (Fig. 8). These results suggest that the
lack of antibody response to the leaderless construct is not
due to the lack of protein expression.
4. Discussion
In this study, we demonstrate that DNA immunization
with plasmids encoding the complete Der p 1 sequence or
fragments of it induces antibodies against the native allergen.
Constructs encoding the full-length mature protein (amino
acids 1–222) or the globular predominantly -helix domain
(amino acids 1–116) were produced (Fig. 1). Each of the
constructs was inserted into the pEGFP-N3 reporter plasmid
to determine its expression, or into pCIneo for immunization.
It was first determined that plasmid immunization with
DNA carrying the complete Der p 1 cDNA sequence,
pcDNA3-pre–pro-Der p 1, can elicit antibodies with native
Der p 1 specificity (Fig. 2). At least two immunizations were
required to detect the response. A booster injection given
2–3 weeks after primary resulted in circulating anti-Der p
1 antibodies for over 2 months.
The design of the subsequent plasmids was based on sev-
eral structural considerations. The pre-sequences of other
cysteine proteases such as human cathepsin B and papain
have been reported cytotoxic for E. coli in which they im-
paired protein synthesis [28,29]. Therefore, we designed
plasmids in which the Der p 1 signal peptide was replaced
by that of another mite allergen, Der p 5. The pro-enzyme
sequence was deleted to avoid the production of enzymat-
ically active Der p 1 in vivo. In order to enhance immunity,
we have tested these different constructs with different
immunization protocols. Our results showed the antibod-
ies induced by pro-region deleted, pre-region substituted
pCIneo-Der p 5L/Der p 1 (1–222) were comparable to those
induced by full-length Der p 1 DNA (Fig. 3).
Addition of electroporation to the immunization pro-
tocol greatly enhanced both the frequency of responders
(90–100% of the mice for all experiments) and the titer of
anti-Der p 1 antibodies. As shown for other DNA vaccines
[30], electroporation enhances uptake of genes by perme-
abilization of the muscle fibers, and this results in a very
high frequency of transfected bundles as well as higher
intensity of expression. The enhancement of immunity ap-
parently follows the increased availability of antigen. Either
the Der p 5 L/Der p 1(1–116) fragment or the Der p 5 L/Der p
1(1–222) resulted in transfectant protein synthesis and in the
induction of comparative antibody responses. Incidentally,
the second half of Der p 1 sequence (114–222) encoding
the C-terminal -sheet domain was evaluated, but there was
no detectable protein expression or antibody response (data
not shown). This observation is currently under further
investigation.
While the humoral response was still dominated by IgG2a,
it is noteworthy that the enhancement of the overall level
of humoral response by electroporation also induced de-
tectable amounts of IgG1 anti-Der p 1, in particular when
using the Der p 5L/Der p 1(1–116) (Fig. 6). The reason for
one plasmid inducing a greater isotype shift than another is
not clear. It could be due to higher levels of secretory pro-
tein. Although IgG1 is usually referred to as a Th2 antibody,
IL-12-dependent IgG1 production has also been demon-
strated [31]. Whether the IgG1 anti-Der p 1 induced in this
case is IL-4- or IL-12-driven needs to be clarified.
Immunization with leaderless constructs (Fig. 7) resulted
in no detectable antibody induction. This was confirmed by
testing the antisera not only on native Der p 1, but also
recombinant peptides corresponding to the first 116 amino
acids, GST-(1–116), or the second 109 amino acids domain,
GST-(114–222). Even if the conformation of the leaderless
product induced antibodies that did not recognize the native
allergen, antibodies specific for continuous epitopes present
in the denatured sequence could be detected in this assay.
Der p 5 leader constructs induced high titers of anti-peptide
antibodies and still no response could be detected when im-
munizing with the leaderless construct.
It was reasoned that the lack of humoral response was
possibly due to the lack of expression of the leaderless plas-
mids. In order to address this issue, immunogenic Der p 5
L/Der p 1(1–116) constructs or the leaderless Der p 1(1–116)
was each inserted into a reporter vector, pEGFP. Fluores-
cence was indicative of biosynthesis of the inoculated gene.
Confocal examination revealed that muscle cryosections
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transfected with Der p 5/Der p 1(1–116) had bright green
spots early after injection that extended to cover whole
muscle bundles for extended periods of time. Surprisingly,
the pictures looked quite similar for cryosections of mus-
cles inoculated with Der p 1(1–116). We conclude that the
lack of antibody response was not due to lack of protein ex-
pression. With the leaderless constructs, we observed green
fluorescence of similar intensity in the muscle samples,
while there is no detectable antibody response. This could
be possibly due to the different localization of the expressed
protein. When the protein is expressed extracellularly, it can
be phagocytosed by antigen presenting cells, and processed
in lysosome, loaded onto MHC class II molecules, so as to
stimulate the CD4+ T cells, which is critical for the anti-
body production. However, when the protein is expressed
in the cytoplasm, most likely it will enter the endogenous
antigen presenting pathway, in which case the processed
peptides are loaded onto MHC class I molecules and have
less chance to activate CD4+ T cells [32].
This finding raises the exciting possibility that leaderless
constructs exclusively induce cellular immunity, which has
to be further confirmed. If this immunity was characterized
by the selective stimulation of IL-12/IL-18 producing cells
and down-regulation of IL-4, IL-5 and IgE, leaderless con-
structs would make good candidates for the development of
vaccines for allergic diseases.
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Efficacy evaluation of Der p 1 DNA vaccine for allergic
asthma in an experimental mouse model
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Abstract
Der p 1 is a major allergen that reacts with IgE in more than 70% allergic sera, hence a good candidate for DNA vaccine development.
Previous study demonstrated that intramuscular injection of plasmid DNA containing wild type Der p 1 gene induced specific Th1 skewed
immune response. The aim of this study is to further optimize the DNA construct to achieve preventive and therapeutic efficacies. An optimized
construct, containing mouse Ig light chain leader sequence followed by codon optimized mature Der p 1 gene, was generated and used to
prevent or treat Der p1 induced allergic asthma in an experimental model. Results showed that this optimized construct was effective in the























dfficacy. It also showed therapeutic efficacy in IgE inhibition and up-regulation of IgG2a and IFN-. The information obtained here could
acilitate the design of DNA vaccines for allergy in general.
2005 Elsevier Ltd. All rights reserved.
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. Introduction
House dust mites are the most important sources of indoor
llergens responsible for the development of sensitization and
llergic diseases. The prevalence of allergic asthma related
o house dust mite is high and keeps increasing worldwide
1]. Der p 1 is a major house dust mite allergen from Der-
atophagoides pteronyssinus. More than 70% of sera from
llergic individuals showed IgE reactivity to Der p 1. It has
een suggested that exposure and sensitization by the major
ite allergens may facilitate the sensitization to other less
revalent allergens [2]. Therefore, Der p 1 is a potential can-
idate for DNA vaccine development.
Der p 1 protein is a cysteine protease; its full-length cDNA
ncodes a precursor of 320 amino acid residues, comprising
f a signal peptide (18 amino acids), a proenzyme region (80
mino acids), and a mature enzyme (222 amino acids) [3].
ur previous study demonstrated that intramuscular injection
f plasmid DNA containing cDNA encoding mature Der p 1
as sufficient for in vivo expression of Der p1 and subsequent
∗
induction of specific Th1 skewed immune response in mice
[4]. The enzymatic activity of this in vivo expressed Der p 1
could be detrimental to the host [5,6], and thus was abolished
by excluding its own pre proenzyme sequences. However,
the resultant magnitude of the immune response was too low
to achieve satisfactory protective efficacies. In 2003, Bauer
et al. showed that optimization of codon usage increased
immunogenicity of DNA vaccination of a major plant aller-
gen in mice [13]. In this study, we further demonstrated the
use of an efficient mouse Ig light chain leader sequence in
addition to codon usage optimization strategy in improving
the preventive as well as therapeutic efficacies of DNA
immunization using a Der p 1 induced experimental allergic
asthma mouse model. The information obtained from this
study could facilitate future designs of DNA vaccine.
2. Materials and methods
2.1. Generation of codon optimized Der p 1 constructCorresponding author. Tel.: +65 6874 4345; fax: +65 6775 7593.
E-mail address: paecky@nus.edu.sg (K.Y. Chua).
The codon optimized Der p1 gene was designed based
on codon preference of highly expressed human transcripts.
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Briefly, partially overlapping oligonucleotides spanning the
mature part of Der p 1 coding sequence were synthesized
and used to generate the codon optimized DNA fragment
(hmDerp1) in a two-step PCR amplification [7]. A mouse
Ig light chain signal sequence (m) was tagged in-frame to
the 5′ end of the hmDer p1 by PCR and subsequently the
entire DNA fragment were cloned into the pVax1 expres-
sion vector and DNA sequence confirmed. The prophylactic
and therapeutic potentials of the resulting construct, pVax1-
m-hmDerp1 (LHM), were evaluated with Der p 1 induced
experimental mouse models.
2.2. Experimental mouse models
A total of 6–8 weeks old female BALB/cJ mice were
purchased from Laboratory Animals Centre (Sembawang,
Singapore) and housed in the Animal Holding Unit facility
in National University of Singapore under institutional
guidelines for the care and use of laboratory animals.
Immunization was done according to the regiments shown
in Fig. 1. DNA immunization was carried out by injection
of 50g of LHM (in 50l PBS) intramuscularly (IM)
followed by in vivo electroporation using the BTX ECM830
square wave electroporator (BTX, San Diego, CA, USA)
[8]. Intraperitoneal (IP) immunization was done by injecting
1g of Der p1 emulsified with 4 mg alum as adjuvant.
Challenge by aerosol inhalation of Der p 1 (50g/ml
native Der p 1 in PBS) was carried out using an ultrasonic
nebulizer (DeVilbiss Health Care, Sommerset, PA). Briefly,
the mice were kept unrestrained in a desiccator chamber
with continued flow of aerosol for 30 min. Blood samples,
taken at day 0 and every week thereafter, were centrifuged
at 2000× g and sera were collected and stored at −20 ◦C
for determination of Der p 1 specific immunoglobulin
responses.
2.3. Detection of Der p 1 speciﬁc mouse
immunoglobulin responses
The levels of Der p 1 specific IgE, IgG1, and IgG2a
were determined by ELISA. Mouse sera were incubated
in duplicate with the Der p 1 coated wells for overnight
at 4 ◦C. Biotin-conjugated monoclonal rat anti-mouse IgE
(R19-15), anti-mouse IgG1 (G1-1.5) and anti-mouse IgG2a
(R35-92) were used for detection and followed by addition of




pig. 1. Schematic representation of wild type Der p 1 gene structure and the codon o
reventive efficacy (B) and therapeutic efficacy (C). D, DNA immunization. C, PBS c
erosol, Airway challenge with aerosolized native Der p 1. AHR, measurement of a
1/Alum intraperitoneally.ptimized DNA construct (A), and immunization regiments for evaluation of
ontrol. S, Systemic sensitization with native Der p 1/Alum intraperitoneally.
irway hyperresponsiveness. Challenge, systemic challenge with native Der
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addition of p-nitrophenylphosphate substrate. ELISA index
unit was defined as the OD405 nm reading corresponding
to the reading of 1 ng/ml of purified mouse IgE, IgG1, or
IgG2a in a sandwich ELISA with anti-mouse Ig as the
capture antibody in the same plate. All the antibodies used
were purchased from Pharmingen (Pharmingen, San Diego,
CA).
2.4. Non-invasive measurement of airway
hyperresponsiveness
Approximately 24 h after the last challenge, conscious and
unrestrained mice were analysed for airway hyperresponsive-
ness (AHR) to different concentration of methacholine, mea-




dig. 2. Prophylactic efficacy on the inhibition of Der p 1 specific IgE. Mice were imm
lectroporation on days 0 and 7. Der p 1 sensitization was done by systemic immuni
er p 1 challenges from days 35 to 42 (Fig. 1B). Blood samples were collected w
etermined by ELISA. Results are shown as Mean±S.E.M. *p< 0.05.unized with codon optimized Der p 1 DNA construct intramuscularly with
zation intraperitoneally on day14 and day 21 followed by three aerosolized
eekly and the titer of Der p 1 specific IgE, IgG1 and IgG2a in serum was
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the whole-body plethysmography (Buxco Electronics Inc.,
Troy, New York, USA) [9]. Briefly, mice were exposed to an
aerosol of PBS (baseline readings) followed by cumulatively
increased doses of aerosolized methacholine (5–40 mg/ml).
Aerosol was generated by a portable ultrasonic nebulizer
(DeVilbiss Health Care, Sommerset, PA) and drawn through
the chamber for 3 min with the Bias Flow Supply. The signals
were recorded for the subsequent 5 min and interval between
each dose was 1 min.
2.5. T cell cytokine proﬁling
Single-cell suspensions were prepared from spleen and
red blood cell lysis was performed. Splenocytes (4× 105
cells/well) were cultured in the presence or absence
of 20g/ml of Der p 1 in 96-well round-bottomed
plates (Costar, Corning, NY) containing RPMI 1640
medium supplemented with 10% heat-inactivated bovine
calf serum (StemCell Technologies Inc.), 2 mM l-glutamine,
1 mM sodium pyruvate, 100 U/ml penicillin and 100g/ml
streptomycin (Hyclone Laboratories, Logan, UT) and
5.5× 10−2 mM 2-mercaptoethanol (Life technology, Grand
Island, NY). After 72 h, culture supernatants were collected,
stored at−20 ◦C and assayed in duplicate for the presence of
the cytokines IL-4, IL-5, IL-13, IFN-, and IL-10. Antibodies
pairs for ELISA were purchased from Pharmingen (Pharmin-





1ig. 3. Prophylactic efficacy on the Der p 1 specific T cell cytokine profiles. Mice
ay as described in Fig. 1B (grey bar). Mice that were sensitized with Der p 1 pro
ncluded as controls. Two days after the last airway allergen challenge, mice were s
. The concentration of IL-4 (A), IL-5 (C), IL-10 (E), IL-13 (D), and IFN- (B) wewere immunized with DNA vaccine and challenged with Der p 1 the same
tein alone (black bar), or received DNA vaccination alone (open bar) were
acrificed and the splenocytes were cultured in RPMI with or without Der p
re measured from the culture supernatants with ELISA. *p< 0.05.
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3. Results and discussion
3.1. Prophylactic evaluation of DNA immunization
Our previous result has shown that the Der p 1 gene with-
out its pre, proenzyme sequence could be expressed in vivo
resulting in induction of Der p 1 specific immune responses
after intramuscular DNA immunization [4]. However, the
induced specific immune responses were insufficient to sup-
press the development of asthma in the mouse model. Here
we aimed to improve prophylactic and therapeutic efficacies
of Der p 1 gene vaccination by optimization of codon usage of
Der p 1 cDNA sequence to that of highly expressed human
genes (Sequence information available upon request). The
humanized mature Der p 1 gene was tagged with a strong
leader sequence from mouse Ig chain, and inserted into
pVax1 expression vector (Fig. 1A) The resulting construct,
pVax1-m-hmDerp1 (LHM), was shown to induce 10-fold
higher antibody titers in immunized mice as compared to
pCI-neo-Der p 5 l/Der p 1(1–222), a DNA construct in pCI
neo expression vector containing native Der p 1 with a Der
p 5 leader sequence. (Data not shown [4].) For the prophy-
lactic efficacy assessment, mice were pre-immunized with
LHM construct and challenged intraperitoneally with Der
p 1 protein in alum according to the prophylactic regiment




















of Th2 response by DNA vaccination, we further examined
the cytokine profile of spleen T cells upon in vitro stimulation
with Der p 1. Mice that were immunized and challenged as
shown in prophylactic regiment (Fig. 1B) were sacrificed on
day 44 and in vitro culture of splenocytes was carried out
with or without Der p1. As shown in Fig. 3, the levels of
Th2 cytokines IL-4, IL-5, IL-10, IL-13 were significantly
decreased in DNA vaccinated mice, while the Th1 cytokine
IFN- levels were boosted. The ratios of IL-4 to IFN- were
also significantly decreased from 2.5 in control mice to 1
Fig. 5. Therapeutic efficacy on the attenuation of Der p 1 specific IgE. Mice
were systemically sensitized by intraperitoneal injection of native Der p
1 intraperitoneally with alum, followed by aerosol allergen challenge on
days 21, 22, 23. On days 35 and 42 mice were either treated with DNA
immunization (treated, grey bar) or PBS (control, black bar). On day 77,
mice were challenged with Der p 1 intraperitoneally again (Fig. 1C). Blood
were collected on days 56 and 84 and titers of Der p 1 specific IgE (A),
IgG2a (B) and IgG1 (C) were determined by ELISA. Results are shown as
Mean±S.E.M. *p< 0.05.accinated mice was significantly down-regulated (Fig. 2A);
hereas both IgG2a and IgG1 levels were greatly boosted
n these mice after intraperitoneal Der p 1/alum challenge
Fig. 2B). These data indicated that Der p 1 gene immuniza-
ion induced Th1 skewed immune responses, which probably
ediated the attenuation of Th2 responses upon subsequent
llergen challenge.
Allergen specific Th2 skewed immune response is critical
or the development of allergic asthma [10]. Studies have
hown that Th2 cytokines also have direct effects on the
athogenesis of this disease [11]. To confirm the suppression
ig. 4. Prophylactic efficacy on the reduction of airway hyperresponsiveness
AHR). Mice were immunized and challenged the same way as described in
ig. 1B. AHR was measured with whole-body plethysmography 24 h after
he last aerosolized allergen challenge. AHR was successfully established
n Der p 1 sensitized and challenged mice (control group, filled square).
NA immunization before the Der p 1 sensitization reduced the Penh val-
es significantly (vaccinated group, open square). The differences between
accinated group and control group are statistically significant at Mch doses
0 and 40 mg/ml. *p< 0.05.
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in DNA vaccinated mice, which confirmed the significant
suppression of Th2 responses concurrent with a shift to Th1
response. Furthermore, the airway hyperresponsiveness,
which is a hallmark of the asthma symptom, was significantly
attenuated in the LHM vaccinated mice (Fig. 4).
3.2. Therapeutic evaluation of DNA immunization
To evaluate the therapeutic effects of DNA vaccination
with LHM construct, experimental asthmatic mouse model
was established and treated with LHM immunization regi-
ment as shown in Fig. 1C. The Der p 1 specific IgE levels
were compared on day 56 and day 84, 2 weeks after the sec-
ond DNA immunization and 1 week after the final Der p 1
challenge, respectively. At both time points, the Der p 1 spe-
cific IgE levels in the LHM treated mice were significantly
lower than that in the control group (Fig. 5A). On the other
hand, Der p 1 specific IgG2a levels, but not the IgG1 levels,
were significantly higher in the vaccinated group on day 84
(Fig. 5B and C). T cell cytokines profiling showed that there
was an elevation of IFN- levels in DNA treated mice, but
there was no significant difference in Th2 cytokines levels
(data not shown). The data on airway hyperresponsiveness
were inconclusive. Recently, Jarman and Lamb [12] reported
significant therapeutic effect of a plasmid DNA encoding T
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